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Abstract 
Endothelial-to-mesenchymal transition (EndMT) is a dynamic biological process 
present during development and involved in a variety of pathological vascular 
remodelling scenarios. However, despite our growing understanding of the key 
cellular alterations required, the precise molecular determinants governing this 
phenotypical transition remain elusive. With long non-coding RNAs (lncRNA) now 
emerging as powerful regulators of gene expression we sought to understand their role 
in the process of EndMT. 
To replicate EndMT in vitro and characterise its molecular signature, human umbilical 
vein endothelial cells (HUVEC) and human pulmonary artery endothelial cells 
(HPAEC) were exposed to a continuous co-treatment of transforming growth factor-
beta 2 (TGF-β2) and interleukin 1 beta (IL-1β) for a total of 7 days. Using high-
throughput RNA-sequencing analysis of these cells, a total of 103 differential 
expressed lncRNAs were identified. Of these, the downregulation of the lncRNA 
MIR503HG was found to be a prevalent feature present in multiple human primary 
EC types undergoing EndMT in vitro. Further analysis revealed that depletion of 
MIR503HG was sufficient to elicit a robust EndMT phenotype, with a significant 
increase in the expression of SNAI2, ACTA2 and COL1A1, accompanied by 
repression of CD31. Conversely, ectopic expression of a single MIR503HG transcript 
suppressed these hallmark EndMT-associated changes despite TGF-β2 and IL-1β co-
treatment. Accompanying RNA-sequencing of these cells showed that the 
overexpression of MIR503HG alone was able to inhibit over 25% of the EndMT 
transcriptional profile. Crucially, these changes were found to be independent of the 
functional regulation of miR-503 and miR-424, found within the MIR503HG locus. 
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Our findings were then confirmed in vivo using a sugen/hypoxia-induced model of 
pulmonary hypertension (PH) established in endothelial lineage-tracing mice. Here, 
the expression of the MIR503HG mouse homolog (Gm28730) was significantly 
downregulated in association with an EndMT profile in the lung. Conversely, targeted 
up-regulation of MIR503HG in the mouse lung significantly suppressed the 
appearance of mesenchymal markers in CD31+ cells during PH. Notably, MIR503HG 
availability was also found to be decreased in lung tissue sections from patients with 
idiopathic pulmonary arterial hypertension (IPAH) and cultured blood outgrowth ECs 
isolated from patients with heritable pulmonary arterial hypertension (HPAH). 
Collectively, our studies identify MIR503HG as essential in maintaining EC 





Spanning the entirety of the human body, the vasculature is a highly complex network 
of blood vessels composed of several specialised cell types. Unsurprisingly, alterations 
to the function of these cells can have severe consequences to the structure of the 
vessels and ultimately drive the development of pervasive clinical conditions such as 
hypertension and atherosclerosis. This disease process is often referred to as vascular 
remodelling and it generally encompasses changes in the diameter, elasticity and 
responsiveness of blood vessels. During this process, the endothelial cells (ECs) 
forming the inner layer of the vasculature lose their identify and become highly 
dysfunctional. This is called endothelial-to-mesenchymal transition (EndMT). Despite 
our understanding of the global changes that lead to EndMT during disease, the precise 
mechanisms that drive this transition are relatively unknown. Novel molecules known 
as long non-coding RNAs (lncRNAs) have now started to show promise as regulators 
of cell function and may also be involved EndMT. In this thesis we describe the 
previously unknown role of lncRNAs in maintaining EC function and preventing 
EndMT.  
To do this, we first replicated the EndMT process by exposing human ECs to factors 
known to influence vascular remodelling and drive the transition. After evaluating all 
RNA present in our samples, we discovered that the lncRNA MIR503HG was 
significantly lower in ECs undergoing EndMT. Interestingly, by specifically targeting 
MIR503HG in ECs to decrease its expression we were able to fully reproduce the 
EndMT process, while increased levels of the lncRNA prevented this.  
Crucially, the presence of MIR503HG was also found to be nearly abolished in the 
remodelled vasculature of patients with pulmonary hypertension (PH). This was also 
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found to be true in an animal model of PH in association with EndMT.  
Together, the data presented here identify MIR503HG as essential in preventing 
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The vasculature is an intricate and highly adaptable network of blood vessels spanning 
the entirety of the human body. Unsurprisingly, alterations to the structural and 
mechanistic functioning of the vascular wall can have severe consequences that 
underline the development of pervasive subclinical conditions such as hypertension 
and atherosclerosis. Vascular remodelling is the term used to describe this maladaptive 
process, broadly encompassing changes in vascular diameter, elasticity and 
responsiveness. Neointima formation and intimal hyperplasia are often present during 
vascular remodelling scenarios and feature in the pathogenesis of several diseases such 
as vein-graft restenosis 1, atherosclerosis 2 and pulmonary arterial hypertension (PAH) 
3. This is often accompanied by dysregulated cell migration, proliferation and 
apoptosis, along with increased inflammation and excessive deposition of extracellular 
matrix (ECM). 
Within the setting of PAH, despite its complex aetiology, it is accepted that the key 
elements in the pathogenesis of the disease encompass a variety of structural changes 
to the vascular wall 4. This includes stiffening of proximal pulmonary arteries, 
increased intimal and medial arterial thickness, along with the eventual development 
of complex neointimal lesions. Underlying many of these changes is the increased 
deposition of ECM and appearance of smooth muscle-like cells with a highly 
proliferative and migratory potential 5.  
Similarly, the common use of venous bypass grafts for surgical revascularisation in 
patients with coronary artery disease can also be followed by a rapid decrease in lumen 
diameter 6. As with the previous condition, despite their aetiological differences, the 
observed pathological post-grafting remodelling is characterised by the development 
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of neointimal lesions composed of proliferative smooth muscle cells (SMC) and ECM 
proteins 7,8. 
Leading from the initial disruption of normal endothelial function, neointimal 
formation and hyperplasia is believed to be preceded by a cascade reaction involving 
the activation and adhesion of circulating thrombocytes and leukocytes which work to 
initiate medial SMC differentiation, migration and proliferation 9. Nevertheless, while 
the appearance of neointimal cells is widely reported, their origin is still up for debate 
10,11. Emerging paradigms, supported by lineage tracing studies, now propose that in 
part these SMC-like cells are of endothelial origin 12–14. Specifically, these studies 
highlight the pathological contribution offered by the endothelial cell (EC) capacity to 
transition between proliferative mesenchymal phenotypes 15. With emerging evidence 
showing that endothelial-to-mesenchymal transition (EndMT) is present during 
pathological vascular remodelling, new therapeutic avenues may also arise. However, 
despite our growing understanding of the key cellular alterations involved, the 
molecular determinants governing this phenotypical transition still remain elusive. 
This is particularly true with the discovery of long non-coding RNAs (lncRNA) as 
powerful regulators of gene expression both at the transcriptional and post-
transcriptional level.  
In this thesis, we summarise the current body of knowledge on the role of EndMT in 
the context of pathological vascular remodelling, and the role played by ncRNAs in 
governing this phenotypical transition. Lastly, we provide evidence for the role of the 
lncRNA MIR503HG in preventing the initiation of EndMT both in vitro and during 
disease. 
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1.2 Endothelial-to-Mesenchymal Transition 
Lining the totality of the vasculature, the endothelium directly interacts with nearly 
every system in the body to regulate most aspects of vascular development, 
homeostasis and pathogenesis. The EC monolayer that constitutes this barrier is in 
itself a distinctively versatile population, showing extraordinary physiological and 
morphological heterogeneity throughout different parts of the vasculature 16. These 
differences reflect the variety of functions they perform and the shifts in the priority 
of these roles across different anatomical locations in the cardiovascular system. For 
instance, the angiogenic capacity of ECs plays a vital role during embryological 
growth, tissue development, and wound healing in damaged tissues 17. Maintenance of 
vessel function, and therefore cardiovascular homeostasis, is highly dependent on the 
ability of the endothelium to react to external stimuli, mediating not only vasodilation 
and constriction but also thrombogenic, immune and inflammatory responses 18,19. 
Dysregulated, these mechanisms can lead to, among others, the unrestrained vessel 
formation often seen in cancerous tumours 20 and the pathological remodelling of 
mature vessels associated with the development of pervasive conditions such as 
hypertension 21 and atherosclerosis 22.  
Recently, several studies have started to look at the process by which ECs adopt 
mesenchymal phenotypes and the role that this transition plays both in the initiation 
and maintenance of vascular disease. This transition refers to the process whereby ECs 
will progressively lose their cell-specific markers, change their morphology and adopt 
a mesenchymal cell-like phenotype accompanied by increased motility, cytoskeletal 
modifications and cell-to-cell junction rearrangement 23 (Figure 1.1). First described 
as a key developmental process for heart valve formation, during disease these cells 
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are thought to acquire invasive and proliferative properties along with the ability to 
deposit large amounts of ECM 23. 
In order to transition to a mesenchymal phenotype, ECs must first lose their cell-to-
cell tight and adhesion junctions via increased cleavage of vascular endothelial (VE)-
cadherin and platelet endothelial cell adhesion molecule 1 (PECAM1) proteins, 
accompanied by decreased gene expression 15. Occurring in parallel with this, there 
are distinct changes in shape from their normal arrangement to an elongated 
morphology 24. As the transition progresses, the cells will begin to express 
mesenchymal markers – specifically, there is an increased expression of known 
fibroblastic markers such as α-smooth muscle actin (α-SMA) and fibroblast-specific 
protein 1 (FSP1), along with various leukocyte adhesion molecules and a combination 
of ECM proteins, such as collagen I and III, vimentin and fibronectin 10,14,25.  The 
transition, and associated cellular changes, involves an intricate series of signalling 
pathways which regulate both its initiation and potentiation. 
 
Figure 1.1: Markers of EndMT. 
EndMT progression is characterised by changes in a variety of markers.  Following the upregulation of 
EndMT-associated transcription factors, early endothelial responses include the downregulation of 
endothelial markers and adherens junction dismantling. As it progresses, mesenchymal markers such as 
cytoskeletal and ECM proteins, are strongly upregulated.   
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EndMT responses can be induced by a variety of events leading to a rise in cellular 
stress, such as hypoxia 26, direct vascular injury 27 or increased inflammation 28. These 
events can trigger the activation of transforming growth factor-β (TGF-β), Wnt and 
Notch intercellular signalling pathways, which in turn act to direct and/or mediate 
EndMT by interacting with several transcription factors regulating endothelial and 
mesenchymal gene expression 14,27,29,30.  
 
Broadly speaking, our understanding of the transcriptional factors involved in the 
initiation of EndMT largely build on previous foundational studies conducted on 
epithelial-to-mesenchymal transition (EMT). With this, five transcription factors have 
emerged as key regulators of both EMT and EndMT. Namely, the SNAIL family zinc 
finger transcription factors SNAI1 and SNAI2, the zinc-finger E-box-binding 
homeobox 1 (ZEB1) and 2 (ZEB2), and the twist Basic Helix-Loop-Helix transcription 
factor 1 (TWIST1). The transcription factors SNAI1 and SNAI2, for instance, were 
first shown to actively repress E-cadherin expression in transitioning epithelial cells 
31,32. During EndMT, the same transitional repressors have been found to lower the 
expression of the analogous VE-cadherin and PECAM1 in ECs 15. As described by 
Lopez and colleagues, both proteins can bind to E-box motifs in the human VE-
cadherin promoter region and thus repress the expression of the adhesion molecule 33. 
Similarly, the zinc-finger E-box-binding proteins ZEB1 and ZEB2 were first described 
as direct transcriptional repressors of E-cadherin expression during EMT 34–36. In the 
context of EndMT, while this mechanism hasn’t been thoroughly explored, the two 
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transcription factors are often associated with loss of EC markers 37,38.  
Part of a large family of helix‐loop‐helix (HLH) transcription factors, TWIST1 can 
function by both dimerising with other basic HLH member proteins and binding 
specific E‐box motifs to regulate gene transcription in EMT and EndMT 39. Again, this 
has been historically associated with repression of E-cadherin transcriptional 
expression, shown to promote EMT during development and in tumor metastasis 40,41. 
As with SNAI1/2 , TWIST1 can also directly repress VE-cadherin transcription and is 
associated to EndMT-like changes in a variety of settings, including heart valve 
formation, vascular lesion development and fibrosis 33,42–45. During the formation of 
the heart valves in mice, for example,  persistent TWIST1 expression leads to 
increased cell proliferation and increased ECM gene expression, characteristic of 
early developmental EndMT 43. 
Interestingly, despite being broadly described in the literature as central to EndMT, the 
mechanism by which these transcription factors regulate mesenchymal gene 
expression remains somewhat unclear and surprisingly under-researched. Nonetheless, 
there is clear evidence that all of these are intrinsically linked to the initiation of 
EndMT and associated transcriptional changes. Overexpression of SNAI1 alone is 
sufficient to induce an EndMT-like profile, not only repressing VE-cadherin and 
PECAM1, but also leading to the increased production of mesenchymal markers such 
as SM22α and FSP1 40. In a model of SMC differentiation in vitro, ZEB1 was shown 
to interact with the TGF-β effector protein SMAD3 to activate αSMA and smooth 
muscle myosin heavy chain (SM-MHC) promoters 46. While not validated in ECs it’s 
possible that similar mechanisms are recapitulated during EndMT. 
Lastly, while SNAI1 and SNAI2 are often cited as key factors for EndMT induction, 
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overexpression of either transcription factor alone is not sufficient to fully induce 
transition 47,48. Given that several of these mediators are often expressed together, it is 
possible that a synergistic network of factors regulating EndMT induction exists. 
 
Linked to a variety of cardiovascular diseases associated with tissue remodelling 49,50,  
TGF-β signalling is well established as one of the key signalling pathways involved in 
the initiation of EMT and, more recently, EndMT 51,52. This includes the thoroughly 
described prototypic members of the TGF-β Family, TGF-β1 and TGF-β2 12,14,53. 
In most cell types, members of the TGF-β family will commonly exert their cellular 
effects by specifically binding a transmembrane complex composed of type I and type 
II receptors, where upon binding type I receptors are phosphorylated by a type II 
receptor. Different TGF-β family proteins can bind various combinations of type I and 
type II receptor complexes, activating specific signaling pathways. There are seven 
known type I receptors, also described as activin receptor-like kinases (ALK), listed 
as ALK1 to ALK7. Five type II receptors have been described so far, including the 
activin receptor type IIA (ActRIIA), activin receptor type IIB (ActRIIB), BMP type II 
receptor (BMPR2), TGF-β type II receptor (TGF-βR2) and AMH type II receptor 
(AMHRII) 15. Activated, the receptor complexes lead to a signaling cascade 
transmitted by a series of receptor-regulated (R)-SMAD proteins (i.e. SMAD1, 2, 3, 5, 
or 8), which can then form complexes with a common-mediator (Co)-SMAD 
(SMAD4), shuttle to the nucleus and participate in the transcriptional regulation of 
target genes 15,54,55. 
In ECs, TGF-β1 and 2 will typically exert their cellular effects via the constitutively 
active TGF-βR2 which will transphosphorylate the broadly expressed type I receptor 
31 
AKL5 or the endothelial specific ALK1 in a common complex. Either receptor 
complex can then recruit and phosphorylate a variety of R-SMADS – ALK5 will 
induce the activation SMADS2/3, whereas ALK1 is associated with SMADS1/5/8. 
Notably, which receptor complex is activated has been shown to be largely context 
dependent, associated with a variety of factors such as TGF-β ligand concentration, 
relative expression levels of each receptor, and co-activated inhibitory pathways 54,56–
58. Regardless of their arrangement, the phosphorylated R-SMADS will form 
additional complexes with SMAD4 and translocate to the nucleus to regulate various 
aspects of endothelial function 15. The SMAD1/5/8 and SMAD4 complex, for 
example, has been shown to promote EC functions such as angiogenesis 56,59,60. During 
EndMT, the SMAD2/3/4 complexes are thought to interact with SNAI1/2, ZEB1/2 and 
TWIST1, resulting in the regulation of endothelial, mesenchymal and other EndMT-
associated genes (Figure 1.2) 14,48,61.  
Additionally, TGF-β can activate other, non-canonical, SMAD-independent pathways 
also implicated in EndMT. For example, exposure to TGF-β2 can induce an in vitro 
EndMT profile associated with the activation of p38 MAPK signalling, which when 
blocked will supress SNAI1 expression and inhibit transition 48. While the mechanisms 
by which p38 MAPK signalling regulates EndMT are yet to be defined, a similar role 
has been described in EMT both during development and disease 62. Further, in TGF-
β1-induced EndMT, both protein kinase C-delta (PKC-δ) and c-Abl can regulate the 
transition via the inactivation of GSK3β 63. Crucially, GSK3β has been shown to 
directly bind SNAI1 ultimately increased its degradation 64,65. 
Activation of TGF-β signalling, be it via canonical or non-canonical pathways, while 
important cannot fully explain the appearance of EndMT. Several publications have 
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demonstrated this, highlighting that only partial transition phenotypes are possible  
and that additional pathways must also be activated in parallel. 
 
Figure 1.2: Summary of the Regulatory Signaling Cascades Involved in EndMT. 
EndMT can be induced by a variety of signal transduction pathways, including those activated by TGF-
β, Wnt and Notch ligands, as well as shear stress, hypoxia and inflammation. These in turn act to regulate 
gene expression by interacting with transcription factors such as SNAI1, SNAI2, ZEB1/2 and TWIST1. 







Under chronic inflammation, continuous endothelial activation by tumour necrosis 
factor alpha (TNF‐α), interleukin‐1 beta (IL‐1β) and other pro-inflammatory 
cytokines, can drastically impair normal EC function contributing to the initiation and 
progression of vascular disease 67,68. Interestingly, a growing number of studies have 
found this increase in inflammatory signalling to also be associated with EndMT 
(Figure 1.2) 69. For instance, 48 hour exposure of aortic valve ECs to TNF‐α induced 
loss of PECAM1 and VE-cadherin, along with increased α-SMA expression and the 
acquisition of an invasive phenotype in a dose-dependent manner 28. While this was 
only seen in a specific subset of ECs, a follow-up study by the same group went on to 
demonstrate that this EndMT subset also expressed higher levels of Notch1 and TGF-
β1  70.  
EMT studies have suggested regulation can happen via the TNF‐α mediated activation 
and nuclear translocation of the transcription factor NF-κB (Nuclear factor kappa-
light-chain-enhancer of activated B cells), which can then regulate SNAI1 expression 
71–73. A recent study as also suggested that the downregulation of the BMP Receptor 
Type 2 (BMPR2) is also necessary for TNF‐α to induce EndMT. In fact, ectopic 
overexpression of BMPR2 in primary human coronary aortic endothelial cells 
(HAoECs) was sufficient to partially prevent EndMT 74. Nevertheless, while often 
alluded to in the literature, these complex cross-regulatory pathways have yet to be 
thoroughly explored during EndMT. 
Several publications have also demonstrated that activated inflammatory and TGF-β 
signalling can act in a synergistic manner to induce EndMT. For example, as reported by 
Rieder et al, human intestinal microvascular ECs (HIMECs) display a stronger EndMT 
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profile when treated with a combination of TNF‐α and TGF‐β1 75. Exposure to either 
factor alone only elicited partial EndMT, where TGF‐β1 was associated with increased 
αSMA expression while TNF‐α mainly induced a downregulation of PECAM1 and 
VE‐cadherin 75.  
IL‐1β expression has long been known to induce significant phenotypical changes to 
endothelial and epithelial cells 76–79, more recently associated with EndMT-mediated 
fibrosis 77,80. This critical role has been confirmed further by Maleszewska and 
colleagues, showing that IL‐1β will act synergistically with TGF‐β2 to induce a 
pronounced EndMT profile in human umbilical vein endothelial cells (HUVEC) 81. 
This strategy was also associated with progressive increase in TGF‐β2 expression and 
the activation of NF-κB signalling 81. 
 
Despite the well-defined pathway, TGF-β signalling does not fully encompass the 
totality of the mechanisms involved in the activation of EndMT. Crucially, while some 
of the pathways described here appear to partially converge with that of TGF-β, other 
independent pathways have been characterised (Figure 1.2). 
Notch Signalling Pathway 
Notch signalling, active during cardiac development and disease 82,83, is an important 
regulator of EC proliferation, migration and differentiation 84–87.  Dependent on cell–
cell contact, the interaction between Notch receptors (NOTCH1-4) and their respective 
transmembrane ligands (i.e. Jagged1) will initiate the canonical Notch signalling 
pathway. Ligand–receptor interaction leads to 2 successive cleavage events by a 
disintegrin and metalloproteinases (ADAM) and presenilin, releasing the Notch 
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receptor extracellular subunit and the Notch intracellular domain (NICD), 
respectively. This facilitates the translocation of NICD into the cell nucleus where it 
will form a transcriptional complex able to recruit various transcription factors to 
regulate gene  expression 82,83. In ECs, activation of NOTCH1 for instance, can repress 
expression of p21, an endogenous cell cycle inhibitor, to increase proliferation in 
pulmonary arterial endothelial cells (PAEC) and regulate vessel remodelling in a  
pulmonary hypertension (PH) model 88. Additionally, Notch signalling has also been 
shown to directly interact with the runt-related transcription factor 3 (RUNX3) to 
induces the expression of several EndMT genes, including SNAI2 89. In fact, 
overexpression of activated NOTCH4 NICDs is sufficient do induce both the loss of 
endothelial phenotype and acquisition of mesenchymal markers in ECs from different 
vascular beds 30.  
Wnt/β-Catenin Signalling 
Wnt/β-Catenin signalling is another conserved pathway reported to be activated during 
EndMT. Canonical Wnt signalling broadly functions by facilitating the accumulation 
and eventual nuclear translocation of β‐catenin, where it acts on gene transcription 
90,91. In the absence of Wnt activation, a constitutively active ‘destruction complex’ 
will phosphorylate cytoplasmic β-catenin, which eventually leads to its degradation. 
Activation via binding of extracellular Wnt ligands to Frizzled (Fzd) and LRP5/6 
receptor proteins will promote disassembly of this ‘destruction complex’ and inhibit 
the phosphorylating activity of GSK3β, ultimately allowing for signalling transduction 
via β‐catenin 90,91.  
Both in vivo and in vitro studies describe this process as essential for EndMT-mediated 
heart cushion formation in mice, which can be halted by the deletion of β-catenin 92. 
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Using an endothelial reporter mouse line, expressing a Cre-activated fluorescent 
marker in cells of endothelial origin, a recent publication has also demonstrated that 
endocardial ECs give rise to mesenchymal progenitors in response to paracrine Wnt 
signalling 93. During disease, again using an endothelial-lineage tracing reporter mouse 
line,  myocardial infarction has been shown to trigger EndMT via canonical Wnt 
signalling 27.  
It is important to highlight, however, that the transcriptional mediators of EndMT 
activated by β-catenin have not yet been elucidated. Nonetheless, Wnt signalling can 
inhibit GSK3β activity which, as previously emphasised, may result in the stabilisation 
of SNAI1 and SNAI2 64.  
Lastly, despite our growing understanding of the mechanisms behind EndMT and the 
role that specific genes and signalling cascades can have on its initiation, there is still 
vast scope to expand on the underlying components that regulate EndMT and its 
associated pathologies. One such component has started to gather attention as research 
increasingly acknowledges the several types of ncRNAs involved in the regulation of 
gene expression and translation. Evidence now suggests that small non-coding 
microRNAs (miRNA) and long non-coding RNAs (lncRNA) may act as regulators of 
key cellular functions including differentiation, migration and proliferation. As such, 
the role ncRNA during the initiation and maintenance of EndMT may be a significant 
one. We will continue to explore the role of ncRNAs in endothelial function and 
EndMT, in Sections 1.4 and 1.5 of this thesis. 
 
EndMT was originally reported in series of seminal studies by Markwald and 
colleagues, describing a subset of endocardial ECs undergoing a phenotypical change 
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between embryonic development days E8.5 and E12. These would subsequently 
invade the adjacent cardiac jelly and initiate the formation of the cardiac cushions in 
the chick embryo 94–96. Now described in a variety of animal models, EndMT has been 
known to be one of the key events driving endocardial cushion formation, leading to 
the development of the cardiac valves 97. Crucially, endothelial-specific deletion of 
EndMT signalling pathways in mouse embryos results in decreased endocardial 
cushion size, followed by critical defects in atrioventricular septa and valves 92,98,99. 
The development of endothelial-lineage tracing reporter mouse lines has greatly 
advanced our understanding of this process by allowing for the identification of 
EndMT-derived cells that no longer express endothelial markers 100. For example, 
using Tie2-Cre transgenic mice line, in which expression of Cre recombinase is driven 
by an endothelial-specific promoter (Tie2), de Lange et al demonstrated that a large 
proportion of the mesenchymal cells present in mature valve and septal structures of 
the heart where in fact of endothelial origin 101. 
Further, while controversial, some studies have suggested that EndMT may also be 
active throughout vascular development. This has been reported during the formation 
of the dorsal aorta in quail embryos 102 and pulmonary artery development of chicken 
embryos 103. Of note, using the more rigorous lineage tracking approach, a recent 
publication has demonstrated that endocardial ECs act as progenitors for pericytes and 
vascular SMCs (VSMC) assembled within the wall of coronary vessels in mouse 
embryos 93.  
 
The past decade has seen an increasing number of reports showing that EndMT can 
occur not only as a mechanism for heart development but also as a driver for a wide 
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range of adult pathologies ranging from cancer to cardiovascular disease 27,104. The 
development of cardiac fibrosis, for example, is now believed to be significantly 
affected by EndMT with murine studies estimating that up to 35% of all fibroblasts in 
fibrotic heart tissue are of endothelial origin 14,37.  Similarly, recent studies have 
highlighted the contribution of EndMT to neointima formation and intimal hyperplasia 
often present during vascular remodelling.  
 
Vascular remodelling can occur in patients after percutaneous coronary interventions 
such as angioplasty or coronary artery bypass graft surgery, resulting in neointimal 
hyperplasia, restenosis and ultimately vessel occlusion. Coronary artery bypass 
surgery using saphenous vein grafts, for example, is reported to have a fail rate of up 
to 40% within 18 months of implantation 105,106. Despite the commonly described 
accumulation of SMCs and excessive deposition of extracellular matrix seen in these 
occluded vessels, much of the aetiology associated with vein graft remodelling stems 
from the damaged endothelial lining failing to adapt to arterial pressure 107,108. 
Nevertheless, the cellular contribution to the development of this population in 
remodelled vessels has often been considered to be lineage restricted 109.  
Challenging the prevailing dogma, an influential publication by Cooley et al showed 
that endothelial lineage-derived cells significantly contribute to active vein graft 
remodelling as a result of EndMT (Figure 1.3) 14. Using cell lineage-tracing in mice, 
where Cre-activated yellow fluorescent protein (YFP) expression allowed for the 
detection of ECs regardless of subsequent changes in cellular phenotype, the group 
demonstrated that 51% of the vascular neointimal cell population developing after vein 
graft surgery were of endothelial origin 14. Post-grafting, this YFP+ neointimal 
39 
population progressively loss the expression of all examined endothelial markers and 
by day 35 uniformly expressed αSMA and SM22α, indicative of active EndMT. Of 
interest, the group also found that while the number of non-endothelial lineage (YFP−) 
neointimal cells seemed to plateau after14 days, the number of YFP+ neointimal cells 
continued to increase up to 35 days post-surgery 14. 
 
Figure 1.3: EndMT during vein graft remodelling. 
Immunofluorescence confocal microscopy showing the expression of CD31 (PECAM1) and SMA in 
endothelial lineage derived (YFP+) cells 7 days after grafting. Scale bars 10 μm. L, lumen. Figure 
adapted from Cooley et al, 2014 14. 
 
Given the well documented activation of TGF-β signalling during vascular 
remodelling 110,111, Cooley et al go on to also show the presence of phosphorylated 
Smad2/3 in YFP+ neointimal cells by day 7, accompanied by increased SNAI2 and 
TWIST1 expression. Treatment of mouse veins with either a TGF-β neutralising 
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antibody prior to grafting, resulted in decreased Smad2/3 activation, accompanied by 
less EndMT and consequently a reduced neointimal area 14. 
 
Leading from the initial disruption of normal endothelial function, atherosclerotic 
plaque formation is thought to involve a complex sequence of biological events within 
the intima of the vessel wall; this includes the recruitment of circulating leukocytes 
and accompanying macrophage formation, lipid deposition, along with the 
accumulation of mesenchymal cells and increased ECM deposition 112,113. This 
mesenchymal cell population actively patriciates in plaque calcification and fibrous 
cap formation facilitating disease progression 112. Historically, the origin of these cells 
was thought to be limited to a phenotypically distinct, albeit migratory, SMC and 
fibroblast population from the local vasculature. However, with a growing number of 
publications highlighting the presence of EndMT in atherosclerosis, these assumptions 
are quickly changing. 
Moonen and colleagues were among the first to report the presence of EndMT in 
human atherosclerotic plaque and neointimal lesions. Here the group described a 
population of ECs, expressing both PECAM1 and αSMA, present in the inner lining 
as well as deeper in the neointimal tissue 114. Given the more frequently observed 
incidence of atherosclerotic plaques at branching points within the vasculature 115, the 
paper also looked at regions exposed to either uniform laminar shear stress or disturbed 
oscillatory flow in the porcine abdominal aortic trifurcation. In the outer walls of the 
vessel trifurcation, showing pronounced neointimal thickening, the group reported the 
appearance of EndMT-like cells expressing αSMA, transgelin, and calponin 114.  
41 
Further, the use of endothelial-specific lineage-tracking has vastly expanded our 
understanding of the contribution of EndMT-derived in atherosclerosis.  By combining 
a tamoxifen‐inducible endothelial‐specific lineage tracing system in a pro‐
atherosclerotic apolipoprotein E knockout (ApoE-/-) mouse line, Evrard et al showed 
that EndMT contributed to approximately 45% of the fibroblast population within the 
intima of advanced atherosclerotic lesions (Figure 1.4) 53. Interestingly, EndMT-
derived cells expressing VSMC markers were significantly less within these lesions. 
This was further confirmed in human atherosclerotic lesions, showing that cells 
expressing both endothelial and fibroblast proteins are increasingly present in 
advanced unstable lesions 53. 
Several reports, using either disease models or patient samples, have now shown a 
clear accumulation of EndMT-derived mesenchymal cells during atherosclerosis. 
Nonetheless, whether EndMT plays a functional role or is simply a consequence of 
atherosclerotic disease still remains somewhat unclear. This was partially addressed in 
a recent study by Chen et al showing that endothelial TGF-β signalling is one of the 
primary drivers of atherosclerosis-associated vascular inflammation 116. Using an 
endothelial-specific inducible deletion of TGFBR1/2 in an atherosensitive ApoE-/- 
mouse line, the authors were able to fully block endothelial TGF-β signalling either 
prior or during the induction of atherosclerosis. Receptor knockout prior to induction 
of atherosclerosis, significantly delayed disease onset and reduced plaque size by over 
60%. Suppression of endothelial TGF-β signalling during established atherosclerosis, 
successfully reduced disease progression.  
Crucially, single-cell RNA-sequencing (scRNA-seq) of aortic ECs obtained from 
these models identified a multifaceted EndMT phenotype in atherosclerotic mice with 
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intact TGF-β signalling. Conversely, in the absence of TGF-β signalling, this EndMT 
signature was dramatically reduced despite the ApoE-/- background and high fat diet116. 
 
 
Figure 1.4: EndMT during atherosclerosis. 
Immunofluorescence confocal microscopy of thoracic aortic sections from endothelial lineage tracing 
ApoE−/− mice after 18 weeks high fat diet, showing expression of endothelial lineage marker YFP, 
fibroblast-specific marker Fap and Ve-Cadherin. Figure adapted from Evrard et al, 2016 53. 
 
The vascular remodelling observed during the development of PAH broadly involves 
gross changes to the endothelial, smooth muscle and fibroblast population within the 
local vasculature 14.  Whilst the aetiology of PAH is fairly complex and multifactorial 
in nature, endothelial dysfunction and EndMT have started to gain attention as possible 
mediators during the development and progression of the disease 117.  Accumulating 
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data now suggests that the well described expansion and build-up of α-SMA and 
collagen-producing cells, contributing to the pathophysiological vascular remodelling 
observed in all forms of PAH, is not solely mediated by pulmonary artery SMCs and 
local fibroblasts. These cells may also result from pulmonary artery ECs which have 
undergone EndMT 118–120.  
EndMT was first identified during PAH using an experimental disease model 
supported by endothelial-specific lineage-tracking in mice, reporting the presence of 
endothelial lineage cells expressing αSMA and SM-MHC within the neointima of 
remodelled pulmonary vessels 118. Follow up studies by Ranchoux et al went on to 
show similar in situ evidence of EndoMT in human PAH 120. Here the group identified 
cells co-expressing endothelial (PECAM1, VE-cadherin) and mesenchymal (α-SMA) 
markers in intimal and plexiform lesions from PAH lungs. Interestingly, this was also 
accompanied by increased endothelial expression of TWIST1 in PAH lungs, which 
was not present in control lungs 119,120. Incidentally, overexpression TWIST1 has been 
found to effectively induce EndMT in human PAECs (HPAECs), while knockdown 
not only inhibits hypoxia-induced EndMT both in vitro and in vivo but can also 
attenuate hypoxia-induced PH 121. 
Further, mutations in the BMPR2  gene are commonly found in patients with heritable 
PAH, these are associated with earlier diagnosis and more severe disease progression 
122. Notably, disrupted or impaired BMPR2 signalling has been associated with  
increased activation of canonical and noncanonical TGF-β pathways 123–125. When 
tested in vitro, BMPR2 knockdown in HPAECs results in an increase in SNAI2, but 
not SNAI1, and higher αSMA expression. This effect is again replicated in mice 
lacking endothelial BMPR2 expression, leading to an EndMT-like profile in 
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pulmonary ECs and an enhanced PAH profile 126. 
Lastly, the activation of hypoxia‐inducible factors (i.e HIF1α and HIF2α) is known to 
play an important role in the pathogenesis of PAH 127,128. Acting as transcription 
factors, increased intracellular levels of HIFs can results in the activation of  
transcriptional programs associated with vascular remodelling and inflammation 129. 
In ECs, this pathway was recently reported to directly activate SNAI1/2 expression to 
induce EndMT independently of TGF-β signalling, while its knockdown was sufficient 
to inhibit transition during hypoxia 26,130,131. Remarkably, endothelial-specific deletion 
of HIF-2α significantly attenuated or abolished the progression of hypoxia-induced 
PAH in mice 131.  
Crucial to this thesis, we have continued to expand on the pathophysiological factors 





1.3 Pulmonary Arterial Hypertension 
 
PH is a chronic condition characterised by the progressive obstructive remodelling of 
the pulmonary vasculature leading to a rise in pulmonary arterial pressure (PAP) and 
pulmonary vascular resistance (PVR). Cumulatively these structural and functional 
changes impose a sustained increase in pressure load on the right ventricle (RV) 
resulting in its hypertrophy and ultimately failure 132–134. Despite being generally 
defined as an increase in mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, 
it can arise from a variety of aetiologies and often presents with a wide spectrum of 
severities and symptoms. The most up-to-date classification strategy, based on the 5th 
World Symposium 132 and latest ESC/ERS Guidelines 133, categorises PH into five 
major groups: 1) PAH; 2) PH due to left heart disease; 3) PH due to interstitial lung 
diseases and/or hypoxia, including chronic obstructive pulmonary disease and 
sustained exposure to high altitude; 4) chronic thromboembolic PH; and 5) PH with 
unknown and/or multifactorial mechanisms, including hematologic, systemic and 
metabolic disorders (Table 1.1). These are largely grouped based on shared 
pathological mechanisms, clinical features, and therapeutic options, allowing for in-
depth study and sub-categorisation of each group. 
Given the complex heterogeneity of PH, and in order to avoid excessive disease 
characterisation, this thesis will largely focus on the more physiologically relevant 
PAH. PAH itself can be categorised into several subgroups such as idiopathic 
pulmonary arterial hypertension (IPAH), heritable PAH (HPAH) if there is a family 
history of PAH; or associated PAH (APAH) if other causes, such as HIV infection, 
portal hypertension or congenital heart disease, are involved (Table 1.1) 132–134.    
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1 Pulmonary arterial hypertension  
1.1 Idiopathic PAH  
1.2 Heritable PAH  
   1.2.1 BMPR2  
   1.2.2 Other mutations  
1.3 Drug and toxin induced  
1.4 Associated with:  
   1.4.1 Connective tissue disease  
   1.4.2 HIV infection 
   1.4.3 Portal hypertension 
   1.4.4 Congenital heart disease  
   1.4.5 Schistosomiasis  
1’ Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis  
1’.1 Idiopathic PAH  
1’.2 Heritable PAH  
   1’.2.1 EIF2AK4 
   1’.2.2 Other mutations 
1’.3 Drug, toxin and radiation induced  
1’.4 Associated with:  
   1’.4.1 Connective tissue disease  
   1’.4.3 HIV infection  
1’’Persistent pulmonary hypertension of the newborn (PPHN) 
2 Pulmonary hypertension due to left heart disease 
2.1 Left ventricular systolic dysfunction  
2.2 Left ventricular diastolic dysfunction  
2.3 Valvular disease  
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital Cardiomyopathy  
2.5 Congenital/acquired pulmonary vein stenosis 
3 Pulmonary hypertension due to lung diseases and /or hypoxia  
3.1 Chronic obstructive pulmonary disease  
3.2 Interstitial lung disease  
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern  
3.4 Sleep-disordered breathing  
3.5 Alveolar hypoventilation disorders  
3.6 Chronic exposure to high altitude  
3.7 Developmental lung diseases  
4 Chronic thromboembolic pulmonary hypertension 
5 Pulmonary hypertension with unclear multifactorial mechanisms 
5.1 Hematologic disorders: chronic hemolytic anaemia, myeloproliferative disorders, splenectomy  
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis  
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders  
5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH 
Table 1.1: Comprehensive clinical classification of pulmonary hypertension.  
Table adapted from the 2015 ESC/ERS Guidelines for the diagnosis and treatment of PH 133. 
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These subgroups, despite the different aetiologies, share several similar 
pathophysiological features and thus treatment strategies. 
One of the larger European datasets on PAH comes from a 2006 French multicentre 
registry, initiated in 17 hospitals throughout the country and collecting data on 674 
adult patients with the disease over a 3-year period 135. The register estimates a 
population prevalence 15 cases per million adult inhabitants with an annual incidence 
of 2.4 cases per million. Interestingly, a large Scottish dataset collecting data on 374 
PAH patients hospitalised between 1986 and 2001, suggests a much higher population 
prevalence of 52 cases per million population with an incidence of 7.1 cases per 
million 136. Although these numbers have lowered considerably by 2005, with a 
prevalence of 26 cases per million population, these estimates still remain 
comparatively high to the French cohort 136. A similar trend is seen in the United 
Kingdom and Ireland with a total of 482 patients were diagnosed in 2009, showing an 
annual incidence of 6.6 cases per million 137.  
Further, based on current estimates, the vast majority of patients are diagnosed with 
IPAH. From the French 674 PAH patient register, 39.2% were diagnosed with IPAH, 
3.9% with HPAH and the remaining 56.9% with a variety of other associated 
conditions 135. Other large cohorts from the US show similar distributions with 46.5% 
cases diagnosed as IPAH, 2.9% as HPAH and 50.6% as APAH 138.  
Lastly, while variable, the majority of published studies also suggest a significantly 
higher prevalence in females. The French cohort, for example, suggested a female 
predominance at a ratio of 1.6:1 for IPAH, 2.2:1 for HPAH and 14.9:1 for APAH 135.  
 
Heritable forms of PAH, although less common, are often of interest in the study of 
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the disease as they may provide additional clues to how it develops and progresses. 
Although previously mapped to a 3-cM region on chromosome 2q33 139–141, termed 
primary pulmonary hypertension 1 (PPH1), a genetic linkage analysis of 35 families 
with a history of PAH published in 2000 was the first to report shared mutations within 
the BMPR2 gene locus 122. Since then, not only over 300 mutations in the BMPR2 
gene have been reported 142–145, but also within the activin receptor-like kinase-1 
(ACVRL1) 146 and endoglin (ENG) genes 147.  
BMPR2 mutations in particular have been found to be present in up to 75% of HPAH 
patients 148. Compared with noncarriers, patients with BMPR2 mutations are younger 
at diagnosis and present with more severe hemodynamic compromise 149. The BMPR2 
gene itself encodes for a serine/threonine kinase receptor which is specifically 
recognised by BMPs belonging to the TGF-β superfamily. Activation by BMP ligands 
will lead to the recruitment of receptor-regulated SMAD proteins, typically SMAD 
1/5/8, which in a complex with SMAD4, will enter the nucleus to promote the 
expression of transcription factors like ID1/2/3 to regulate cell function 150–152. In the 
lung this signalling cascade is believed to play an important role in maintaining 
vascular homeostasis. With vascular ECs, for example, impaired BMPR2 signalling 
has now been linked to increased pro-inflammatory response 153, loss of barrier 
function 154 and apoptosis 155,156.  Recent reports also show an increase activation of 
canonical TGFβ-SMAD2/3 and lateral TGFβ-SMAD1/5 signalling, which may 
facilitate activation of processes such as EndMT 125. Notably, BMPR2 expression has 
also been found to be significantly decreased not only in other forms of PAH but also 
other PH groups 145,157, as well as in a variety of experimental models of PH 158,159. 
While less common, mutations to the ACVRL1 gene, also known as ALK1,  have been 
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described in PAH 146,160,161. Similar to BMPR2, ACVRL1 is a serine/threonine-protein 
kinase cell-surface receptor for the TGF- β superfamily. It interacts with four major 
ligands, TGF-β1 and TGF-β3, in a complex with TGF-βRII; and with BMP-9 and 
BMP-10, in a complex with the ActRIIA or BMPRII 56,59,60,110,162. Activation of these 
pathways has been linked to variety of EC functions including developmental and 
pathological angiogenesis 59. Unsurprisingly,  ACVRL1 defects been also been 
suggested to have a role in the arterialisation and remodelling of arteries in other 
vascular disorders such as hereditary haemorrhagic telangiectasia (HHT), 
characterised by development of arteriovenous malformations 163. Crucially, activation 
of ACVRL1 by TGF-β can also antagonise ALK5 activity and with it the activation of 
the SMAD2/3 cascade 56,57 linked to EndMT (described in Section 1.2). 
It’s worth nothing that given the significantly lower prevalence of heritable forms of 
PAH, it is clear that other factors are also involved in the initiation and progression of 
PAH. As referenced previously, PAH also has a higher prevalence in females. This, 
however, seems to happen irrespective of BMPR2 mutation status 123, again suggesting 
that additional factors may also be at play.  
 
Despite its complex aetiology, likely to vary depending on the underlying genetic or 
pathogenic cause 164, PAH is largely associated with progressive structural and 
mechanical changes to the vascular wall, leading to sustained vasoconstriction and 
narrowing of both proximal and distal pulmonary arteries 4,165–167. Described as 
pulmonary vascular remodelling, this process is generally characterised by alterations 
to the migratory and proliferative profile of the resident endothelial, smooth muscle 
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cell and fibroblast population, often accompanied by increased apoptotic resistance 
and glycolytic metabolism 168,169.  
 
Figure 1.5:  Histology of vascular remodelling in PAH.  
Top panel: Plexiform lesions. Upper left, evidence of cell proliferation as shown by proliferating cell 
nuclear antigen (PCNA) in red and αSMA (SM) in green. Bottom panel: Medial hypertrophy, intimal 
hyperplasia and adventitial fibrosis. Figure adapted from Archer et al, 2011 168. 
 
Cumulatively, these changes result in intimal hyperplasia, medial thickening 
(hypertrophy) and adventitial fibrosis across muscular pulmonary vessels (500-70 µm 
in diameter) leading to eventual occlusion, along with the formation of plexiform and 
complex concentric lesions (Figure 1.5) 166–170. With distal pre-capillary arterioles (70-
20 µm in diameter), in addition to loss and obliteration, we also see increased vessel 
muscularisation with appearance of cells expressing mesenchymal markers 119,131,170–
172. Adding to the changes seen across the distal pulmonary arteries and arterioles, 
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pathological vascular remodelling can also affect the larger main, lobar and segmented 
pulmonary arteries of patients with PAH 167,173. Increased wall thickness has been 
shown to occur in these vessels, leading to decreased vascular compliance and 
ultimately stiffening of the elastic proximal pulmonary arteries, which is strongly 
related to mortality in patients with PAH 173–177. 
 
Based on histological analysis of pulmonary artery cross sections, the intima will 
normally account for 10% of the vascular wall. However, this has been found to be 
significantly increased in PAH, irrespective of cause (Figure 1.6). As demonstrated by 
Statcher and colleagues, the PAH lung vasculature can present with up to 3-fold 
increase in intimal fractional thickness 165. This thickened intima was associated with 
a 40-fold increase in pulmonary vascular resistance, making these structural changes 
of significance importance during disease progression 165.  
During the early stages of PAH, triggered by circulating toxins 178, increased 
production of reactive oxygen species 179 and local autoimmune response 180, resident 
PAEC start to undergo apoptosis which allows for the emergence of a proliferative, 
apoptosis-resistant, SMC-like EC population 181–183. In addition to contributing to 
intimal hyperplasia, this will also stimulate release of mediating factors, such as TGF- 
β1,  which facilitate increased pulmonary arterial SMC (PASMC) proliferation 182,184. 
Moreover, as they proliferate in increasingly disordered patterns, this EC population 
may also contribute to the formation of plexiform lesions, one of the hallmarks of 
advanced PAH (Figure 1.6 F-H) 181,185–187. Nonetheless, we still have a limited 
understanding of how ECs contribute to the formation of these lesions. Interestingly, 
studies have shown the presence of a several angiogenetic markers throughout these 
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lesions, such as vascular endothelial growth factor (VEGF), VEGF receptor 2 
(VEGFR2), and HIF-1α 187. This was confirmed in a recent study using laser-assisted 
microdissection of plexiform lesions from PAH patient lung samples, showing that the 
lesions consisted of vascular channels lined by continuously proliferating ECs 
surrounded by tightly layered mesenchymal/myogenic cells 188. The authors go on to 
show an up-regulation of HIF-1a and TGF-β1 along with variety of other tissue 
remodelling-associated genes, such as Angiopoietin-1 and Thrombospondin-1 188. 
This was accompanied by increased availability of sprouting-associated markers, such 
as NOTCH4 and several matrix metalloproteinases (MPP) 188.  
Additional intima lesions, historically described as intimal fibrosis 189, are also 
frequent in PAH lungs 190. Presenting in laminar or non-laminar formations, these are 
composed of fibroblasts, myofibroblasts and other mesenchymal-like cells, along with 
large deposits of connective tissue including ECM (Figure 1.6 B-E) 191. Laminar 
intimal fibrosis, distinct due to their concentrically arranged fibrotic layers, occlude 
the lumen of small distal pulmonary arteries in patients suffering from IPAH and PAH 
associated with connective tissue diseases such as systemic sclerosis 191,192. 
Interestingly, these are mostly paucicellular despite containing high amounts of ECM.  
However, it is important to note that the extent to which the pulmonary intima is 
compromised during PH can largely vary depending on its aetiology 166. For example, 
intimal fractional thickness has been found to be greater in IPAH pulmonary samples 
compared to other forms of associated PAH 165. This was found to be even higher in 
PAH patients with a known BMPR2 mutation, which may justify the earlier diagnosis 
and more pronounced disease progression seen in these patients 123,165.  
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Figure 1.6:  Pulmonary artery remodelling during PAH.  
A) Medial hypertrophy showing SMC proliferation and adventitial fibrosis (Magnification x200, 
Weigert-hematoxylin-phloxine-saffron staining). B) Concentric non-laminar intimal fibrosis showing 
myofibroblast accumulation (arrows). C) Eccentric intimal fibrosis corresponding to organised 
thrombotic material (Br: bronchus, Ar: pulmonary artery) (Magnification x100, HES staining). D) 
Thrombotic lesion with partial recanalisation by microvessels (Magnification x100, 
HES). E) Concentric laminar intimal fibrosis (Magnification × 200, HES). F) Plexiform lesion with 
proliferation of small sinusoid-like vessels on a fibrotic matrix (Magnification x100, HES). G) Multiple 
dilation lesions emerging of the central plexiform lesion (Magnification × 40, Elastica-van-Gieson 
staining). H) The same plexiform lesion show in G) after immunohistochemical staining with anti-CD3, 
a T-lymphocytic marker (Magnification x100). Figure adapted from Montani et al, 2013 191. 
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In addition to intimal changes, the media layer of the vascular wall will also undergo 
significant remodelling during most forms of mild to moderate PAH. Of note, while 
the normal media thickness will correspond to approximately 5% of the total diameter 
of pulmonary artery wall, during PAH this will increase up to 20% (Figure 1.6 A) 
165,166. This is widely believed to correspond to enhanced PASMC growth and 
proliferation within the media. During this process PASMC are reported to present 
with enhanced proliferative  phenotypes along with increased resistance to known 
apoptosis inducers 193–196. They have also been shown to acquire a synthetic rather than 
a contractile phenotype, increasing production of collagen and elastin 197, further 
supporting the role of a dysfunctional PASMC population which facilitates the 
remodelling pulmonary vasculature. Additionally, factors implicated in the 
pathogenesis of PAH, such as TGF-β1 198, BMP-4 199, serotonin 200 and endothelin-1 
(ET-1) 201, can each induce PASMC hypertrophy, leading to increased cell size, 
contractile protein expression and fractional cell shortening 202. Moreover, PASMC 
behaviour can be greatly influenced by dysfunctional vascular ECs. During PH these 
can decrease production of factors that suppress PASMC proliferation, such as apelin 
203,204 and increase expression of growth factors that enhance proliferation,  such as 
TGF- β1 182,184 and fibroblast growth factor-2 (FGF-2) 205,206.  
Nonetheless, despite the identified disease predisposing increase in PASMC 
proliferation, migration and decreased apoptosis, structural changes to the media 
during PAH will seldom happen in isolation. In fact, isolated medial hypertrophy has 
so far only been described as an early, and partially reversible, event seen in high-
altitude PAH 207. Interestingly, using the well-established Sugen 5146/Hypoxia 
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(SuHx) model of PAH (induced based on a combination of the VEGF receptor blocker 
SU5416 and chronic hypoxia), Taraseviciene-Stewart and colleagues demonstrated 
that PASMC proliferation in the pulmonary vessels largely happened during the early 
stages of the disease and waned at later, more advanced, stages 181,208. Further, while 
previous studies have found the excessive growth of pulmonary vascular cells to be 
associated with predisposing genomic changes 185. Using array-based comparative 
genomic hybridisation (aCGH), a recent publication has demonstrated that the 
genomes of PASMCs explanted from IPAH patient lungs were comparably stable with 
no net gain or loss of genetic material 195. Indicating that the reported altered phenotype 
of PASMC during PAH may not be associated to specific chromosomal abnormalities 
and thus influenced by other factors.  
Lastly, while it is clear that media remodelling and muscularisation of the distal 
pulmonary vascular occurs during PAH, the idea that this is solely due to the increased 
proliferation of a single resident cell population is now continuously being challenged 
as evidence supporting the role of active EndMT during the PAH grows.  
 
Given its complexity and pathological heterogeneity, the treatment of PH often 
requires a tailored multidisciplinary approach in order to improve patient outcomes 209. 
This is particularly true regarding PAH which, despite advancements in treatment 
options, retains unreasonably high mortality rates. Current PAH-specific therapeutic 
approaches mostly target three major signalling pathways that regulate vascular tone 
and are often altered during PAH. Namely, the prostacyclin (PGI2), ET-1 and nitric 
oxide (NO) signalling pathways 191,209. Approved PAH treatments targeting the PGI2 
pathway include a variety of PGI2 synthetic analogues and derivates, along with PGI2 
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receptor (IPr) agonists 133. PGI2 is a major active metabolite of arachidonic acid (AA) 
produced by ECs, acting as an agonist of adenylate cyclase 210. Generally, PGI2 
synthetic analogues and IPr agonists, like endogenous PGI2, will activate IPr which in 
turn signals adenylyl cyclase to produce cyclic AMP (cAMP) and thus direct 
vasodilation and inhibition of platelet aggregation in PAH 209.  
Highly expressed in the lung, ET-1 is a potent vasoconstrictor released by the ET-1 
converting enzyme (ECE) found on the membrane of ECs. Activation of the ET-1 
receptors, ET-A and ET-, on PASMCs leads to increased formation of inositol 
triphosphate (IP3) 211. Cytoplasmic IP3 will in turn stimulate the release of calcium by 
the sarcoplasmic reticulum leading to smooth muscle contraction, making it an 
attractive target for the management of PAH 211. Commonly used ET-1 pathway 
targeting strategies include endothelin receptor antagonists (ERAs) such as bosentan, 
which selectively antagonise the binding of ET-1 to ET-A and/or ET-B receptors, 
blocking their activity and thus decreasing pulmonary and systemic vascular resistance 
209,212,213.  
The use of phosphodiesterase type 5 (PDE-5) inhibitors and sGC stimulators is also 
recommended to directly target and modulate the dysregulated NO pathway in PAH 
133,214. As with most vascular beds, NO is essential in the regulation of pulmonary 
vascular tone. NO acts as a SMC relaxant by stimulating soluble guanylate cyclase 
(sGC) and the subsequent conversion of guanosine triphosphate (GTP) to cyclic 
guanosine monophosphate (cGMP). The effects of NO are normally terminated by the 
breakdown cGMP by phosphodiesterase (PDE) enzymes like PDE-5, which are 
abundantly expressed in the PASCMs 214–216. PDE5 inhibitors, such as sildenafil, are 
effective pharmacological agents for the treatment of PAH due to either ability to bind 
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to the PDE5 enzyme and inhibit the breakdown of cGMP, allowing for longer NO 
availability in PASMCs 217,218. Alternatively, sGC stimulators, such as Riociguat, can 
also be used 133,214. Instead of slowing cGMP degradation, these instead mimic the 
effects of endogenous NO and thus increase the production of cGMP. 
Current PAH-specific treatment strategies, recommended by the 5th World Symposium 
132 and latest ESC/ERS Guidelines 133, suggested targeting at least one of the three 
pathways mentioned above. Patients at low or intermediate risk can be initially treated 
with monotherapy, while high risk patients require tailored combination therapy using 
drugs with different action mechanisms. Despite some of the conflicting results seen 
in earlier short-term randomised controlled trials, recent evidence on the long-term 
outcomes indicates that combined PAH treatment strategies can help  improve patient 
quality of life 219.  
Further, in patients that remain unresponsive to maximum combined therapy, bilateral 
lung transplantation continues to be an important treatment option recommended by 
all up-to-date guidelines 133,220. While successful transplantation often leads to 
considerable improvements in patient quality of life, survival rates remain limited. 
According to the International Society for Heart and Lung Transplantation 5-year 
survival transplantation survival rates were of approximately 45 to 50% in 2006 221. 
Notably, recent reports now place 5-year survival rates at 52-75% 222,223 and 45-66% 
at 10 years 224. 
Ultimately, while the development of PAH-specific therapies has greatly improved 
patient symptoms, these remain largely palliative, mostly slowing down the 
progression rate of the disease with limited long-term patient survival. Data collected 
from a 2003 French national register comprised of 354 adults patients with idiopathic, 
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heritable, or anorexigen-associated PAH, estimated one, two and three year survival 
rates at 82.9%, 67.1% and 58.2%, respectively 225. Recent data from the UK and 
Ireland accounting for 479 patients in the national pulmonary hypertension registry, 
reports one, two, three and five year survival rates of 92.7%, 84%, 73.3%, and 61.1%, 
respectively 137. Crucially, patients with associated co-morbidities tend to also have 
worse outcomes. In a recent US population study, patients with systemic sclerosis 
(SSc) and incident group I PAH had cumulative survival rates of 93%, 88%, and 75% 
at one, two and three years after diagnosis, respectively 226. Pregnancy is considered 
one of the major contradictions in PAH, associated with 30-50% increased mortality 
rates in patients, thus current guidelines continue to recommend the use of effective 
contraception methods for women of childbearing age with PAH 227.  
In conclusion, it is clear that our understanding of the mechanism underlying PAH 
remains far from complete and we must continue to explore novel therapeutic avenues.  
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1.4 Non-Coding RNA Biology and Function 
With only an estimated 1.2% of the human genome coding for proteins 228,  focus is 
positioned to assess the possible functional roles for the other 98.8% of the genome 
with little to no protein-coding capacity 229. While their function is often debated 230, 
ncRNA transcripts compose approximately 70 to 80% of our genome and include 
thousands of operationally significant RNAs implied in all manner of biological 
processes 231–233. These include, not only the thoroughly described transfer RNAs 
(tRNA) and ribosomal RNAs (rRNA), but also small nucleolar RNAs (snoRNA) and 
PIWI-interacting RNAs (piRNAs), among others. From these novel ncRNA 
categories, the miRNA and lncRNA gene families have sparked great interest within 
the research community as they have been found to be critical in development and 
dysregulated in disease. 
The development of high-throughput RNA sequencing (RNAseq) approaches now 
adds extraordinary range and depth to ncRNA gene profiling; making it easier to 
distinguish miRNAs from other similar transcriptional products and to identify any 
post-transcriptional effects they may have on specific genes. The same applies to the 
highly abundant, yet poorly characterised, lncRNAs.  
 
 
Since their discovery in 1993, miRNAs have emerged as regulators for several cellular 
processes, from apoptosis and proliferation, to stress response reactions 234. 
Ubiquitously expressed in all human cells, miRNAs regulate mRNA translation by 
binding to their complementary base-pair sequences on the 3’UTR of mRNA 
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transcripts and ultimately suppressing protein synthesis 235,236 (Figure 1.7). MiRNA 
biogenesis is a complex multi-step process and, in a rapidly evolving field, our 
understanding of it continues to develop. The basis of this process, however, has now 
been thoroughly described.  
MirRNA host genes are first transcribed in the nucleus by RNA polymerases to 
produce ~1 kb long primary miRNAS (pri-miRNA), normally arranged in a stem-loop 
structure with two long single-stranded flanking regions 237,238. This transcription 
process is commonly performed by the RNA polymerase II (Pol II) multiprotein 
complex, however in specific cases where Alu elements are present within the 
promoter region this can also be carried out by RNA polymerase III (Pol III) 239,240. 
Interestingly, multiple miRNA clustered in the same region can often be transcribed 
within a single pri-miRNA and processed separately at later stages 241. 
Once transcribed, the pri-miRNA structure is further processed into a 70 to 120 
nucleotide-long premature miRNA (pre-miRNA) hairpin stem loop by a nuclear 
microprocessor complex composed of the RNase type III enzyme Drosha, and the 
RNA binding protein DGCR8, also known as Pasha 241,242.  
Next, the pre-miRNA hairpin is moved into the cytosol for further maturation. 
Transportation into the cytoplasm is accomplished through Exportin-5 (XPO5) in 
complex with the GTP binding nuclear cofactor Ran-GTP. A defined length of the 
stem-loop overhangs is crucial for successful binding by XPO5, ensuring that only 
correctly processed pre-miRNAs are translocated 241. In the cytoplasm, the pre-
miRNA is further processed by the RNase III enzyme Dicer, which cleaves the loop 
regions of the pre-miRNA to form a miRNA duplex 243. This is achieved in complex 
with the transactivation response RNA binding protein (TRBP) and protein activator 
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of PKR (PACT) and Argonaute 2 (Ago2), which form the RNA-induced silencing 
complex (RISC) 244–247. Crucially, after incorporation only one miRNA strand remains 
active (guide strand) within the RISC complex while the second strand (passenger 
strand) is often degraded. With regards to strand selection, while both the 5p end (from 
the 5’ arm of the pre-miRNA duplex) and the complementary 3p end (from the 3’ arm) 
have the potential to function as a guide strand, preference seems to be given to strands 
with a less stably paired 5’ ends possessing either A or U as their terminal nucleotides 
248–251.  
Finally, the mature miRNA guides the RISC complex to complementary sites on 
messenger RNAs (mRNA), leading to epigenetic regulation via mRNA degradation or 
translation inhibition. Target recognition by the RISC complex will happen via the 
binding of the miRNA seed sequence to its complementary target normally found 
within the 3’ UTR of mRNAs 241. This canonical seed/target-site complementarity 
forms the basis for most miRNA target prediction algorithms available today 252–254. 
Generally, the miRNA-bound RISC complex can silence gene expression via target 
mRNA degradation (through mRNA cleavage or deadenylation) or translation 
repression. While mRNA cleavage by Ago2 is possible, this is rare in mammals 
requiring seed sequences perfectly complementary to that of the target mRNA255. 
MiRNA-mediated degradation by deadenylation is present in 66-90% of events, 
accounting for the vast majority of mRNA silencing 256. Via this pathway the target 
mRNA is first deadenylated by the Ccr4–Not and Pan2–Pan3 deadenylation 
complexes 257. Once deadenylated, the mRNA is decapped by the aptly named 
decapping protein 2 (DCP2) and ultimately degraded through the action of the 
cytoplasmic nuclease exoribonuclease 1 (XRN1) 258,259. 
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Less common, translation repression is also another form of miRNA-mediated gene 
silencing seen in mammalian cells.  While this process is now believed to happen 
through the inhibition of cap-dependent translation via RNA helicases such as eIF4A, 
our understanding of the precise molecular mechanisms that define this remain unclear 
260–263. 
 
Figure 1.7:  Standard microRNA biogenesis and function.  
MiRNA genes are first transcribed in the nucleus by RNA polymerases as pri-miRNA, and further 
processed into a long oligonucleotide stem loop pre-miRNA by a protein complex composed of drosha, 
and DGCR8. In an alternate pathway, miRNA genes are transcribed directly as short hairpin pre-
miRNA. The pre-miRNA is then pumped into the cytosol by Exportin-5, where it is further processed 
by Dicer, which cleaves the loop regions of the pre-miRNA to form a miRNA duplex. Facilitated by a 
TRBP, the two strand microRNA duplex is incorporated into the RISC along with Ago2 and other RNA 
binding proteins. After incorporation, only one miRNA strand remains active (guide strand) within the 
RISC complex while the second strand (passenger strand) is degraded. The miRNA guides the RISC 
complex to complementary sites on mRNAs, leading to epigenetic regulation via mRNA degradation 
or translation inhibition. Figure adapted from Bhaskaran & Mohan, 2014 264.  
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Due to their prevalence, miRNAs have been put forward as possible biomarkers and 
treatment targets for many pathologies, from cancer to renal fibrosis and CVD 265. 
Numerous miRNA signatures have now been found to be associated with various types 
of cardiovascular disease, including atherosclerosis 6, myocardial infarction 266, heart 
failure 267  and hypertension 268. This is of particular significance in the endothelium, 
with multiple miRNAs starting to be identified in ECs, regulating their behaviour and 
significantly affecting the process of vascular remodelling.  For example, within the 
vascular endothelium, the targeted disruption of the Dicer gene and consequent loss of 
miRNA maturation, leads to significant abnormalities in endothelial biology, directly 
impacting on EC survival and migration 269,270. 
Harris and colleagues 271 demonstrated that miRNAs may also impact the development 
vascular inflammation. The endothelial-specific miR-126, abundantly found in resting 
adult ECs, was shown to suppress vascular inflammation by inhibiting the expression 
of the vascular cell adhesion molecule 1 (VCAM-1). Expression of VCAM-1 itself is 
increased by pro-inflammatory cytokines and allows for leukocyte adhesion to the cell 
surface as an inflammatory response such as that observed during early phase 
atherosclerotic disease 271,272. 
Developmental studies in ECs have also shown miR-221 and 222 to control the activity 
of stem cell factor (SCF) by targeting its receptor c-Kit 273. Often a marker for 
progenitor cells, stem cell factor/c-kit signalling has been repeatedly associated with 
increased cell survival, migration and capillary tube formation 274. Recently, both miR-
221/222 and miR-155 were found to negatively correlate to the expression of ETS1 
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genes, involved in the control of various endothelial-mediated inflammatory 
molecules during vascular inflammation and remodelling 275,276. 
Within the wider spectrum of disease, accumulating evidence suggests that miRNAs 
can significantly modulate many of the pathological vascular remodelling processes 
which lead to PH.  The miR-143/145 axis, for instance, appears to be dysregulated in 
mouse models of PH being over expressed in remodelled vessels 277,278. Furthermore, 
previously published work by our group as described a novel miR-143-3p-mediated 
cell-to-cell communication pathway between pulmonary vascular cells which 
contributes to altered cell migration in PH. Inhibition of this pathway, by miR-143-3p 
knockdown, effectively blocked experimental PH in mice exposed to chronic hypoxia 
279.  
Outside of PH, the key regulatory roles of miRNAs continue to emerge in other 
vascular remodelling scenarios such as in-stent restenosis 280 and vein graft 
remodelling 281. 
 
Given the role of EndMT during vascular remodelling, the past decade as also seen 
increasing numbers of publications citing miRNA-based regulatory pathways. 
Published data from microarray analysis has mostly revealed tenuous links between 
specific miRNAs and EndMT during different cardiovascular disease states with no 
specific mode of action 282. Nevertheless, a recent report has shown that the 
constitutively active miR-31 was required for the modulation of mesenchymal markers 
such as α-SMA, actin reorganisation and myocardin-related transcription factor A 
(MRTF-A) activation. A putative mechanism for this phenomenon includes the 
guanine nucleotide exchange factor VAV3, associated with actin remodelling and 
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MRTF-A activity, which was identified as a possible target for miR-31 283.  Tumour-
associated EC studies further suggest that the cell-specific miR-302c, when over 
expressed in HUVEC, reduces cell motility and alters the expression levels of EndMT 
markers – namely, VE-cadherin is up-regulated, whereas β-catenin, FSP1, and α-SMA 
are down-regulated 284. Reporter assays also revealed that miR-302c may directly 
inhibit metadherin (MTDH) expression by binding to the 3′UTR of its mRNA and 
suppressing its translation. In fact, silencing of MTDH expression in HUVECs also 
leads to lower levels of β-catenin, FSP1 and α-SMA 284. 
 
 
Although the regulatory role small ncRNAs is now well established, the concept of 
widespread control of cell function by lncRNAs has only been advocated within the 
last decade 285. Originally believed to be non-functional transcriptional by-products, 
lncRNAs have started to spark great interest with an increasing number of studies 
describing them as critical in development and dysregulated in disease 286.  
Generally defined as transcripts longer than 200 bp in length without any protein 
coding potential, lncRNAs are significantly less abundant than their mRNA 
counterparts and have a higher rate of evolutionary turnover 287. Recent publications 
now estimate that nearly 27,000 lncRNA transcripts are produced in humans with over 
1,000 of those conserved in mammals 287,288. 
Biogenesis 
Unlike miRNA biogenesis, which has been extensively studied, our understanding of 
the lncRNA transcriptional process is still somewhat limited. Nonetheless, several 
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studies commonly draw parallels between lncRNA biogenesis and that of protein-
coding RNAs. Indeed, much like mRNAs, most known lncRNAs have distinct multi-
exonic structures, which are subject to alternative splicing, polyadenylation and 5’ 
capping 289–292. For instance, in a ground-breaking genome-wide chromatin-state 
analysis, Guttman and colleagues suggest that transcribed lncRNAs can present with 
epigenetic marks at their promoter regions similar to that of mRNAs, including 
increased trimethylation of lysine 4 of histone 3 (H3K4me3) 293. LncRNA transcription 
is also reported to be largely carried out by the action of the RNA polymerase (RNAP) 
II complex 294–296. This was demonstrated in a recent experiment where HeLa cells 
were exposed to the RNAP II inhibitor, α-amanitin, and their transcriptional profile 
analysed using a custom oligoarray interrogating thousands of lncRNA and protein-
coding transcripts 297. In a similar fashion to mRNA transcripts, lncRNAs showed 
significantly supressed expression levels following α-amanitin treatment 297. 
Interestingly, RNAP III-dependent mechanisms may also be possible as similar 
experiments report continued expression of some lncRNAs despite α-amanitin 
treatment 294. 
With regards to polyadenylation, while several transcripts retain polyadenylation 
signals and are subsequently processed by canonical poly(A) polymerase activity, non-
polyadenylated lncRNAs have also been described 298,299. Notably, it is possible that 
the number of non-polyadenylated lncRNAs has been historically underestimated 
when analysing RNAseq results due to the common use of oligo(dT) primers for 
cDNA synthesis, which select for poly(A)-containing transcripts. 
Lastly, a crucial feature that discriminates lncRNA from mRNA transcripts is the lack 
of sequence similarities between lncRNAs and low conservation across different 
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species, making their transcriptional patterns hard to predict and classify 300. 
Nonetheless, lncRNAs such as Xist (X-inactive specific transcript), despite having 
poor linear sequence conservation, share key common functional features with 
homologues present in other species 301–304. Conservation analysis studies also show 
that the promoter regions of lncRNAs are generally conserved at levels similar to that 
of protein-coding genes, suggesting a retention of the regulatory machinery rather than 
their transcribed sequence 300,305.  
Classification 
While collectively lncRNAs may evade an exact definition other than their 
transcriptional length, they can be classified into a variety of subclasses based on the 
attributes originally used to detect and study them. Among others, this includes their 
genomic association to neighbouring protein coding genes, the chromatin signatures 
of their transcriptional start sites (promoter, enhancer), their mode of regulation 
(transcriptional vs post-transcriptional), cellular localisation and functional 
mechanism (Figure 1.8) 306.  
Serving as the foundation for the GENCODE categorisation of lncRNAs, their 
genomic location with respect to neighbouring protein-coding genes allows for the use 
of five distinct categories: sense, antisense, bidirectional, intronic or intergenic 
289,306,307. Sense and antisense lncRNAs, for example, are RNA molecules partially 
overlapping one or more exons of a protein-coding gene and are transcribed from 
either the same (sense) or opposite (antisense) strand. Sense-overlapping lncRNAs can 
be broadly thought of as non-coding transcript variants of protein-coding genes, as 
they overlap with same genomic strand while lacking the needed open reading frames 
(ORF) for protein translation 306. This category includes un-spliced partially intronic 
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RNAs, known as PINs, and mRNA-like spliced transcripts 306. Antisense-overlapping 
lncRNAs have on average 10-fold lower expression levels and are often less likely to 
be spliced 308,309. Further, bidirectional lncRNAs are RNA molecules whose 
transcription can be initiated in a divergent fashion from a promoter of a protein coding 
gene. While there is no exact cut-off distance, bidirectionality is usually defined if the 
two transcription start sites are within a few hundred bases pairs and 1 kb distance 
from each other 310,311. Interestingly, while bidirectional lncRNAs seem to mostly 
share similar expression patterns with their protein coding neighbouring locus 311, 
inverse expression patters are also possible 312,313.   
In contrast to the overlapping-sense and antisense categories, intronic lncRNAs are 
located exclusively within the intronic region of protein-coding genes without 
intersecting any exons 294. Found in a sense or antisense orientation, these can either 
be independently transcribed or display transcriptional patterns similar to that of the 
overlapping protein-coding transcript, indicating a shared transcriptional regulation 
294. Finally, intergenic lncRNAs, also known as long intergenic non-coding RNAs 
(lincRNAs), are located between the loci of two protein-coding genes but have 
separate transcriptional units. Most definitions of this category require the lincRNA to 
be 5-1 kb away from the nearest protein-coding genes 293. 
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Figure 1.8:  LncRNA Classification and Function.  
Several LncRNA categories exist based on their transcription start site, surrounding coding genes and 
regulatory function. Based on their transcriptional start site, these can be either promoter-driven or 
enhancer-derived. Relative to the surrounding coding genes and transcriptional direction, lncRNAs can 
be categorised as sense-overlapping, intronic, antisense, bidirectional or intergenic. LncRNAs whose 
function has been characterised tend to fall into distinct groups based on their molecular interactions. 
By interacting with a variety of RNA binding proteins, lncRNAs can act to control activity or 
localisation of a specific protein or play a structural role within a larger protein complex. LncRNAs can 
also act as transcriptional regulators by interacting with transcription factors, or by recruiting chromatin 
modifying complexes to a specific gene locus. In addition to acting as miRNA host genes, lncRNA can 
also act as miRNA sponges, titrating away specific miRNAs for degradation. At the post-transcriptional 
level, lncRNAs can also participate in mRNA translation and degradation. Figure adapted from 
Monteiro et al, 2019  314.  
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Cellular localisation 
LncRNAs also show a variety of subcellular distributions allowing for an additional 
subset of lncRNA categories to be described. LncRNAs are found to accumulate 
predominantly in either the cytoplasmic or nuclear cellular fractions, but can also be 
distributed between both 315. For example, in ECs, different subpopulations can 
express high levels of the nuclear enriched lncRNAs such as TUG1, MEG3, and 
MALAT1 316, while the lncRNA SENCR shows both cytoplasmic and nuclear 
accumulation 317. 
Additionally, as demonstrated by the 2012 ENCODE consortium, lncRNAs appear to 
localise to distinct nuclear subdomains, adding a further layer of complexity to 
lncRNA categorisation 232. The extensively described nuclear lncRNAs NEAT1 and 
MALAT1, despite the proximity of their respective genomic locus (approximately 53 
kb apart within Chromosome 11), appear to localise in distinct nuclear compartments. 
MALAT1, for example, can be found within splicing factor-enriched subnuclear 
compartments known as nuclear speckles, where it is reported to regulate alternative 
splicing of pre-mRNAs 318–320.  On the other hand, NEAT1 has been shown to be 
involved in nucleating and maintaining the paraspeckle nuclear domain 321–324. 
Additionally, the lncRNA Xist is found distributed along the target X-chromosome, 
where it silences gene expression by triggering repressive chromatin modifications 325–
328.  
While many of these lncRNAs may be catalytically inactive on their own, by binding 
and coordinating specific regulatory protein complexes they aid in shaping nuclear 
compartmentalisation 329. Unsurprisingly, this subcellular localisation is often 
indicative of lncRNA function within the cell, which we will describe in more detail. 
71 
Function 
In comparison to the tens of thousands of annotated lncRNAs genes, relatively few 
have been functionally characterised. Nonetheless, those who have demonstrate a 
remarkable mechanistic diversity with epigenetic, transcriptional and post-
transcriptional effects, able to activate or suppress gene expression and translation 
(Figure 1.8) 292,330.  
At the transcriptional level, several lncRNAs have been shown to bind chromatin-
modifying complexes either activating or repressing gene expression 331,332. Over the 
past decade many publications have started to elucidate the mechanism of several such 
lncRNAs, including Xist 333 and HOTAIR (HOX transcript antisense RNA) 334. Xist, 
for example, is now established as one of the master regulators of X‐chromosome 
inactivation (XCI) in female eutherian mammals 335. Upon expression, the lncRNA is 
retained within its transcriptional region where it will start to coat the X-chromosome 
with the aid of RNA and DNA-binding proteins such as SAF-A (scaffold attachment 
factor-A, also known as HNRNPU) 336–338. The lncRNA can then recruit Polycomb 
group complexes (PcG), such as PRC2, catalysing H3K27 histone trimethylation 
leading to chromatin modification and transcription inactivation 335,339,340.  It is 
important to mention, however, we still do not have a complete understanding of how 
Xist carries out its function and, in addition to the interaction described here, several 
other accompanying XCI models have been proposed 341. Similarly, in a seminal paper 
by Rinn et al, HOTAIR was also shown to regulate PcG-mediated transcription 
inactivation of the HoxD gene cluster 334. In a series of in vivo experiments, Li and 
colleagues further demonstrated that HOTAIR binds to PRC2 and Lsd1, catalysing 
H3K27 methylation and  H3K4 demethylation, respectively 342.  
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In addition, lncRNAs can also regulate gene expression by interacting with specific 
DNA sequences and forming RNA-DNA hybrid duplex or RNA-DNA triplex 
structures with key regulatory regions 343–345. A recent study by Mondal and colleagues 
demonstrated that the chromatin-interacting lncRNA MEG3 (Maternally expressed 
gene 3) will bind GA-rich target sequences which allow for the formation of RNA–
DNA triplex structures. The group showed that this allowed for the recruitment of 
chromatin modifiers to promoter regions of TGF-β pathway genes, including TGFBR1 
346. The same study went on to suggest that these RNA-DNA triplex structures are 
widespread in vivo and may be a common mechanism for target-site recognition and 
gene regulation by lncRNAs 346.  
In some cases, lncRNA transcription itself can have an in cis regulatory function that 
affects the expression of neighbouring genes.  This was recently demonstrated in a 
large-scale study by Engreitz and colleagues looking the effects of manipulating the 
genetic locus of several lncRNAs on the expression of nearby genes. Using variety of 
CRISPR/Cas9-mediated genome editing strategies, the group demonstrated that 5 out 
of 12 lncRNA loci studied had an impacted gene expression in a sequence-independent 
manner 347. For example, changes to the length of the transcribed region of the lncRNA 
Blustr (Bivalent Locus Sfmbt2) affected the total amount of Sfmbt2 activation (located 
5 kb upstream of the Blustr locus), but changes to the lncRNA sequence did not 347. 
Another proposed mechanism involves the reannealing of the nascent RNA to the 
DNA template, which gives rise to RNA-DNA hybrid structures known as R-loops 348. 
For example, as it is transcribed the antisense lncRNA VIM-AS1 forms an R-loop 
structure around the promoter region of the gene coding for vimentin (VIM). In 
epithelial cell lines, this lead to chromatin structural remodelling which in turn 
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facilitated the binding of transcriptional activators of the NF-κB pathway 349. 
Additionally, they can also act as decoys for DNA-binding proteins and prevent their 
association to a target gene 350,351. The lncRNA H19 was previously shown to directly 
inhibits p53 activation, resulting in altered gene expression profiles and with that 
promoting gastric cancer progression 352. Further, the growth arrest-specific 5 (Gas5) 
lncRNA regulates cancer cell growth by directly interacting with the DNA-binding 
domain of the glucocorticoid receptor (GR) acting as a decoy glucocorticoid response 
element (GRE) and thus suppressing its transcriptional activity 353–355. 
At the post-transcriptional level, a growing number of studies have also implicated 
lncRNAs at various stages of control by regulating mRNA stability 356 or enhancing 
mRNA translation357. For instance, the lncRNA TINCR (Terminal differentiation-
induced ncRNA) has been shown to directly interact with the protein Staufen 1 
(STAU1) to mediate mRNA stabilisation. This was seen in human cancer cell lines, 
where the TINCR-STAU1 complex is able to impair Krüppel-like factor 2 (KLF2) 
mRNA stability, thus supressing its growth-inhibitory and pro-apoptotic functions 358. 
Interestingly, previous studies have suggested that a 25-nucleotide motif, aptly named 
TINCR box, is strongly enriched in mRNAs targeted by TINCR 359.  
Historically, some lncRNA have also been described as host genes for miRNA found 
within their locus. One of the first published examples of this was H19, whose 
expression was strongly associated with that of the H19-derived miR-675 360. 
Conversely, lncRNAs can additionally show the ability to function as decoy molecules 
for mature miRNAs 361,362. Several publications have started to describe biologically 
significant cross-regulatory interactions between noncoding RNAs classes, adding a 
further functional role for lncRNAs which we will discuss further in Section 1.4.3. 
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While examples of miRNA-mediated vascular remodelling are vast, they are not the 
only ncRNAs implicated throughout the pathological process.  It is now becoming 
clear that abnormal lncRNA levels are linked to aberrant cell migration, proliferation, 
and function, all defining features of active vascular remodelling.  As one of the 
foremost cellular basis for the vascular remodelling process and the focus of early 
lncRNA research, the past two decades have seen several lncRNA emerge as 
regulators of SMC function. One of the first examples of this is the lncRNA ANRIL 
(Antisense noncoding RNA in the INK4 locus), identified by disease genomewide 
association studies (GWAS) within one of the best known genetic susceptibility locus 
for coronary artery disease (CAD), atherosclerosis and type 2 diabetes 363–366. ANRIL 
has since been shown to regulate VSMC growth and proliferation through 
neighbouring genes CDKN2A/B 367,368. More recently, the lncRNA GAS5 (Growth 
arrest specific 5) has also emerged as a negative regulator for VSMC survival in 
vascular remodelling, able to suppress cell proliferation and neointima formation in a 
vascular injury model 369.  
Within ECs, the first regulatory lncRNA to be studied was tie-1AS, transcribed 
antisense to the tie-1 gene (tyrosine kinase containing immunoglobulin and epidermal 
growth factor homology domain-1) in zebrafish, mouse, and humans. Expressed 
during embryonic development, the lncRNA was shown to regulate tie-1 levels by 
selectively binding and degrading the mRNA, resulting in specific defects in EC 
contact junctions 370. Contemporary publications also identified the ubiquitously 
expressed nuclear lncRNA MALAT1, whose knockdown in ECs was able alter cell 
proliferation and induce a pro-migratory response 316,371. Crucially, in vivo both genetic 
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deletion and pharmacological inhibition of MALAT1 effectively inhibited 
proliferation of ECs leading to reduced neonatal retina vascularisation 316. Building on 
these earlier studies, a growing number of lncRNAs have since been linked to all 
manners of endothelial function, including not only EC proliferation and migration 
(e.g. MALAT1, H19), but also angiogenesis (e.g. MEG3, MANTIS), inflammatory 
response (e.g. UMLILO, LISPR1) and, more recently, EndMT (e.g. GATA6-AS). We 
will continue to explore these EC-specific regulatory functions in Section 1.5. 
Lastly, in the setting of pulmonary hypertension, lncRNA research is still limited. 
Despite the emerging cell-specific, regulatory function suggested, these have yet to be 
translated into the clinical setting. However, preliminary studies have already 
identified over 300 lncRNAs  differentially expressed among rat models of pulmonary 
hypertension 372. Additionally, lncRNA profiling of endothelial tissues from patients 
with chronic thromboembolic pulmonary hypertension also revealed the differential 
expression of 185 lncRNAs compared to healthy control tissues 373. 
 
As mentioned, lncRNAs can act as endogenous miRNA sponges by binding and 
sequestering miRNAs away from a particular target mRNA and allowing for its 
translation 273,343. Take the muscle-specific lncRNA linc-MD1, it carries a miRNA-
binding site in its 3′-UTR able to ‘sponge’ miR-133 away and abolish its suppressive 
effect on transcription factors that activate muscle-specific gene expression 374. 
By competing for the same miRNA-binding sites, antisense lncRNAs can further 
reduce mRNA destabilisation. More specifically, as shown by Faghihi et al, the 
BACE1as lncRNA can compete with miR-485-5p for the same mRNA binding site 
76 
and increase translation of beta-secretase-1 (BACE1), an enzyme involved in 
Alzheimer's disease pathophysiology 375. 
As suggested, lncRNAs can also serve as host transcripts for small ncRNAs, including 
miRNAs. For example, the LOC554202 gene, which is effectively transcribed into a 
recently discovered lncRNA, also functions as a host gene for miR-31 – a major 
contributor to breast cancer progression and metastasis 376. Similarly, Dey et al 
expanded on the previously unknown role of the H19 lncRNA in skeletal muscle 
differentiation by reporting that the first H19 exon encodes for miRNAs 675-5p and 
675-3p – both miRNAs were shown to effectively induce muscle cell differentiation 
and regeneration 377. Conversely, microRNA-mediated regulation of lncRNA can also 
occur. Reports show that miR-9 can target the MALAT1 for degradation in the nucleus 
by binding directly to miRNA recognition elements on the lncRNA itself 378. 
Nonetheless, despite the growing body of evidence linking miRNAs and lncRNAs 
through a series of cross-regulatory networks, our mechanistic understanding of these 
processes is still in its infancy and there is much to be learned.   
77 
1.5 LncRNAs as Regulators of Endothelial Function 
 
As interest in lncRNA function grows, a wealth of established in vitro and in vivo 
models are now being used to study lncRNA expression patterns. These, however, are 
yet to be thoroughly examined and a full representation of endothelial lncRNA 
expression throughout the cardiovascular system is still to be obtained. Nonetheless, a 
number of studies on EC function have yielded genes with high functional impact, 
which we will describe here in further detail (Table 1.2).  
For instance, several studies now point to several lncRNAs that are likely to directly 
impact on endothelial function through pro-apoptotic or pro-migratory effects on ECs. 
Stimulation of ECs using lipopolysaccharides, for example, will induce endothelial 
dysfunction, apoptosis and sepsis, eventually leading to elevated CVD risk. This 
process, as demonstrated by Singh et al, also happens in association with the 
differential expression of hundreds of so far uncharacterised lncRNAs 379. Another key 
feature of innate EC response is the release of chemotactic intermediaries produced 
from the CXCL locus involved in neutrophil recruitment. Recently, these were found 
to be primed for activation in TNFα-stimulated HUVECs by UMLILO, a proximal 
enhancer-transcribed lncRNA 380.  
Further, hypoxic conditions commonly observed in myocardial infarction, peripheral 
ischemia and stroke, often triggering distinct endothelial responses to prevent further 
tissue damage and restore blood supply. Several hundred genes with hypoxia-sensitive 
expression have been independently reported in vitro using HUVECs, leading to the 





Table 1.2:  LncRNAs Associated with Endothelial Function in Cardiovascular Disease.  
List of lncRNAs reported to have endothelial regulatory functions in cardiovascular disease. LncRNAs 
are presented together with their type and evolutionary conservation, followed by details regarding their 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































With additional in vitro and in vivo characterisation, several of these lncRNAs were 
shown to regulate a variety of hypoxia-induced EC functions such as proliferation, 
migration and angiogenesis 316,381,382.  
Interestingly, lncRNAs initially identified and studied in different cell types, such as 
MEG3, MIAT and RNCR3, have been linked to retinal EC angiogenesis and are now 
associated with microvascular visual impairment 383–385 (Figure 1.9). 
In the study of endothelial development, several models using human embryonic stem 
cells (hESCs) have also been widely implemented to identify lncRNA expressed at 
early stages during cell development and cell fate commitment. Crucially, these 
models have so far identified lncRNAs as such SENCR 386 and PUNISHER 387, both 
of which are not only upregulated during EC fate commitment but may also be 
important in maintaining endothelial homeostasis at later stages. For example, 
knockdown of the endothelial-associated lncRNA SENCR in HUVEC was found to 
trigger VE-cadherin internalisation, leading to perturbed adherens junctions and 
defective membrane integrity 388. Interestingly, the expression of SENCR was also 
shown to be altered in vascular samples from patients with critical limb ischemia and 
coronary artery disease 386.  
Additionally, given the wide variety of vascular microenvironments to which EC are 
exposed, it is important to consider the extracellular cues that may also guide their 
function 389. For example, the release of extracellular vesicles (EVs) by surrounding 
neighbouring cells is known to be a major factor involved in regulating endothelial 
function and dysfunction 390. Unsurprisingly, recent studies have started to show that 
lncRNAs can be selectively packaged, , along with other regulatory molecules,  into 
EVs to facilitate cell-to-cell communication and induce a variety of phenotypic 
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changes391. For example, the release of EVs carrying the lncRNA RNCR3, produced 
by ECs, was shown to prompt an increase in VSMC proliferation and migration392. 
While conversely, exposure to exosomes released by monocytes containing the  
atherosclerosis-associated lncRNA GAS5 was found to enhance apoptosis in ECs in 
vitro 393.   
 
 
Figure 1.9: Known Function of Endothelial LncRNAs.  
List of lncRNA reported to have endothelial regulatory functions with impact on cell differentiation, 
EndMT, angiogenesis, inflammation, EHT and vessel homeostasis. Figure adapted from Monteiro et al, 
2019 314.  
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Additionally, exosomes isolated from liver cancer cells enriched with the lncRNA H19 
promoted an angiogenic phenotype and increase cell adhesion by stimulating VEGF 
and VEGFR1 production in HUVEC 394.  
It is important to acknowledge however, that while the studies described have 
facilitated the discovery and characterisation of EC-associated lncRNAs, several of 
these publications do not account for EC heterogeneity and have a clear bias towards 
HUVEC-based models. Further highlighting this issue, to this day only one lncRNA-
screening study actually included primary EC subpopulations other than HUVEC 395. 
More specifically, by applying custom lncRNA microarrays, representing 23155 
putative lncRNAs, to HUVEC and human dermal microvascular ECs (HMVECs). 
Crucially, the groups analysis identified a total of 116 EC-enriched lncRNAs, of which 
29 where common between HUVECs and HMVECs, while 28 were unique to HUVEC 
and 59 to HMVEC 395. This is of particular importance given the cell-specific and 
context-dependent nature of lncRNAs 396. Manipulation of the lncRNA MIR503HG, 
for example, was shown to reduce cell proliferation and migration in HUVEC but had 
no effect on HPAECs 381.  Nevertheless, as the use of RNA sequencing approaches 
becomes common place, lncRNA research addressing EC heterogeneity is likely to 
increase over the coming years. 
 
While the influence of lncRNAs on cell function and dysfunction is starting to become 
apparent, research surrounding EC-based mechanisms other than those supporting 
angiogenesis and homeostasis has been, comparatively, limited. This is particularly 
true regarding EndMT, with no published data of transcriptome-wide shifts in lncRNA 
expression, the transition process has so far only been associated with two known 
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lncRNAs (Table 1.2; Figure 1.9). The lncRNA MALAT1 (metastasis associated lung 
adenocarcinoma transcript 1), for example, was the first to be implicated in the 
modulation of EndMT. Upregulated in human endothelial progenitor cells (EPC) 
treated with TGF-β1, the lncRNA was shown to repress the expression of DICER and 
with it the availability of miR-145. Effects on EndMT progression, however, were 
found to be largely mediated by miR-145 which directly targets TGFBR2 and SMAD3 
397. Recently, the lncRNA GATA6-AS (GATA6 antisense RNA) was shown to 
suppress TGF-β-induced EndMT in vitro via the lysyl oxidase homolog 2 (LOXL2) to 
regulate chromatin remodelling.  Although this interaction may be present, the study 
relied largely on vein ECs and results may not be applicable to EndMT in other ECs  
398.  While these studies do represent a step forward in the field, further comprehensive 




1.6 LncRNA Potential for Clinical Translation 
While the putative therapeutic applications of lncRNAs are often mentioned 
throughout the literature, the majority of clinical studies tend to focus on their utility 
as markers of disease. For example, the lncRNA HOTAIR has now been described by 
a growing number of studies as a potential biomarker for breast, liver, gastric, lung, 
and oesophageal cancer399. Further, the expression of MALAT1, originally associated 
with lung cancer metastasis, has now been linked to the development and progression 
of a variety other cancers 400–404. As shown in a recently published meta-analysis using 
data from 14 independent studies, MALAT1 expression was found to an independent 
predictor of overall survival rates in patients with respiratory, digestive and other 
system cancers 402. Similarly, the lncRNA SNHG15 (Small Nucleolar RNA Host Gene 
15) was also reported as a potential prognostic marker in hepatocellular carcinoma, 
with increased tissue levels of the lncRNA shown to be associated with decreased 
survival rates 405. 
Despite not being endothelial-specific, several lncRNAs with biomarker potential have 
also been described in CVD. For example, plasmas levels of the lncRNA H19 and 
LIPCAR (long intergenic non-coding RNA predicting cardiac remodelling) were 
found to be significantly increased in patients with coronary artery disease (CAD) 406. 
Increased expression of LIPCAR in particular has consistently been described as an 
independent predictor of cardiovascular-related death in patients with heart failure 
407,408.  Similarly, when comparing lncRNA expression in peripheral blood cells 
collected from patients with acute MI, the expression of ANRIL, along with MALAT1,  
were shown to be not only upregulated but also accurate predictors of left ventricular 
dysfunction after MI 409.  Expressed throughout the vasculature, increased levels of 
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ANRIL have also been reported in plaque and plasma samples of patients with 
atherosclerosis 365,410 and associated with the incidence of in-stent restenosis 411. Given 
the importance of promoting re-endothelialisation after vascular stenting 412 and 
considering the lncRNAs reported regulatory functions in EC, including VEGF 
expression 413, ANRIL may be a potential prognostic factor for vascular remodelling. 
Interestingly, several single nucleotide polymorphisms (SNPs) in ANRIL locus itself 
have also been associated with increased susceptibility to CAD and diabetes 414,415.  
Nonetheless, despite their promise, the introduction of lncRNA targeting strategies 
into the clinical setting comes with several challenges and real-world examples of 
therapeutic applications remain limited. For instance, due to the pleiotropic nature of 
most lncRNAs, tissue-specific delivery is essential to guarantee not only treatment 
efficiency but also minimising potential off-target effects. While increased ANRIL 
expression may link to ISR and atherosclerosis, unrestrained systemic modulation 
strategies may ultimately be just as harmful, given that the lncRNA is also commonly 
altered during tumour development and progression 416. Further, with an average of 
≃4 different isoforms per lncRNA, the transcriptional complexity of any particular 
lncRNA locus must be carefully considered and characterised before considering 
translation into the clinical setting 417. Thus, in order to be effective, clinical strategies 
targeting or using lncRNAs must take into account not only possible off-target effects, 
the route of delivery used, drug immunogenicity, treatment dosage and duration but 
also sub-cellular transcript location, transcript size and sequence. Nevertheless, given 
the transient and tissue-specific expression patterns of certain lncRNAs, the 
implementation of tissue-selective approaches may not always be necessary. This is 
particularly true for the cardiac fibroblast-specific lncRNA WISPER (Wisp2 super-
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enhancer–associated lncRNA), making it an attractive candidate for antifibrotic 
therapies 418.  
Lastly, it is also important to consider the lack of sequence conservation seen with 
lncRNAs in particular, which may prevent the translation of pre-clinical animal 
studies. The lncRNAs MIRT1 (myocardial infarction-associated transcript 1) and 
MIRT2 for example, despite being shown to have a robust up-regulation during MI in 
association with multiple genes known to be involved in left ventricular remodelling, 
have no corresponding human homologs and thus limited options for translation into 
the clinical setting 419. On the other hand , lncRNAs such as SMILR (smooth muscle 
enriched lncRNA), which are conserved only in humans, may prove difficult to 
research due to the lack of preclinical animal models 420. It is possible, however, that 
while primary sequence conservation may not be readily apparently, homolog 
secondary and tertiary structures may still exist 421,422. Thus, adding the possibility to 






1.7 Hypothesis and Aims 
With emerging evidence showing that EndMT is active during pathological vascular 
remodelling, new therapeutic avenues may also appear. Given the regulatory functions 
of lncRNAs, we hypothesise that the highly conserved lncRNA MIR503HG plays a 
crucial role in the initiation and progression of EndMT. To address this hypothesis, the 
work presented within this thesis aimed to:  
• To investigate the role of MIR503HG in the progression of EndMT; 
• Identify shared cross-regulatory features of the MIR503HG miRNA locus; 
• Determine whether MIR503HG is dysregulated during vascular remodelling in 
PAH.  
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Chapter 2: Materials and Methods
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2.1 Ethical Approval 
 
All experimental procedures using human cells conform to the principles outlined in 
the Declaration of Helsinki (Ethics 15/ES/0094). For experiments involving blood 
outgrowth endothelial cell (BOEC) generation, all blood donors provided informed 
consent in accordance with human study 07/H0306/134 (Cambridgeshire 3 Research 
Ethics Committee). All human tissues shown were obtained from the Papworth NHS 
Foundation Trust Hospital Tissue Bank (Papworth Everard, UK). Papworth Hospital 
ethical review committee approved the use of human tissues (Ethics Ref. 
08/H0304/56+5) and informed consent was obtained from all subjects. Both BOEC 
and patient lung tissues were kindly provided by Professor Nicholas W. Morrell (BHF 
Cambridge Centre of Excellence, University of Cambridge, UK). 
Paraffin wax–embedded lung samples were available from patients with PAH who had 
undergone lung transplantation and from controls. Control samples comprised tissue 
from pneumonectomy specimens resected for malignancy, but distant from the site of 
tumour (Table 2.1). 
Tissue Number Sample  Age Sex 
TB16.0389.A7 Control 55 years 3 months Female 
TB16.0484.B Control 68 years 0 months Female 
TB16.0526.B Control 75 years 8 months Female 
TB16.0733.C Control 74 years 7 months  Male 
TB07.0029.A1 IPAH 41 years  Female 
TB07.0272.6 IPAH 45 years Male 
TB07.0956.6 IPAH 40 years Female 
TB15.0859.I1 IPAH 24  years 5 months Female 
Table 2.1:  List of donor PAH and control patients. 
Tissue bank number, age and sex of donors with PAH who had undergone lung transplantation and 
control patients whose tissue samples were used for in situ hybridisation and immunohistochemistry 
staining. All tissues were obtained from the Papworth NHS Foundation Trust Hospital Tissue Bank. 
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All animal procedures conform to the United Kingdom Animal Procedures Act (1986) 
and with the “Guide for the Care and Use of Laboratory Animals” published by the 
US National Institute of Health (NIH publication No. 85-23, revised 1996). Animal 
approval was granted by the University of Edinburgh Committee Board. 
2.2 General Laboratory Practice 
The laboratory reagents and equipment used were all of the highest commercially 
available standard. All chemicals, unless otherwise stated, were purchased from Sigma 
Aldrich (Dorset, UK). Any hazardous chemicals were handled and disposed of in 
compliance with Control of Substances Hazardous to Health (COSHH) guidelines. 
Laboratory coats, nitrile powder-free gloves and fume hoods were used where 
appropriate. 
2.3 Cell Culture Methods and Reagents  
All procedures described were carried out under sterile conditions in a standard class 
II biological safety vertical laminar flow cabinet. Cabinets used were appropriately 
cleaned, both before and after use, with 1% virkon and 70% ethanol. During culture, 
all cell lines here described were kept at 37°C in a humidified atmosphere containing 
5% CO2. 
 
All HUVEC used were purchased from Lonza (#C2519A; Lonza, Slough, UK) and 
contained pooled male and female donor cells. HUVEC were kept in either T75 or 
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T150 cell culture flaks (Corning, Poole, UK) and maintained in endothelial cell growth 
medium (EGM-2 BulletKit™) (Lonza, Slough, UK) supplemented with 10% foetal 
bovine serum (FBS) (Life Technologies, Paisley, UK) and 100 U/mL 
penicillin/streptomycin (Gibco, Paisley, UK). Cells were typically passaged after 90% 
confluence was reached. In order to passage cultured cells, after a wash with warm 
Dulbecco’s calcium and magnesium free phosphate buffered saline (PBS) (Gibco, 
Paisley, UK), 3 mL of Trypsin-EDTA (Gibco, Paisley, UK) were added to each flask 
and allowed to incubate at 37°C for 2 min. After total cell detachment from the flask, 
7mL of supplemented EGM-2 were added to neutralise the trypsin. The cell culture 
was then pelleted by centrifugation at 1500 rpm for 5 min. Any supernatant was 
discarded and the cells re-suspended in normal culture medium before being 
distributed at a ratio of 1:4. If needed at a specific density, the cells were first counted 
using a haemocytometer and then seeded in a new cell culture vessel. All cell lines 
used were held between passages 3-8. 
 
All HPAEC used where purchased from Lonza (#CC-2530; Lonza, Slough, UK) and 
contained single donor cells, batches from multiple donors were used throughout. 
HPAEC were kept in either T75 or T150 cell culture flaks (Corning, Poole, UK) and 
maintained in supplemented EGM-2 as described in Section 2.3.1. Cells were typically 
passaged after 90% confluence was reached. Passage and seeding of cultured cells was 
performed following the protocol described in Section 2.3.1. All cell lines used were 
held between passages 3-8. 
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Human blood outgrowth endothelial cells (BOEC) used were generated and provided 
by Prof. Nicholas W. Morrell (University of Cambridge, Cambridge, UK). These were 
derived from peripheral venous blood isolated from donors diagnosed with PAH or 
healthy control, as previously described by Toshner et al 423. Patients cells were kept 
in either T25 or T75 cell culture flaks (Corning, Poole, UK) and maintained in 
supplemented EGM-2 as described in Section 2.3.1. Cells were typically passaged 
after 90% confluence was reached. Passage and seeding of cultured cells was 
performed following the protocol described in Section 2.3.1. All cells used were held 
between passages 6-8. 
 
All human embryonic kidney (HEK) 293T cells were kept in T150 cell culture flaks 
(Corning, Poole, UK) and maintained in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% FBS (Life Technologies, Paisley, UK) and 100 
U/mL penicillin/streptomycin (Gibco, Paisley, UK). Passage of cultured cells was 
performed by washing attached cells in warm PBS (Gibco, Paisley, UK) and 
incubating with 3mL of Trypsin-EDTA (Gibco, Paisley, UK) at 37°C for 2 min. After 
total cell detachment from the flask, 7mL of supplemented DMEM were added to 
neutralise the trypsin. The cell culture was then pelleted by centrifugation at 1500 rpm 
for 5 min. Any supernatant was discarded and the cells re-suspended in normal culture 
medium before being distributed at a ratio of 1:5. If needed at a specific density, the 
cells were first counted using a haemocytometer and then seeded in a new cell culture 
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vessel. For large-scale lentiviral vector production HEK293Ts were instead passaged 
at a ratio of 1:2, this was done 24 h prior to triple transfection. 
2.4 Endothelial to Mesenchymal Transition in vitro Models 
 
Before cytokine stimulation, cells were plated at a density of 7x104 cells/well using 6-
well culture plates (Corning, Poole, UK) and left to incubate for 24 h. HUVEC and 
HPAEC lines, cultured in supplemented EGM-2 as described above, were exposed to 
a daily dose of recombinant human TGF-β2 (10 ng/mL) and/or IL1- β (1 ng/mL) 
(PeproTech, NJ, USA). Cytokine co-stimulation was repeated daily for 7 days. Both 
recombinant human TGF-β2 and IL1- β were re-constituted in RNase/DNase free H2O 
at 20 ug/mL and 10 ug/mL, respectively. To minimise freeze thaw, all reagents were 
aliquoted at single use quantities and stored at -80ᵒC. 
 
Prior to treatment, cells were plated at a density of 7x104 cells/well using 6-well culture 
plates (Corning, Poole, UK) and left to incubate for 24 h. HUVEC, cultured in 
supplemented EGM-2 as described above, were exposed to a daily dose of 
recombinant human TGF-β2 (50 ng/mL) and/or H2O2 (200nM) (PeproTech, NJ, USA; 
SigmaAldrich, Dorset, UK). Cell stimulation was repeated daily for a total of 7 days. 
Recombinant human TGF-β2 was re-constituted and stored as described above. H2O2 
stocks were kept at 4ᵒC and diluted in RNase/DNase free H2O prior to use. 
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2.5 Cell Transfection 
 
Double stranded dicer-substrate short interfering RNA (DsiRNA) targeting specific 
MIR503HG transcript groups were designed and synthesised following the 
instructions provided by Integrated DNA Technologies (IDT, Leuven, Belgium) and 
selected based on gene knockdown effectiveness (Table 2.2). Additionally, a 
commercial DsiRNA control (IDT, Leuven, Belgium) was used in parallel with all 
RNA interference experiments as it does not target any sequence in the human, mouse, 
or rat transcriptome. Transient transfection was performed using Lipofectamine 
RNAiMAX Tansfection Reagent (Life Technologies, Paisley, UK) according to the 
manufacturer’s instructions, along with 20nM of either si503HG or siControl. 24 h 
post transfection, the transfection medium was removed and cell culture maintained 
for a total of 7 days using supplemented EGM-2, as described.  
 
Antisense LNA GapmeR targeting MIR503HG were generated using Qiagen's LNA 
GapmeR design tool (Qiagen, Hilden, Germany) and selected based on gene 
knockdown effectiveness (Table 2.2). A commercial Antisense LNA GapmeR 
Negative Control (Qiagen, Hilden, Germany) was used in parallel with all LNA 
GapmeR based RNA interference experiments as it did not target any sequence in the 
human transcriptome. Transient transfection was performed using Lipofectamine 
RNAiMAX Transfection Reagent (Life Technologies, Paisley, UK) according to the 
manufacturer’s instructions, along with 20nM of Gap_503HG or gapControl. 24 h post 
transfection, the transfection medium was removed and cell culture maintained for a 
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total of 7 days using supplemented EGM-2, as described 
Name Target Sense Strand (5' → 3') Antisense Strand (5' → 3') 
siCONTROL Negative Control 1 CGUUAAUCGCGUAUAAUACGCGUAT 
AUACGCGUAUUAUACGCGA
UUAACGAC 
si503HG MIR503HG_2/4/5 CAAAUAGAAGGGUAAUAUAUAAUCA 
UGAUUAUAUAUUACCCUUC
UAUUUGGG 
GapCONTROL Negative Control A AACACGTCTATACGC  
Gap503HG MIR503HG_2/4/5 TTGGAACAAAGAAGTG  
Table 2.2:  Cell Transfection Methods.  
List of DsiRNA and GapmeR sequences used. 
 
All miRNA silencing experiments were conducted using miRCURY LNA miRNA 
Inhibitors targeting either miR-424-5p or miR-503-5p (Qiagen, Hilden, Germany). An 
appropriate miRCURY LNA miRNA Inhibitor Negative Control (Qiagen, Hilden, 
Germany) was used in parallel with all miRNA silencing experiments as it did not have 
known microRNA targets. See Table 2.3 for a complete list of miRNA inhibitors used. 
Transient transfection was performed using Lipofectamine RNAiMAX Transfection 
Reagent (Life Technologies, Paisley, UK) according to the manufacturer’s 
instructions, along with 25nM of either miRNA inhibitor. 24 h post transfection, the 
transfection medium was removed and cell culture maintained for a total of 7 days 
using supplemented EGM-2.  
 
All miRNA overexpression experiments were conducted using Pre-miR miRNA 
Precursors for either miR-424-5p or miR-503-5p (Life Technologies, Paisley, UK). 
An appropriate Pre-miR miRNA Precursor Negative Control (Life Technologies, 
Paisley, UK) was used in parallel with all miRNA overexpression experiments as it 
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did not have known microRNA targets. See Table 2.3 for a complete list of miRNA 
precursors used. 
Transient transfection was performed using Lipofectamine RNAiMAX Transfection 
Reagent (Life Technologies, Paisley, UK) according to the manufacturer’s 
instructions, along with 15nM of either miRNA precursor. 24 h post transfection, the 
transfection medium was removed and cell culture maintained for a total of 7 days 
using supplemented EGM-2. 
Name Target Assay ID 
Anti-miR424 hsa-miR-424-5p YI04100987 
Anti-miR503 hsa-miR-503-5p YI04100899 
Anti-miR CT Negative Control YI00199006 
Pre-miR424 hsa-miR-424-5p PM10306 
Pre-miR503 hsa-miR-503-5p PM10378 
Pre-miR CT Negative Control AM17110 
Table 2.3:  Cell Transfection Methods. 
List of miRNA inhibitors and miRNA precursors used. 
2.6 General Cloning Techniques 
The following general cloning techniques were employed in order to create a 
LNT_SFFV plasmid construct containing MIR503HG isoform 2.  
 
Plasmid restriction digest was used for both inserting target DNA sections into 
plasmids and also as diagnostic tools to ensure that the DNA insert was of the correct 
size. Depending on the reaction size, 100-1000ng of plasmid DNA was used. Small, 
diagnostic, reactions were set up using 1 µL NEB buffer, 0.5 µL of each restriction 
enzyme, 100 ng plasmid DNA and made up to a final volume of 10 µL using 
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RNase/DNase free H2O. Large reactions used 5 µL NEB buffer, 1 µL of each 
restriction enzyme, 1 µg plasmid DNA and made up to a final volume of 50 µL using 
RNase/DNase free H2O. Each restriction enzyme use was acquired from New England 
Biolabs (Ipswich, UK). 
Restriction digestion was then performed by incubating each reaction in a water bath 
set at 37°C for 2 h. When required, gel purification was performed as described in 
Section 2.6.2. 
 
Agarose gel electrophoresis was used to separate DNA molecules according to their 
molecular size. All samples were mixed with 6X purple gel loading dye (New England 
Biolabs, Hitchin, UK) for a final 1X concentration and loaded onto a pre-cast agarose 
gel, along with the appropriate DNA size marker (100 base pair and/or 1 kilobase pair 
DNA ladders) (New England Biolabs, Hitchin, UK). 
Agarose powder (Invitrogen, Paisley, UK) was dissolved in 1X Tris-Borate EDTA 
(TBE) buffer (Gibco, Paisley, UK) to a suitable percentage (1-2% w/v) based on the 
sample DNA fragment size. In order to visualise the DNA, SYBR Safe DNA gel stain 
(1 ng/100mL) (Invitrogen, Paisley, UK) was added to molten agarose before casting. 
The loaded agarose gel was electrophoresed at a constant voltage of 80-100 V in TBE 
buffer in BIO-RAD electrophoresis tanks and using a BIO-RAD Power Pac 300. DNA 
bands were later visualised by UV transillumination on a ChemiDoc XRS+ Imaging 
System. 
After agarose gel electrophoresis, the desired DNA fragments, visualised by UV 
transillumination, were excised from the gel using a clean scalpel and purified using 
the PureLink Quick Gel Extraction Kit (Invitrogen, Paisley, UK) following the 
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instructions provided by the manufacturer’s protocol. The purified DNA was stored at 
-20°C until required. 
 
Digested DNA will possess a 5’ phosphate group required for ligation, in order to 
prevent recipient plasmid self-ligation the 5' phosphate can be removed prior to the 
ligation reaction. This was performed using Calf Intestinal Alkaline Phosphatase (CIP) 
(New England Biolabs, Hitchin, UK), following the manufacturers’ protocol.  
Ligation of DNA insert into the dephosphorylated plasmid backbone was performed 
using T4 DNA ligase (New England Biolabs, Hitchin, UK), with a molar ratio of 1:3 
plasmid to insert along with a 1:0 negative control reaction. Molar ratios were 
calculated using the following equation: 
𝑛𝑔(𝑉𝑒𝑐𝑡𝑜𝑟) 	× 	𝐾𝑏(𝐼𝑛𝑠𝑒𝑟𝑡)	
𝐾𝑏(𝑉𝑒𝑐𝑡𝑜𝑟) 	× 	𝑅𝑎𝑡𝑖𝑜 
Ligation reactions were prepared in 200 uL PCR tubes combining 150 ng of 
dephosphorylated plasmid vector, specific amount of insert DNA (as calculated 
above), 1 µL T4 DNA ligase enzyme, 2 µL 10x T4 DNA ligase buffer and made up to 
a final volume of 20 µL using RNase/DNase free H2O. Samples were incubated at 
16°C overnight in a thermal cycler. Ligations were subsequently subjected to further 
diagnostic digests and sequencing before being transformed into competent 
Escherichia coli (E coli). 
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DNA sequencing was used to confirm that the plasmid construct contained the correct 
DNA sequence and that no mutations were present. Each sequencing reaction was 
performed using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems); containing 200 ng of plasmid DNA, 2 nM of forward or reverse 
sequencing primer, 1 µL of v3.1 Ready Reaction Mix (Applied Biosystems), 4 µL of 
5x v3.1 BigDye Sequencing Buffer (Applied Biosystems) and made up to a final 
volume of 20 µL using RNase/DNase free H2O. Each reaction was assembled in a 
200uL PCR tube and performed in duplicate along with a control sequencing reaction 
missing the template DNA. 
Each sequencing reaction was then subject to 25 PCR cycles at 96°C for 50 seconds 
to denature the plasmid, 50-55°C for 20 seconds to facilitate primer annealing and 
60°C for 4 min to extend the target DNA fragment. Samples were then sent to 
Edinburgh Genomics (University of Edinbrugh, Edinburgh, UK) for sequencing 
analysis. 
 
All plasmid DNA was replicated using bacterial transformation of competent E coli. 
Bacterial transformations were performed using a standardised ‘heat shock’ protocol 
combining the desired plasmid DNA and commercially available One Shot TOP10 
(Thermo Fisher, Paisley, UK) or Stellar (Clontech, California, USA) Chemically 
Competent E coli. In summary, 1 ng of the desired plasmid DNA was added to 50 µL 
aliquots of chemically competent bacteria were and placed on ice.  The 
bacteria/plasmid mix was left on ice for 5 min, then submerged in a water bath at 42 
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ᵒC for exactly 45 seconds, removed and immediately placed on ice for an additional 2 
min.  
450 µL of S.O.C. medium (room temperature) was added to each tube, these were 
incubated at 37°C while shaken at 200 rpm for 1 h. In order to ensure antibiotic 
efficiency, a negative control containing only E coli (without plasmid DNA) was 
included. Luria agar (Thermo Fisher, Paisley, UK) plates containing 100 µg/mL of 
ampicillin were inoculated using different amounts of E coli/S.O.C medium. The 
inoculated plates were then incubated overnight at 37 °C to allow for colony formation. 
The following morning, single bacterial colonies were selected and allowed to grown 
in Luria broth (Thermo Fisher, Paisley, UK), containing 100 µg/mL ampicillin, for 
either mini or maxiprep plasmid purification. All purified plasmids were screened 
using diagnostic restriction digests, DNA electrophoresis and plasmid sequencing, as 
described. 
 
Small- and large-scale plasmid DNA purification was performed using either a 
PureLink® Quick Plasmid Miniprep Kit or HiPure Plasmid Maxiprep Kit (Thermo 
Fisher, Paisley, UK), according to the manufacturer’s instructions. Once extracted, 
DNA quantification and quality control was conducted using a NanoDrop ND-1000 
Spectrophotometer (Nano-Drop Technologies, Wilmington, DE). When necessary, 
samples were further diluted by adding RNase/DNase free H2O. All plasmid DNA 
samples were stored at -20°C until required. 
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After transformation, bacteria carrying a specific plasmid were saved for long-term 
storage as glycerol stocks. Prior to maxiprep plasmid isolation, 500 µL of overnight 
culture was added to a cyrovial containing 500 µL of 50% glycerol and stored at -80ᵒC. 
In order to recover stored bacteria, glycerol stocks were thawed and streaked on agar 
plates with the appropriate antibiotic for single colonies selection. 
2.7 Lentiviral Manipulation of LncRNA Expression 
 
A synthetic gene MIR503HG_2 was assembled from synthetic oligonucleotides, based 
on the human genome annotation GRCh38, and inserted into a MA-T plasmid 
backbone (pMA-T) by GeneArt Gene Synthesis (Invitrogen, Paisley, UK). 
 
 
Figure 2.1:  Plasmid Map. 
A) MIR503HG_2_pMA-T plasmid map containing a synthetic MIR503HG_002 sequence, containing 
the XhoI and KpnI restriction sites, assembled from synthetic oligonucleotides and inserted into a MA-
T plasmid (pMA-T). B) LNT_SFFV:503HG plasmid map containing MIR503HG_2 sequence between 
XhoI and KpnI restriction sites. The LNT_SFFV plasmid is under the control of the SFFV promoter 
and exhibits ampicillin resistance. 
        
A B 
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The MIR503HG_2 gene was spliced and cloned into the LNT_SFFV plasmid utilising 
the XhoI and Kpnl restriction sites at 5’ and 3’ ends of the transcript. Cloning was 
performed according to Section 2.6. The MIR503HG_pMA-T and 
LNT_SFFV:503HG plasmid maps are shown in Figure 2.1. 
 
Large-scale lentiviral vector production was conducted using a transient triple-
transfection method, whereby HEK293T cells were transfected using 3 plasmids, 
required for lentiviral production. Namely, an expression plasmid (pHR’SIN-cPPT-
SFFV-MCS-WPRE; pSFFV Lenti MCS) containing the gene interest and a spleen 
focus-forming virus (SFFV) promoter (provided by Prof. Adrian Thrasher, Institute of 
Child Health, University College London, London, UK), a lentiviral packaging 
plasmid (pCMVΔ8.74) containing the Gag, Pol, Tat and Rev genes, and an envelope 
plasmid encoding the vesicular stomatitis virus protein (VSVg) (pMDG). 
Polyethylenimine (PEI) was used as a plasmid transfection reagent.  
All lentivirus preparations were performed in batches of twelve 150 cm2 cell culture 
flasks. For each flask, two separate mixes were prepared; one containing the 3 
plasmids for transfection, and second mix containing PEI. The plasmid mix contained 
50 µg expression plasmid, 17.5 µg PMDG and 32.5 µg pCMVΔ8.74, diluted in 5 mL 
of Opti-MEM reduced serum medium with GlutaMAX supplement (Gibco, Paisley, 
UK), which was filtered using a 0.22 µm sterile filter. The second mix contained 1 µL 
PEI diluted in 5 mL of Opti-MEM reduced serum medium, which was finally sterile 
filtered and added directly to the plasmid mixture. The plasmid/PEI mixture was then 
incubated at room temperature with minimal light exposure for 20 min. Incubation 
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allowed for the formation of DNA:PEI complexes, which have endosomolytic activity, 
and are protected from lysosomal degradation.  
Before transfection, the culture medium was removed from HEK293Ts and the cells 
were washed in fresh Opti-MEM medium. This was then removed and 10 mL of 
medium containing DNA:PEI complexes was added to each flask. The cells were 
allowed to incubate for 4 h at 37°C and 5% CO2. Later, the transfection medium was 
removed, replaced with 20 mL fresh complete culture medium and cells were returned 
to the incubator for 48 h. During this period, after a successful transfection, lentiviral 
particles are produced and released into the medium by the cells. After 48 h the virus 
containing medium was collected and filtered using a 0.22 µm sterile filter unit. A 
further 10 mL of fresh complete culture medium was added to each flask and the cells 
cultured for a further 24 h. The medium was again collected, filtered and combined 
with the medium removed at 48 h.  
 
The lentiviral particles were collected and concentrated using ultracentrifugation. 
Briefly, medium collected from triple-transfected cells was aliquoted into Beckman 14 
x 95 mm (14 mL) plastic tubes (Beckman Coulter, London, UK), previously rinsed 
with 70% ethanol, and loaded into a Sorvall WX+ Ultracentrifuge (Thermo fisher, 
Paisley, UK). The collected medium was centrifuged at 23,000 rpm for 1 h at 4°C. The 
supernatant was then discarded and the process was repeated until all virus-containing 
medium had been used. After the final centrifugation, the supernatant was again 
discarded and tubes placed up-side down to remove all traces of medium. All 
collection tubes were placed on ice and loaded with 100 µL of Opti-MEM reduced 
serum medium with GlutaMAX supplement (Gibco, Paisley, UK), they were then 
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incubated on ice for 30 min. The lentivirus pellets were finally suspended in the 
medium, aliquoted at single use quantities and stored at -80ᵒC until required. 
 
Viral titre, in particle infectious units per mL (PIU/mL), was quantified by TaqMan® 
qRT-PCR based detection. See Table 2.4 for sequence of primers and probe used.  
Briefly, HEK293T cells were first cultured and then seeded into a 12-well cell culture 
plate (Corning, Poole, UK) at a density of 5x104 cells per well. The next day, 
decreasing concentrations of the lentivirus produced were added to each well and left 
for 72 h. The cells were washed in 1X PBS (Gibco, Paisley, UK) and left with 200 µL 
of 1x PBS in each well. 
Name Sequence (5' → 3') 
PRIMER (FW) 5’-TGTGTGCCCGTCTGTTGTGT-3’ 
PRIMER (RV) 5’- GAGTCCTGCGTCGAGAGAGC-3’ 
PROBE 5’-(FAM)-CAGTGGCGCCCGAACAGGGA- (TAMRA)-3’ 
Table 2.4:  Viral titre primer and probe sequence list. 
Prior to DNA extraction, transduced cells underwent one freeze thaw cycle placing the 
plates at -20°C for 10 min and removing them. Total DNA was then extracted using 
the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). Once extracted, DNA 
quantification was conducted using a NanoDrop ND-1000 Spectrophotometer (Nano-
Drop Technologies, Wilmington, DE), all samples were then diluted to 250 ng/µL 
using RNase/DNase free H2O. In order to calculate the viral titre, serial dilutions of 
the purified expression plasmid (SFFV-LV) were used to generate a standard curve of 
1x1013 to 1x104 plasmid copies.  
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The calculations required to determine the µL of virus needed to generate the top 
standard are shown below: 
1. Molecular weight of 1 copy of expression plasmid 
													
𝑆𝑖𝑧𝑒	𝑜𝑓	𝑝𝑙𝑎𝑠𝑚𝑖𝑑	(𝑏𝑝) × 	𝑠𝑖𝑧𝑒	𝑜𝑓	1	𝑏𝑝	(660𝐷𝑎)	
𝐴𝑣𝑜𝑔𝑎𝑑𝑟𝑜’𝑠	𝐶𝑜𝑛𝑠𝑡𝑎𝑛𝑡 	= 	𝑔	𝑝𝑒𝑟	𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒 
Daltons = g/mole 
     Avogadro's Constant = 6.023 x 1023 molecules/mole 
        
2. Determine copy number of plasmids in 1 mL stock.  
														
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛	𝑜𝑓	𝑠𝑡𝑜𝑐𝑘	𝑝𝑙𝑎𝑠𝑚𝑖𝑑	(𝑔/	𝑚𝐿)	
𝑔	𝑝𝑒𝑟	𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒 	= 	𝑛𝑜. 𝑜𝑓	𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠	𝑝𝑒𝑟	𝑚𝐿 
 
3.  Preparation of top standard (1x1013 copies) 
															
𝑁𝑜. 𝑜𝑓	𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠	𝑝𝑒𝑟	1	𝑚𝐿		






A TaqMan® qRT-PCR reaction master mix was prepared containing 2x TaqMan® 
Universal Master Mix, 2 µL Primer/Probe mix, 3.125 µL Nuclease-free H2O, 1 µL of 
DNA standard or DNA samples collected from lentiviral titre. Finally, 11.5 µL of 
master mix was added to each well of a 384-well PCR plate. All reactions were 
performed in triplicate using a QuantStudio 7 Flex Real-Time PCR System real time 
PCR system (Thermo Fisher, Paisley, UK) as described under Section 2.16. The titre 
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of each sample was calculated by plotting the CT values from the standard curve and 
solving the equation of the line for each sample.  
The number of copies plasmid DNA per cell was then identified by using the equation 
below: 
 
       Copies of plasmid in sample ´ no. of cells used in 250 ng =  
 
The total copies of plasmid per cell was then used to generate both the PIU/mL and 
the MOI (multiplicity of infection), respectively, shown in 1. and 2. below: 






2. µL of virus per well 
														
𝐶𝑒𝑙𝑙	𝑛𝑜.× 	𝑀𝑂𝐼		
𝑉𝑖𝑟𝑎𝑙	𝑇𝑖𝑡𝑟𝑒 	= 	µL	of	virus	/	well 
 
 
Lentiviral transduction was performed over a period of 24 h on a confluent monolayer 
of HUVEC. Briefly, healthy HUVEC, maintained in supplemented EGM-2, were 
plated at a density of 7x104 cells/well on a 6-well cell culture plate (Corning, Poole, 
UK).  The cells were allowed to attach to the plate surface overnight at 37°C and 5% 
CO2. A negative control (LNT_CT) or lncRNA containing lentivirus (LNT_503HG) 





was added directly to the culture medium of each well at a multiplicity of infection 
(MOI) of 5 (MOI is the ratio of the number of virus particles to the number of target 
cells). 24 h post transduction, the transduction medium was removed and cell culture 
maintained in supplemented EGM-2 alone or containing recombinant human TGF-β2 
(10 ng/mL) and IL1- β (1 ng/mL) (PeproTech, NJ, USA).  The medium was replaced 
daily, along with cytokine co-stimulation, for 7 days. 
2.8 Animal Models 
 
Inducible endothelial tracking (Ind.EndoTrack) transgenic mice were developed based 
previously published endothelial lineage tracing models by Madisen et al and 
Monvoisin et al 424–426. In brief, Cdh5-Cre-ERT2-TdTomato (Ind.EndoTrack) 
transgenic mice were generated by crossing Cdh5-Cre-ERT2 (strain Tg(Cdh5-
cre/ERT2)1Rha) with a ROSA-TdTomato reporter mouse line (strain B6.Cg-
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J). The Cdh5-Cre-ERT2 line was produced using a 
P1 artificial chromosome (PAC) vector containing the tamoxifen-inducible Cre-ERT2 
sequence and a VE-cadherin (Cdh5) promotor to direct endothelial-specific gene 
expression (Ralf H Adams, MGI:3848982) 424. ROSA-TdTomato reporter line was 
produced by inserting a Rosa-CAG-LSL-tdTomato-WPRE targeting vector into the 
Gt(ROSA)26Sor locus (#007909,  The Jackson laboratory) 426.  
Induction of Cre-recombinase activity was achieved by administering 400 mg/kg body 
weight per dose of tamoxifen dissolved in sterile corn oil by gavage on 3 alternate days 
for 5 days, this was followed by two weeks of rest before initiating the 
Hypoxia/SU5416 PH model. 
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Eight to eleven-week-old female mice were injected once weekly with Sugen 5416 at 
25 mg/kg body weight per dose for a total of 21 days. Stock Sugen 5416 powder was 
suspended in CMC solution (0.5% [w/v] carboxymethylcellulose sodium, 0.9% [w/v] 
sodium chloride, 0.4% [v/v] polysorbate 80 and 0.9% [v/v] benzyl alcohol in deionized 
water), then vigorously vortexed and sonicated to produce a homogenous solution. 
Any age/sex matched controls received the same volume of vehicle alone.  
During this period the mice were exposed to either normoxic conditions or chronic 
hypobaric hypoxia inside a ventilated plexiglass chamber with a controlled atmosphere 
of 10% oxygen. Excess ammonia was removed by ventilation and activated charcoal 
filtration through an air purifier. At the end of the treatment period the animals 
underwent terminal anaesthesia and right ventricular systolic pressure (RVSP) 
measurement. Following RVSP measurement, lung tissues were harvested for cell 
isolation or histology. 
2.9 Intranasal Delivery of Lentivirus 
The lentivirus construct was delivered to eight to eleven-week-old female mice on 3 
alternate days for a total of 5 days, this was followed by a 2 day rest period before 
initiating the Hypoxia/SU5416 PH model as described below. Prior to the intranasal 
procedure, each mouse was anesthetised in an induction chamber containing 3% (v/v) 
isoflurane (Abbot Laboratories, Berkshire, United Kingdom) supplemented with O2 at 
a flow rate of 0.5 L/min. Post-induction, the mouse was gently restrained by scruffing 
and held in a vertical position while the liquid was administered directly through the 
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nostrils. Each delivery consisted of 25uL of Opti-MEM medium (Gibco, Paisley, UK) 
containing either LNT_503HG_2 or LNT_Control at 4×108 piu/mL. 
2.10 Assessment of Pulmonary Hypertension 
 
Anaesthesia was initiated in an induction chamber containing 3% (v/v) isoflurane 
(Abbot Laboratories, Berkshire, United Kingdom) supplemented with O2 at a flow 
rate of 0.5 L/min. Post-induction, mice were fitted with facemask supplying 1.5% (v/v) 
isoflurane supplemented with O2 at flow rate of 0.5 L/min. Appropriate levels of 
anaesthesia were confirmed by the absence of hind limb reflex before and during 
surgery. 
 
RVSP of anaesthetised mice was measured by catheterisation of the right ventricle 
(RV) of the heart to allow for the measurement of right ventricular pressure. RV 
catheterisation was achieved via the right jugular vein using a 1.4 F Millar catheter 
(SPR-671, Millar, Houston TX, USA). Once in place, continuous RVSP measurement 
was carried out using a calibrated 25 mm gauge heparinised saline filled needle 
attached to an Elcomatic E751A pressure transducer connected a MP100 data 
acquisition system (BIOPAC Systems Inc, Santa Barbara, USA). Mean RVSP, systolic 
and diastolic RVSP were measured at three independent areas of the steady trace and 
PH was determined when reaching values exceeding 30 mm Hg. 
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2.11 Mouse Lung Cell Isolation  
TdTomato+ and/or CD31+ endothelial mouse lung cells were isolated as previously 
described  Fehrenbach et al 427. In brief, exposed lungs were first filled with and later 
fully submerged in digestion buffer. The lung digestion buffer consisted of a PBS mix 
containing 1mg/ml of LiberaseTM (SigmaAldrich, Dorset, UK), 0.1mM EDTA 
(Thermo Fisher, Paisley, UK) and 1U/uL DNase (Thermo Fisher, Paisley, UK). 
Submerged lung samples were then incubated in a shaking water bath for a total of 15 
min at 37°C. The lung tissue was then transferred to a gentle MACS C Tube, topped 
with wash buffer, and further processed using the gentleMACS Dissociator (Miltenyi 
Biotec, Auburn, CA). The wash buffer added consisted of a PBS mix containing 1% 
BSA (Thermo Fisher, Paisley, UK) and 1mM EDTA (Thermo Fisher, Paisley, UK). 
The dissociated cell mix filtered through a 70 μm nylon mesh (Miltenyi Biotec, 
Auburn, CA) and centrifuged at 2000 rpm for 5 min at 4°C. Once pelleted, the 
supernatant was removed, the cell mix resuspended in cold ACK lysis buffer (Thermo 
Fisher, Paisley, UK) and left for 10 min on ice; this was again centrifuged at 2000 rpm 
for 5 min. The pelleted cell mix was resuspended in wash buffer and finally sorted 
using the BD FACSAria II cell sorter (BD Biosciences) based on their CD31+ or 
TdTomato+ status.  
2.12 Histology 
 
Prior to staining, the formalin-fixed and paraffin embedded (FFPE) tissue sections 
were de-paraffinised and rehydrated by washing in Xylene for 5 min, followed by 
sequential 5 min washes in 100%, 96%, 70% ethanol and water, respectively. The 
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rehydrated tissue sections were then submerged in warm sodium citrate buffer (10mM, 
pH6.0) and boiled for 10 min in a microwave for antigen retrieval. After boiling, these 
were left to cool at room temperature in sodium citrate buffer for 15 min. All samples 
were then washed under running water for 10 min, followed by two washes using tris-
buffered saline plus 1% tween-20 (TBS-T) for 5 min each. 
Next, the sections were blocked in 3% goat serum/TBS for 1 h at room temperature to 
reduce non-specific background staining. Primary antibodies, diluted in in 3% goat 
serum/TBS, were then added and left for 1 h further at room temperature. The antibody 
dilutions used were as follows: 1/100 vWF (#A0082, Dako) and 1/1000 αSMA 
(MO851, Dako), matching Mouse IgG (#10400C, Invitrogen) and Rabbit IgG 
(#ab172730, Abcam) negative controls were used at the same concentrations. After 
the incubation period, the sections were washed in TBS-T three times for 5 min and 
incubated with their corresponding fluorescent conjugated secondary antibodies for 1 
h at room temperature. The secondary antibody dilutions were as follows: 1/500 Goat 
Anti-Mouse (#A11001, Alexa Fluor 488, Invitrogen) and 1/500 Goat Anti-Rabbit 
(#A11010, Alexa Fluor 546, Invitrogen). The stained tissue sections were finally 
washed in TBS-T three times for 5 min and mounted using ProLongTM Gold antifade 
reagent (#P36935, Invitrogen). All slides were imaged using an Axio Scan slide 
scanner (Zeiss) and ZEN imaging software (Zeiss). 
 
Cells were first in PBS containing 4% (w/v) paraformaldehyde for 5 min and the 
permeabilised in PBS with 0.2% (w/v) Triton X-100 for a further 5 min. This was 
followed by incubation in PBS/3% BSA for 30 min, then overnight with primary 
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antibodies anti-Slug (#IC7408P, R&D systems), anti-aSMA (#IC1420A, R&D 
systems), anti-CD31 (#555445, BD Biosciences) at 4°C.  The next day cells were 
incubated with secondary antibodies conjugated with Alexa Fluor (Life Technologies, 
Paisley, UK) at room temperature for 1 h, followed by three washes with PBS. Finally, 
the before being mounted using glass coverslips and ProLong® Gold Antifade 
Mountant. Immunofluorescence images of HUVEC and HPAEC were acquired with 
Andor Revolution XDi spinning disk confocal microscope and analysed with Image J 
Software. All settings for the microscope and software were optimised and then 
maintained for each set of experiments, so that set of cells can be compared accurately. 
 
Prior to staining, the formalin-fixed and paraffin embedded (FFPE) tissue sections 
were deparaffinised and rehydrated by washing in Xylene for 5 min, followed by 
sequential 5 min washes in 100%, 96%, 70% ethanol, DEPC treated water and PBS 
respectively. The miRCURY LNA miRNA ISH Buffer Set (#339450; Qiagen, Hilden, 
Germany) was then utilised for tissue digestion and probe hybridisation. Specifically, 
the rehydrated tissue sections were first incubated with proteinase K (1:1000) in PBS 
4 min at 37oC then rinsed under flowing DEPC-treated water and washed twice in PBS 
for 5 min. The 1x hybridisation buffer was used to dilute the ISH probes (Table 2.5) 
to 25nM. The tissue sections were then incubated with the probe/buffer dilution 
overnight at 55oC in a humidified chamber, the probe dilution was sealed against the 
tissue using coverslips and rubber glue to prevent drying out.  The following morning, 
the sections were washed three times in 5x saline-sodium citrate buffer (SSC) for 5 
min at 55oC and a fourth time at room temperature, this was followed by a 2.5x SSC 
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wash and a final wash in PBS for 5 min. Next, the sections were incubated using the 
Roche Digoxigenin wash and block buffer set (#11585762001, Roche Applied 
Science, Mannheim, Germany) for 1 h. This was followed by a 1 h incubation with an 
anti-Digoxigenin-antibody (#11093274910; Roche Applied Science, Mannheim, 
Germany) diluted in the Digoxigenin wash and block buffer set at 1:500. After, the 
tissue sections were washed three times for 5 min with TBS-T. In order to visualise 
the probes, an NBT/BCIP AP solution (#11697471001; Roche Applied Science, 
Mannheim, Germany) with the addition of levamisole (Vector Laboratories, SP-500) 
was added to each section and left at room temperature until detection occurred 
(approx. 2-3 h). After detection, the sections were rinsed in DEPC-treated water and 
counterstained with nuclear fast red. This was followed by sequential 20 second 
washes of 70%, 96% and 100%, followed by 2 min in xylene. Finally, the sections 
were mounted using glass coverslips and Pertex mounting media. 
Name Sequence 
503HG__ISH /5DigN/CGGATGGCGCGGGCTTGGT/3Dig_N/ 
Table 2.5:  In Situ RNA Detection. 
List of MIR503HG detection in situ probe sequence. 
2.13 Flow Cytometry 
Single-cell suspensions were first in PBS containing 4% (w/v) paraformaldehyde for 
5 min and the permeabilised in PBS with 0.2% (w/v) Triton X-100 for a further 5 min. 
This was followed by incubation in PBS/1% BSA containing anti-CD31 (FITC) 
(#555445, BD Biosciences), anti-aSMA (APC) (#IC1420A, R&D systems) and anti-
SLUG/SNAI2 (PE) antibodies (#IC7408P, R&D systems), alongside unstained and 
single stain controls for 1 h at 4°C. Cells were then centrifuged at 2000 rpm for 5 min 
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and resuspended in PBS/1% BSA three times. Resuspended samples were then 
analysed using the BD LSR5 Fortessa Analytic Flow Cytometer (BD Biosciences). 
Cells were first separated from debris by plotting forward versus side scatter, single 
cells were then selected using forward scatter area (FSC-A) versus forward scatter 
height (FSC-H) and side scatter area (SSC-A) versus side scatter height (SSC-H). 
From the single cell population, viable cells were selected by gating for DAPI negative 
events. Marker expression was then determined from this gated population compared 
to unstained and single stain controls. Representative histograms and mean 
fluorescence intensity (MFI) calculations were generated using FlowJo v10 (BD 
Biosciences).  
2.14 Total RNA Isolation and Quantification 
Total RNA isolation was performed using QIAzol Lysis Reagent and miRNEasy Mini 
Kit (Qiagen, Hilden, Germany), following the manufacturer’s protocol. An additional 
in-column DNase digestion step was added to remove any further traces of genomic 
DNA. RNA quantification and quality control were conducted using a NanoDrop ND-
1000 Spectrophotometer (Nano-Drop Technologies, Wilmington, DE). All RNA 
samples were stored at -80°C until required. 
 
RNA quality was evaluated by RNA integrity number (RIN) analysis using an 
Agilent® 2100 Bioanalyser in conjunction with RNA 6000 Nano LabChip kits 
(Agilent Technologies, Berkshire, UK). Loaded RNA molecules were separated by 
automated electrophoresis to produce electropherograms and gel-like images, allowing 
for the assessment of RNA quality and RIN calculation. RIN values were calculated 
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based on the size and distribution of RNA particles within each sample. This technique 
was used to evaluate the quality of RNA samples prior to RNA-seq, with RIN values 
of 8 and above being deemed as high quality.  
2.15 RNA Sequencing Library Construction and Analysis 
All RNA samples used for RNAseq experiments were obtained in biological 
triplicates. For the “EndMT” RNAseq, RNAs were obtained from HUVEC and 
HPAEC (treated with TGF-b2 and IL-1β separately or in combination as well as 
control untreated cells). Ribosomal-depleted stranded libraries were prepared by 
Beckman Coulter Genomics using the TruSeq Stranded Total RNA kit with Ribo-Zero 
Gold. Libraries were sequenced with HiSeq Illumina at an average of 50 million reads 
per samples (paired end 2x125 bp). For “MIR503HG overexpression” RNAseq, polyA 
stranded libraries were prepared and sequences on HiSeq Illumina at an average of 20 
million reads per samples (paired end 2x150bp).For both RNAseq analysis, mapping 
was performed on the human genome reference sequence GRCh38 (GENCODE 
Release 26 primary assembly), using STAR (version 2.5.1b) 428. Gene quantification 
(read count and normalised expression value as FPKM) was obtained using RSEM 429 
(options: -bowtie2 -forward-prob 0 -paired-end), based on GENCODE annotation 
version 26 (primary assembly). For the “EndMT” RNAseq, the differential expression 
was assessed using DESeq2 430 by comparing treated conditions with the untreated 
control cells. For the RNAseq of MIR503HG overexpression samples, the differential 
expression analysis was done using edgeR, While DESeq2 is more specific, edgeR 431 
has a better sensitivity 432 and is therefore more appropriate for samples that can 
present coverage variability. We considered a threshold of absolute fold Change >= 2 
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and adjusted p-value<0.01 to identify significant changes between two conditions. We 
also applied an expression value threshold of 1 FPKM (average of the three replicates) 
in the considered groups. Sample clustering was evaluated using the Principal 
component analysis (PCA) tool available in DESeq2 on the regularised log 
transformed data. The 3D plot was obtained using the rgl R package. The gene 
ontology analysis was done using topGO on enriched genes over a background of 
expressed genes (FPKM>2 in at least one condition). 
2.16 Quantitative real time PCR for gene expression 
 
For gene expression analysis, cDNA was synthesised from total RNA (400ng per 
reaction) using the MultiScribe™ Reverse Transcriptase kit (Life Technologies, 
Paisley, UK). Synthesis was performed by subjecting each sample to 10 min at 25°C 
for primer annealing, 30 min at 48°C to allow for reverse transcription and 5 min at 
95°C for reverse transcriptase inactivation. After synthesis, all samples were stored at 
-20°C until required. Target dependant, quantitative real-time polymerase chain 
reaction (qRT-PCR) was later performed using either Power SYBR green (Life 
Technologies, Paisley, UK) or TaqMan® (Thermo Fisher, Paisley, UK) gene 
expression assays. 
 
SYBR Green based qRT-PCR analysis was conducted utilising Power SYBR Green 
PCR Master Mix (Thermo Fisher, Paisley, UK) and custom PCR primers (Eurofins 
MWG, Ebersberg, Germany). Each custom primer pair was designed to target unique, 
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transcript specific, sequences of MIR503HG. Additionally, a primer pair targeting 
Ubiquitin protein C (UBC) was used as an endogenous control in order to allow for 
normalisation of changes in gene expression. See Table 2.6 for a list of all primers 
used. Further, each reaction was conducted in triplicate using a QuantStudio 7 Flex 
Real-Time PCR System (Thermo Fisher, Paisley, UK), subject to 10 min at 95°C 
followed by 40 cycles of 15 seconds at 95°C and 60 seconds at 60°C for primer 
annealing and extension. Primer specificity was confirmed both by melting curve 
analysis and gel electrophoresis. 
Primer Name Gene Name Sequence 
UBC_Fw UBC 5’ TTGCCTTGACATTCTCGATG 3’ 
UBC_Rv UBC 5’ ATCGCTGTGATCGTCACTTG 3’ 
503HG_1_Fw MIR503HG_001 5’ CCACAGGACAACGAAGAAAACC 3’ 
503HG_1_Rv MIR503HG_001 5’ TACTCCTTTTCCAGTCCTCCCC 3’ 
503HG_2_Fw MIR503HG_002 5’ GTGGAACCCCACACAGGAAA 3’ 
503HG_2_Rv MIR503HG_002 5’ GGACAGTTGCCCATATTAACGG 3’ 
503HG_3_Fw MIR503HG_003 5’ GGACCTGAGCTGTCGATTTCA 3’ 
503HG_3_Rv MIR503HG_003 5’ GAGGGATGGAGGTGGCTTTA 3’ 
Gm28730_Fw Gm28730 5’ CCCCAAATCTAGGCTCCTTTGT 3’ 
Gm28730_Rv Gm28730 5’ ATCAGGACTGACTCATTTGGTGG 3’ 
18S_Fw 18S 5’ GGCCCTGTAATTGGAATGAGTC 3’ 
18S_Rv 18S 5’ CCAAGATCCAACTACGAGCTT 3’ 
NEAT1_Fw NEAT1 5’ CTTCCTCCCTTTAACTTATCCATTCAC 3’ 
NEAT1_Rv NEAT1 5’ CTCTTCCTCCACCATTACCAACAATAC 3’ 
CDC25A_Fw CDC25A 5’ TAAGACCTGTATCTCGTGGCTG 3’ 
CDC25A_Rv CDC25A 5’ CCCTGGTTCACTGCTATCTCT 3’ 
Table 2.6:  SYBR Green qRT-PCR Analysis of Gene Expression.  
List of MIR503HG transcript-specific and housekeeper primers used for SYBR Green-based qRT-PCR 
analysis. 
 
TaqMan® qRT-PCR was performed using the TaqMan® Universal Master Mix II and 
TaqMan® Gene Expression probes following the manufacturer’s protocol (Thermo 
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Fisher, Paisley, UK) (Table 2.7 and Table 2.8). Further, each reaction was conducted 
in triplicate using a QuantStudio 7 Flex Real-Time PCR System real time PCR system 
(Thermo Fisher, Paisley, UK) , subject to 10 min at 95°C followed by 40 cycles of 15 
seconds at 95°C and 60 seconds at 60°C for primer annealing and extension. 
 
For microRNA analysis, cDNA was generated from total RNA (5ng per reaction) 
using the TaqMan® miRNA Reverse Transcription kit and specific TaqMan® miRNA 
reverse transcription primers (Thermo Fisher, Paisley, UK) (Table 2.7 and Table 2.8). 
Synthesis was performed by subjecting each sample to 30 min at 16°C for primer 
annealing, 30 min at 42°C to allow for reverse transcription and 5 min at 85°C for 
reverse transcriptase inactivation. After synthesis, all samples were stored at -20°C 
until required. Note that, RNU48 was selected as an endogenous control miRNA to 
allow for normalisation of changes in miRNA expression. 
Gene ID Assay ID  microRNA ID Assay ID 
UBC Hs01871556_s1  RNU48 001006 
PECAM1 Hs01065282_m1  miR-424-5p 000604 
CDH5 Hs00901465_m1  miR-424-3p 002309 
SNAI1 Hs00195591_m1  miR-450a-5p 002303 
SNAI2 Hs00161904_m1  miR-450a-1-3p 469835 
S100A4 Hs00243202_m1  miR-450b-5p 002207 
ACTA2 Hs00426835_g1  miR-450b-3p 002208 
COL1A1 Hs00164004_m1  miR-503-5p 001048 
COL3A1 Hs00943809_m1  miR-503-3p 476380 
VIM Hs00958111_m1  miR-542-5p 002240 
FGF2 Hs00266645_m1  miR-542-3p 001284 
FGFR1 Hs00241111_m1    
Table 2.7:  Taqman qRT-PCR Analysis of Gene Expression in Humans. 
List of gene and microRNA TaqMan probes used for qRT-PCR analysis 
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Gene ID Assay ID  microRNA ID Assay ID 
18S Mm03928990_g1  U6  
PECAM1 Mm01242576_m1  miR-322-5p 001076 
CDH5 Mm00486938_m1  miR-503-5p 002456 
NOS3 Mm00435217_m1    
SNAI2 Mm00441531_m1    
ACTA2 Mm00725412_s1    
COL1A1 Mm00801666_g1    
VIM Mm01333430_m1    
Table 2.8:  Taqman qRT-PCR Analysis of Gene Expression in Mice.  
List of gene and microRNA TaqMan probes used for qRT-PCR analysis 
 
MicroRNA qRT-PCR was performed using specific TaqMan® miRNA RT-PCR 
probes (Table 2.7 and Table 2.8), and TaqMan® Universal Master Mix II following 
the manufacturer’s protocol (Thermo Fisher, Paisley, UK).  
As with previous assays, each reaction was conducted in triplicate using a QuantStudio 
7 Flex Real-Time PCR System (Thermo Fisher, Paisley, UK), subject to 10 min at 
95°C followed by 40 cycles of 15 seconds at 95°C and 60 seconds at 60°C for primer 
annealing and extension. 
 
All qRT-PCR data obtained (SYBR, mRNA and microRNA) was analysed using the 
2-ΔΔCt method, as described by Livak & Schmittgen. 2-ΔΔCt values were used to 
calculate the fold change (described as FC or RQ) in gene expression between the 
experimental and control groups. 
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2.17 Endothelial barrier integrity assay 
The Electric Cell-substrate Impedance Sensing (ECIS) assay was implemented using 
8-well 8W1E arrays via a ECIS® Z-Theta station (Applied Biophysics), as per the 
manufacturer’s instructions.  All arrays were treated using 10 mM L-cysteine (C7352-
25G, Sigma-Aldrich) and coated with Collagen Type I (C3867-1VL, Sigma-Aldrich). 
A total of 4x104 HUVEC were seeded into each well of the array and allowed to adhere 
overnight. The assay was then conducted using a monitoring frequency of 4 kHz for a 
total of 5 h.  All impedance measurements were analysed using ECIS mathematical 
modelling software (Applied Biophysics) to determine cell barrier resistance (Rb), 
expressed as Ohm x cm2 433,434. All data was analysed using GraphPad Prism 8 and 
presented as mean ± SEM. 
2.18 Transwell Migration Assay 
The migration assay was carried out in 24-well migration chambers with 
polycarbonate 8-μm pore membrane filters (#CLS3422; Corning, Poole, UK). Prior to 
use, each chamber was coated with a 10ug/ml fibronectin in 0.1% Gelatine mixture 
and allowed to dry for 2 h. A total of 3x104 HUVEC were seeded with 200 μl 0.1% 
BSA basal medium in the upper layer of each transwell chamber, a total of 400 μl of 
either 10% FBS basal medium or 0.1% BSA basal medium was also added to the lower 
portion of each well. The cells were allowed to incubate at 37°C with 5% CO2 for a 
total of 6 h, the migrated cells then fixed using methanol and stained with DAPI. 
Images of migrated cells were obtained by fluorescence microscopy (Zeiss AxioSkop 
Upright Fluorescence Microscope) and counted in 5 random fields (x10) of each well. 
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2.19 EdU Proliferation Assay and Cell Cycle Analysis 
To measure HUVECs proliferation Click-iT® EdU Flow Cytometry Cell Proliferation 
Assay (Invitrogen) was used according to manufacturer’s instructions. 24 h prior 
harvest cells were counted and re-plated in equal numbers. Cells were incubated with 
10 uM EdU for 4 h alongside an unstained negative control, detached using trypsin 
and labelled with live/dead dye according to manufacturer’s recommendations 
(Zombie NIR™ Fixable Viability Kit (Biolegend, 1:500) before being fixed and 
permeabilised. EdU incorporation was quantified using Click-it chemistry conjugated 
with an Alexa Fluor 488 antibody according to the manufacturer's protocol. To 
separate the cell cycle phases cells were incubated with 2.5 ug/ml DAPI briefly before 
acquiring the samples on BD LSRFortessa™ cell analyser. 
2.20 Statistical Analysis 
All data given was shown as mean ± standard error of the mean (SEM) on biological 
or technical replicates as detailed in the figure legends. All biological replicates using 
human primary cells correspond to independent experiments from distinct expansions 
and passage numbers. All experimental data was analysed by paired two-tailed t-test, 
one-way analysis of variance (ANOVA) or two-way ANOVA with a Bonferroni 
multiple comparisons test, as indicated. A P value of less than 0.05 was considered 
statistically significant. Statistical analysis was performed using ΔCt values, which 
reflect the difference in cycle threshold (Ct) between the target gene and appropriate 
housekeeping gene.   
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Whilst EndMT can be activated by several signalling pathways, its precise 
transcriptional profile and molecular mechanisms are yet to be rigorously defined.  
This is particularly true with the discovery of lncRNA as multifaceted regulators of 
cell function, both at the transcriptional and post-transcriptional level 286. Nonetheless, 
the role lncRNAs in EndMT is yet to be thoroughly explored and relatively few have 
been reported in the regulation of EndMT so far. The lncRNA MALAT1, for example, 
was the first to be implicated in the modulation of TGF-β-induced EndMT, still this 
was show to happen through the regulation of miR-145 on the TGFBR2/SMAD3 axis 
397. Recently, the lncRNA GATA6-AS was shown to suppress TGF-β-induced EndMT 
in vitro via LOXL2 to regulate chromatin remodelling.  Although this interaction may 
be present, the study relied largely on vein ECs and results may not be applicable to 
EndMT in other ECs  398.  
Ultimately, while these studies represent a step forward in the field, more 
comprehensive reports across multiple endothelial phenotypes are needed. Our group 
used high-throughput RNA sequencing (RNAseq) of HUVEC and HPAEC 
undergoing EndMT in vitro. The project aimed to investigate the common 
transcriptional architecture of EndMT across ECs originated from different vascular 
beds and with it identify previously unreported lncRNAs (data presented as part of 
Section 3.3). Initial bioinformatics analysis revealed 103 differentially expressed 
lncRNAs during EndMT in both HUVEC and HPAEC. Among them, the significant 
loss of the lncRNA MIR503HG was found to be a consistent event during the initial 
stages of EndMT. The present chapter will expand on these initial results, describe the 




Figure 3.1:  MIR503HG locus.  
Schematic representation of the MIR503HG, miRNA-424 and miRNA-503 locus (ChrX q26.3) 
(Ensembl Genome Browser (GRCh38.p10). 
MIR503HG is an intergenic lncRNA located on chromosome X (Xq26) with five 
isoforms reported in GENCODE (Figure 3.1). First described in 2014 solely as a 
miRNA precursor, the lncRNA locus was found to be highly conserved across 11 
tetrapod species (human, chimpanzee, bonobo, gorilla, orangutan, macaque, mouse, 
opossum, platypus, chicken and frog) and believed to originate from a common 
tetrapod ancestor 435. Since this first report, a wealth of studies have started to emerge 
showing that the lncRNA not only had its own independent transcriptional pattern but 
also a functional role in both epithelial and endothelial cells 381,436, making it an 
attractive candidate.  
 
Early reports have described MIR503HG as an hypoxia-sensitive non-coding RNA 
with a potential role in EC function. Gain- and loss-of-function in vitro studies by 
Fiedler and colleagues were the first to show that MIR503HG-deficient ECs exhibited 











effects. Similarly, silencing MIR503HG in a engineered heart tissue ex vivo model 
resulted in impaired endothelial biology and tissue vascularisation 381. 
The potential of these pro-angiogenic regulatory features led subsequent studies to 
look at impact of MIR53HG in tumorigenesis and tumour progression.  However, 
unlike earlier EC reports, siRNA-mediated knockdown of MIR503HG was found to 
significantly enhance migration and invasion in human hepatocarcinoma cell (HCC) 
lines, while its overexpression had the opposite effect both in vitro and in vivo 437. 
Similar effects were also observed in choriocarcinoma 438, triple‐negative breast cancer 
439 and human colorectal cancer cell lines 440. 
Conflicting reports were also seen regarding the lncRNAs effect on cell proliferation. 
While MIR503HG knockdown significantly enhanced trophoblast cell proliferation, 
this was supressed in anaplastic lymphoma kinase (ALK)-negative tumour cells 441,442. 
Ultimately, these results highlight cell-specific and context-dependent mechanisms of 
MIR503HG,  a common feature of several lncRNA 396. 
 
Despite the reported differences in MIR503HG function across cell types, the lncRNA 
has often been associated with cell migration and proliferation 381,437,441,442, all key 
features of EndMT 61. Recently, MIR503HG has also been associated to epithelial‐
mesenchymal transition with overexpression of the lncRNA increasing the availability 
of E‐cadherin and decreasing the expression and translation of several transition‐
associated genes, such as ZEB1, SNAI1, N‐cadherin, and vimentin 436,441. This, along 
with our preliminary results showing a remarkable EndMT in vitro phenotype after 
MIR503HG depletion, warrant further functional analysis.  
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3.2 Aims 
Previous RNAseq analysis by our group showed a marked downregulation of 
MIR503HG in both HUVEC and HPAEC during EndMT, which warranted further 
research. As such, the aims of this chapter were as follows: 
• To replicate a baseline EndMT in vitro model and delineate key markers; 
• To validate the expression profile of MIR503HG during EndMT in vitro; 
• Confirm differential MIR503HG expression in multiple EC phenotypes; 
• To identify the function of MIR503HG in ECs; 





In order to replicate EndMT in vitro and delineate its key molecular markers, we used 
a 7 day TGF-β2 and IL-1β co-stimulation model developed by our lab based on 
previous publications 81. This served to guide and interpret the results presented 
throughout this thesis.  
First, we performed gene expression analysis of HUVEC and HPAEC co-stimulated 
with a daily dose of TGF-β2 (10 ng/mL) and IL-1β (1 ng/mL) for a total of 7 days. In 
line with previous validation work performed by our lab (unpublished), this protocol 
induced a significant increase in the expression of SNAI2, ACTA2 and COL1A1, 
accompanied by a marked repression of PECAM1 (Figure 3.2). These changes were 
confirmed by flow cytometry analysis of co-stimulated cells again showing a similar 
decrease in PECAM1 expression, accompanied by an increase in ACTA2 and SNAI2, 
compared to an untreated control (Figure 3.3). Crucially, only TGF-β2 and IL-1β co-
stimulation was able to induce significant changes, suggesting that both cytokines are 
essential to trigger the appearance of an EndMT-like phenotype.   
Consistent with our results, immunofluorescence microscopy showed that the loss of 
intercellular junctions was accompanied disruption of the endothelial monolayer, 
along with an increase in mesenchymal marker expression and the acquisition of a 
fibroblast-like phenotype (Figure 3.4). Together, these findings demonstrate that the 





Figure 3.2: EndMT in vitro model in arterial and venous ECs.  
ECs were treated with TGF-β2 (10 ng/mL) and IL-1β (1 ng/mL) in combination or alone for 7 days. 
Change in expression of EndMT markers in (A) HUVEC and (B) HPAEC expressed as RQ. RQ values 
for gene expression were quantified by qRT-PCR assay relative to UBC (n=3 biological replicates). 











































































































































































































































Figure 3.3: EndMT in vitro model in arterial and venous EC.  
EndMT marker protein expression changes analysed by flow cytometry in HUVEC and HPAEC 
following TGF-β2 (10 ng/mL) and IL-1β (1 ng/mL) treatment in combination or alone for 7 days 
quantified by mean fluorescence intensity (MFI). Data presented with representative histograms of 
untreated control cells (grey) compared to co-treated cells (red) (n=3 biological replicates). Analysis by 
one-way ANOVA; *p≤0.05, ** p≤0.01, and *** p≤0.001. Data represented as mean ±SEM. This work 



























































































































































Figure 3.4: EndMT in vitro model in arterial and venous EC.  
Representative immunofluorescence images of EndMT marker expression in HUVEC and HPAEC 
following TGF-β2 (10 ng/mL) and IL-1β (1 ng/mL) treatment in combination or alone for 7 days (20X, 
scale bar 50 μm). PECAM1 in green, ACTA2/COL1A1/SNAI2 in red and DAPI (nucleus) in blue. 
Images acquired with Andor Revolution XDi spinning disk confocal microscope and analysed with 











In order to further characterise our in vitro EndMT model and identify key 
transcriptional changes, we performed high-throughput RNAseq of both HUVEC and 
HPAEC undergoing transition. Principal component analysis (PCA) of the 
differentially expressed transcriptome revealed that both treatment groups clustered 
separately from their respective untreated control (Figure 3.5 A). Interestingly, both 
HUVEC and HPAEC treatment groups also clustered separately from each other, 
clearly suggesting transcriptional heterogeneity in the induction of EndMT across 
different vascular beds (Figure 3.5 A). Despite the heterogenous EndMT profiles, our 
analysis revealed a pool of expressed genes regulated in both transitioning HUVEC 
and HPAEC. More precisely, 606 genes were up-regulated in both groups, while 583 
were down-regulated (Figure 3.5 B-C). 
Within this shared transcriptional profile, we have further identified a group of known 
lncRNAs whose expression was altered during EndMT.  A total of 69 lncRNAs were 
up-regulated and 34 down-regulated across both different vascular bed ECs.  Of these, 
based on fold change (FC), FPKM levels , genomic location, as well as available 
publications, we selected 9 top candidates: MIR503HG, HOTAIRM1, AC123023.1, 
CTC-378h22.1, LINC00702, MIR3142HG, RP-37B2.1, AC147651.4 and RP11-
79h23.3 (Figure 3.5 D-F). Despite their individual merits, for the purpose of this thesis, 
only MIR503HG was selected for further validation and downstream analysis.   
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Figure 3.5: RNAseq analysis of EndMT identifying a common lncRNA signature.  
(A) PCA plot of Control and EndMT HUVEC and HPAEC RNAseq samples. (B) Venn diagram of the 
overlap between up-regulated genes and down-regulated genes during EndMT in HUVEC and HPAEC. 
(C) Heatmap showing the expression data (as z-score) of differentially expressed genes, including 
lncRNAs. (D) List of selected top candidate lncRNAs for downstream analysis. Representative 
expression of candidate lncRNAs in (E) HUVEC and (F) HPAEC ± EndMT treatment. Expression 
values shown as FPKM. Data represented as mean ±SEM. RNAseq sample preparation was carried out 




















































































































4 5 C on tro l
E n dM T


























































2 0 C on tro l
E n dM T


























RNA sequencing data from our EndMT in vitro model showed a clear downregulation 
of all MIR503HG isoforms. However, only those reaching a minimum FPKM value 
above 1 (isoforms 2, 3 and 5) were selected for further qRT-PCR validation (Figure 
3.6). As with the RNAseq dataset, all selected isoforms exhibited a significant 
downregulation in both HUVEC and HPAEC at day 7 after EndMT co-treatment 
(Figure 3.7).  
To further assess the broad relevance of MIR503HG down-regulation in EndMT, we 
extended our analysis to ECs from different vascular beds, including Human 
Saphenous Vein Endothelial Cells (HSVEC) and Human Coronary Artery Endothelial 
Cells (HCAEC), in addition to HUVEC and HPAEC. Down-regulation of MIR503HG 
after TGF- β2 and IL-1β co-treatment was found to be consistent across all studied 
vascular beds (Figure 3.8).  
Additionally, we also found decreased MIR503HG expression in a previously 
published alternative in vitro model of EndMT, consisting of TGF- β2 and H2O2 co-
stimulation 53 (Figure 3.9).  Ultimately, our results show that independent of 
endothelial origin or in vitro model used, the loss of MIR503HG expression is strongly 
associated with the process EndMT. 
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Figure 3.6: MIR503HG expression during EndMT. 
Representative expression of MIR503HG by isoform in HUVEC after ± EndMT treatment. Expression 
values shown as FPKM. Data represented as mean ±SEM. 
 
 
Figure 3.7:  Validation of MIR503HG expression during EndMT.  
Expression of MIR503HG_2/3/5 in HUVEC ± EndMT treatment (n=4 biological replicates). RQ value 
for gene expression was quantified by qRT-PCR assay relative to untreated control cells. Analysis by 
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Figure 3.8:  MIR503HG expression during EndMT across different EC beds.  
Expression of MIR503HG_2 in HUVEC, HSVEC, HCAEC and HPAEC ± EndMT treatment (n=3 
biological replicates). RQ value for gene expression was quantified by qRT-PCR assay relative to 
untreated control cells. Analysis by two-tailed t-test; *p≤0.05 and ** p≤0.01 vs paired control. Data 
represented as mean ±SEM. This work was performed in collaboration with Dr Axelle Caudrillier and 
Ms Shiau Haln Chen.  
 
 
Figure 3.9: TGF-β2 and H2O2 in vitro model of EndMT. 
Expression of (A) MIR503HG_2, (B) MIR503HG_3 and (C) MIR503HG_5 in HUVEC after treatment 
with TGF-β2 (50 ng/mL) ± H2O2 (200 nM) (n=3 biological replicates). RQ values for gene expression 
were quantified by qRT-PCR assay relative to untreated cells. Analysis by one-way ANOVA; *p≤0.05, 
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Subcellular localisation is of key importance to understand the putative function and 
mechanism of action of a lncRNA 314. Fractionation of EC nuclear and cytoplasmic 
compartments demonstrated that MIR503HG was enriched in the nucleus under both 
basal and TGF-β2 and IL-1β co-stimulation conditions (Figure 3.10).   
 
Figure 3.10: MIR503HG Subcellular Localisation 
Subcellular localisation of (A) MIR503HG_2, MIR503HG_3 and MIR503HG_5, and (B) fractionation 
controls 18S and NEAT in HUVEC ± EndMT treatment. Cell fraction value for gene expression was 
quantified by qRT-PCR assay relative to UBC (n=3 technical replicates). 
 
 
To further asses the contribution of MIR503HG to EndMT we used a Dicer substrate 
siRNA (si503HG) to knockdown the lncRNA in HUVEC. The resulting cellular 
phenotype was evaluated based on our defined EndMT markers (i.e. PECAM1, 
ACTA2, SNAI2, COL1A1). The effectiveness of the knockdown was first confirmed 
in untreated HUVEC 3 days after si503HG transfection, with the expression of all 
MIR503HG isoforms significantly downregulated (Figure 3.11). Further, MIR503HG 
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knockdown was found to be sustained for 7 days after transfection and lead to 
significant changes in EndMT markers in the absence of TGF-β2 and IL-1β co-
stimulation (Figure 3.12 A). RT-qPCR analysis of HUVEC transfected with si503HG 
revealed a decrease of PECAM1, along with an increase in SNAI2, ACTA2 and 
COL1A1 at day 7 (Figure 3.12 B).  These effects were mirrored at the protein level as 
demonstrated by flow cytometry analysis (Figure 3.13 A-B). Further, 
immunofluorescence imaging showed a loss of monolayer formation and clear cell 
morphology changes, as shown by reduced PECAM1 expression, and the gain of 
mesenchymal protein expression with SNAI2 and COL1A1 (Figure 3.13 C).  
 
Figure 3.11: MIR503HG siRNA-mediated knockdown at day 3. 
Expression of MIR503HG_2, MIR503HG_3 and MIR503HG_5 in HUVEC at day 3 after transfection 
with si503HG (20 nM) compared to paired control. RQ value for gene expression was quantified by 
qRT-PCR assay relative to UBC (n=3 technical replicates). Analysis by two-tailed t-test; *p≤0.05, ** 




Figure 3.12: MIR503HG siRNA-mediated knockdown induces EndMT.  
Expression of (A) MIR503HG_2/3/5 and (B) EndMT marker genes in HUVEC 7 days after knockdown 
using si503HG (20 nM) compared to paired control. RQ value for gene expression was quantified by 
qRT-PCR assay relative to UBC (n=5 biological replicates). Analysis by two-tailed t-test; *p≤0.05, ** 



























































































































































Figure 3.13: MIR503HG siRNA-mediated knockdown induces EndMT.  
(A) EndMT marker expression analysed by flow cytometry 7 days after knockdown using si503HG. 
Representative histograms for controls cells (grey) compared to si503HG-cells (red) and (B) MFI 
quantification (n=3 biological replicates). Analysis by two-tailed t-test; *p≤0.05, ** p≤0.01, and *** 
p≤0.001 vs paired siControl. Data represented as mean ±SEM. (C) Representative immunofluorescence 
images of EndMT markers expression in HUVEC (20X, scale bar 50 μm) 7 days after knockdown using 
si503HG (20 nM) compared to paired control. PECAM1 in green, ACTA2/COL1A1/SNAI2 in red and 
DAPI in blue.  Images acquired with Andor Revolution XDi spinning disk confocal microscope and 













































































Given its nuclear localisation, an antisense GapmeR (gap503HG) was also used to 
manipulate MIR503HG expression. Knockdown was validated in untreated HUVEC 
3 days after transfection, confirming that the expression of all MIR503HG isoforms 
was significantly downregulated (Figure 3.14). Knockdown using gap503HG was 
found to induce a robust EndMT profile in the absence of TGF-β2 and IL-1β co-
stimulation at 7 days, show by RT-qPCR analysis (Figure 3.15).  
Duplicating the effect seen with si503HG, this was mirrored at the protein level as 
confirmed by both flow cytometry analysis and immunofluorescence imaging (Figure 
3.16). 
 
Figure 3.14: MIR503HG gapmer-mediated knockdown at day 3.  
Expression of MIR503HG_2, MIR503HG_3 and MIR503HG_5 in HUVEC at day 3 after transfection 
with gap503HG (20 nM) compared to paired control. RQ value for gene expression was quantified by 
qRT-PCR assay relative to UBC (n=3 technical replicates). Analysis by two-tailed t-test; *p≤0.05, ** 







Figure 3.15: MIR503HG gapmeR-mediated knockdown induces EndMT.  
Expression of (A) MIR503HG_2/3/5 and (B) EndMT marker genes in HUVEC 7 days after knockdown 
using gap503HG (20 nM) compared to paired control. RQ value for gene expression was quantified by 
qRT-PCR assay relative to UBC (n=4 biological replicates). Analysis by two-tailed t-test; *p≤0.05, ** 





























































































































































Figure 3.16: MIR503HG gapmeR-mediated knockdown induces EndMT.  
(A) EndMT marker expression analysed by flow cytometry 7 days after knockdown using gap503HG. 
Representative histograms for controls cells (grey) compared to gap503HG-cells (red) and (B) MFI 
quantification (n=3 biological replicates). Analysis by two-tailed t-test; *p≤0.05, ** p≤0.01, and *** 
p≤0.001 vs paired gapControl. Data represented as mean ±SEM. (C) Representative 
immunofluorescence images of EndMT markers expression in HUVEC (20X, scale bar 50 μm) 7 days 
after knockdown using gap503HG. PECAM1 in green, ACTA2/COL1A1/SNAI2 in red and DAPI in 
blue.  Images acquired with Andor Revolution XDi spinning disk confocal microscope and analysed 




By comparing the MIR503HG locus sequence against that of 100 vertebrates, we 
found that the final 595 base-pair region of isoform 2 (MIR503HG_2) was highly 
conserved (Figure 3.17), as was its secondary substructure 438. As such, we chose 
MIR503HG_2 as our transcript of interest. To further understand the role of 
MIR503HG during EndMT, we designed a lentiviral vector carrying the entire 760bp 
sequence of the MIR503HG_2 mature transcript (LNT_503HG), which does not 
include the sequences encoding for miRNA-424 and miRNA-503 found within the 
lncRNA locus (Figure 3.1). The lentiviral construct was initially validated in untreated 
HUVEC 3 days after transduction, this resulted in an increase in MIR503HG_2 
expression but not MIR503HG_3 or 5 (Figure 3.18). In order to confirm that the 
overexpression was restricted to the cell nucleus, given the endogenous lncRNAs 
nuclear localisation, we carried out cellular fractionation and subsequent qPCR 
analysis on HUVECs overexpressing MIR503HG_2. In control conditions, 
MIR503HG_2 is predominately nuclear, with 2.7% cytoplasmic expression. Whilst 
this does increase to 7.3% after overexpression, MIR503HG_2 remains predominately 




Figure 3.17:  MIR503HG locus conservation and annotation in vertebrates. 
MIR503HG transcript annotation and conservation based on UCSC genome Browser data (GENCODE 
v24) from 100 vertebrates (PhyloP score and multiple alignment with Multiz). The red box highlights 




Figure 3.18: Lentiviral overexpression of MIR503HG_2 at day 3.  
Expression of MIR503HG_2, MIR503HG_3 and MIR503HG_5 in HUVEC at day 3 after lentiviral 
transduction with LNT_503HG (isoform 2) with a MOI 5 compared to a paired control. RQ value for 
gene expression was quantified by qRT-PCR assay relative to UBC (n=3 technical replicates). Analysis 






Figure 3.19:  Subcellular Localisation of MIR503HG after lentiviral overexpression. 
Subcellular localisation of (A) MIR503HG_2, MIR503HG_3 and MIR503HG_5, and (B) fractionation 
controls 18S and NEAT in HUVEC at day 3 after lentiviral transduction with LNT_503HG (isoform 2) 
with a MOI 5 compared to a paired control. Cell fraction value for gene expression was quantified by 
qRT-PCR assay relative to UBC (n=3 technical replicates). 
 
By day 7, untreated HUVEC infected by LNT_503HG showed a 4.8 (±1.3) fold 
increase in MIR503HG_2 expression compared to an empty lentiviral control 
(LNT_CT) (Figure 3.20 A), without any changes in endothelial or mesenchymal 
markers (Figure 3.20 B). Under EndMT conditions, MIR503HG overexpressing cells 
presented a significantly higher PECAM1 expression, and a marked suppression of 
SNAI2 and COL1A1 expression by day 7 when compared to co-treated LNT_CT cells 
(Figure 3.20). Immunofluorescence (Figure 3.21) and flow cytometry (Figure 3.22) 
further validated these results at the protein level. 
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Figure 3.20: MIR503HG overexpression represses EndMT in vitro.  
Expression of (A) MIR503HG_2/3/5 and (B) EndMT marker genes in HUVEC 7 days following 
MIR503HG overexpression with LNT_503_2 (MOI 5) ± EndMT (n=5 biological replicates). Analysis 






























































































































































































Figure 3.21: MIR503HG overexpression represses EndMT in vitro.  
Representative immunofluorescence images of EndMT marker expression in HUVEC 7 days following 
MIR503HG overexpression with LNT_503_2 (MOI 5) ± EndMT (20X, scale bar 50 μm). PECAM1 in 
green, ACTA2/COL1A1/SNAI2 in red and DAPI (nucleus) in blue. Images acquired with Andor 
Revolution XDi spinning disk confocal microscope and analysed with Image J Software. This work was 





Figure 3.22: MIR503HG overexpression represses EndMT in vitro.  
Flow cytometry analysis of EndMT marker protein expression in HUVEC 7 days following MIR503HG 
overexpression with LNT_503_2 (MOI 5) ± EndMT. (A) Representative histograms for EndMT-
LNT_CT (grey) compared to EndMT- LNT_503_2 (red) and (B) MFI quantification (n=3 biological 
replicates). Analysis by two-way ANOVA; *p≤0.05, ** p≤0.01, and *** p≤0.001. Data represented as 













































































To identify the contribution of MIR503HG to endothelial function and which regulated 
pathways may be involved in EndMT progression, we performed deep RNAseq on 
cells overexpressing MIR503HG_2 (LNT_503HG_2) during TGF-b2 and IL-1b co-
treatment. PCA revealed that MIR503HG_2 overexpression alone had no major effect 
on the transcriptome of untreated cells (CT_LNT_503HG), However, when over 
expressed during EndMT (EndMT_LNT_503HG), treated cells clustered in  proximity 
to their respective untreated controls (Figure 3.23 A).  Additionally, in 
EndMT_LNT_503HG cells, we found that a total of 877 genes were significantly up-
regulated and 1047 down-regulated by day 7 (Figure 3.23 B-C). Of these, there was a 
substantial overlap in genes that were regulated in opposing directions during EndMT 
prevention and induction, with approximately 28% of EndMT-associated genes 
affected by MIR503HG_2 overexpression (Figure 3.23 B-C). Gene ontology (GO) 
term analysis of genes affected by MIR503HG, relative to all EndMT-associated 
changes, showed an overlap in functions linked to both cell adhesion and migration 
(Figure 3.23 D). Migration-associated genes such as MMP1, ITGA6 and 
HNRNPA2B1 were downregulated, whereas those associated with proliferation such 




Figure 3.23: Transcriptome analysis of MIR503HG overexpression during EndMT 
RNAseq samples represented as (A) PCA plot and (B) Heatmap (z-score). (C) Venn diagram of the 
overlap between significant change after LNT_503HG vs LNT_CT in EndMT-cells and EndMT 
changes (EndMT vs untreated). (D) Gene Ontology analysis of the genes regulated by LNT_503HG 
compared to the genes affected by EndMT (background). Bioinformatic analysis shown was carried out 




Along with key transcriptional changes, EndMT is often associated with abnormal cell 
proliferation 61,172. As such, we used an EdU cell proliferation assay to stain live cells 
and flow cytometry analysis to quantify EdU uptake after a 4 h incubation period. Our 
results showed that knockdown of the MIR503HG locus led to a significant decreased 
in cell proliferation, with only 15.4% of si503HG transfected cells incorporating EdU, 
compared to 35.9% with siControl (Figure 3.24). This mirrored our 7-day in vitro 
model of EndMT, showing similar differences in EdU incorporating between co-
treated and untreated cells (Figure 3.25). 
These changes were found to be associated with abnormal cell cycle progression. Cell 
cycle analysis demonstrated that MIR503HG locus knockdown induced G1-phase 
retention, acutely blocking S-phase entry (Figure 3.26). Again, fully mirroring our 7-
day in vitro model of EndMT (Figure 3.27). 
Notably, these changes were also accompanied by a substantial increase in forward 
scatter (FSC) and side scatter (SSC) intensity as measured by flow cytometry (Figure 
3.28 and Figure 3.29). Changes to FSC intensity are proportional to cell diameter and 
SSC to cell granularity, thus indicating not only changes in cell size, but also the 





Figure 3.24: MIR503HG knockdown mediated changes to cell proliferation. 
(A) Representative FACS histogram plots for EdU incorporation by HUVEC at Day 7 following 
DsiRNA-mediated knockdown. EdU+ box highlights the intensity of EdU signal used as an indicator 
of the proliferative state of the cells. (B) Bar chart showing mean changes for EdU incorporation (n=3 







































Figure 3.25: EndMT mediated changes to cell proliferation. 
(A) Representative FACS histogram plots for EdU incorporation by HUVEC at Day 7 following TGF-
β2+IL-1β treatment. EdU+ box highlights the intensity of EdU signal used as an indicator of the 
proliferative state of the cells. (B) Bar chart showing mean changes for EdU incorporation (n=3 
biological replicates). Data represented as mean ±SEM. Analysis by two-tailed t-test; ***p≤0.001 vs 








Figure 3.26: MIR503HG knockdown mediated changes to cell cycle. 
(A) Representative FACS dot plots of cell cycle profile of HUVECs treated with EdU and DAPI at Day 
7 following DsiRNA-mediated knockdown. EdU+ box highlights the intensity of EdU signal used as 
an indicator of the proliferative state of the cells.  (B) Bar chart showing mean changes in distribution 
of cells between cell cycle phases (n=3 biological replicates). Data represented as mean ±SEM. Analysis 






Figure 3.27: EndMT mediated changes to cell cycle. 
(A) Representative FACS dot plots of cell cycle profile of HUVECs treated with EdU and DAPI at Day 
7 following TGF-β2+IL-1β treatment. EdU+ box highlights the intensity of EdU signal used as an 
indicator of the proliferative state of the cells.  (B) Bar chart showing mean changes in distribution of 
cells between cell cycle phases (n=3 biological replicates). Data represented as mean ±SEM. Analysis 
by two-tailed t-test; *p≤0.05, ** p≤0.01, and ***p≤0.001 vs paired untreated control. This work was 





Figure 3.28: MIR503HG knockdown mediated changes to cell size.  
(A) Representative FACS contour plots depicting cell distribution of HUVEC 7 days after knockdown 
using si503HG (Red) compared to paired siControl (Grey). (B) Bar chart showing mean fold change in 
relative cell size calculated as a ratio of FSC-A of si503HG treated cells to siControl cells. Data 
represented as mean ±SEM (n=3 biological replicates). Data analysed as one sample t-test compared to 
hypothetical value of 1; **p≤0.01 vs paired siControl. This work was performed in collaboration with 




Figure 3.29: EndMT mediated changes to cell size.  
(A) Representative FACS contour plots depicting cell distribution of HUVEC after TGF-β2 (10 ng/mL) 
and IL-1β (1 ng/mL) co-treatment for 7 days (Red) compared to an untreated control (Grey). (B) Bar 
chart showing mean fold change in relative cell size calculated as a ratio of FSC-A of TGF-β2+IL-1β 
treated cells to control cells. Data represented as mean ±SEM (n=3 biological replicates). Data analysed 
as one sample t-test compared to hypothetical value of 1; **p≤0.01 vs paired control. This work was 

































Figure 3.30: MIR503HG knockdown mediated changes to cell migration.  
(A) Representative transwell migration assay images of HUVEC 7 days after knockdown using 
si503HG (20nM) compared to siControl (20 nM).  Fixed migrated cells were stained using DAPI and 
imaged by confocal microscopy. (B) Migrated cell average after siRNA transfection. Average 
calculated by counting cell number in five random x10 fields (n=3 biological replicates). Data 
represented as mean ±SEM. Analysis by two-tailed t-test; *p≤0.05 vs paired siControl.  
 
 
Figure 3.31: EndMT mediated changes to cell migration.  
(A) Representative transwell migration assay images of HUVEC 7 days after TGF-β2 (10 ng/mL) and 
IL-1β (1 ng/mL) co-treatment compared to an untreated control. Fixed migrated cells were stained using 
DAPI and imaged by confocal microscopy. (B) Migrated cell average after co-treatment. Average 
calculated by counting cell number in five random x10 fields (n=3 biological replicates). Data 

























Another key feature of cells undergoing EndMT is the acquisition of a migratory 
phenotype. As such, we analysed the effect of MIR503HG depletion on HUVEC using 
a Transwell migration assay. Cell migration was significantly decreased after 7 days 
after MIR503HG knockdown, with the average number of cells per viewing field 
dropping to 216.6±23.5 as opposed to 392.3±50 when using siControl (Figure 3.30). 
Nearly identical results were seen after TGF-β2 and IL-1β co-treatment, with the 
average number of cells per viewing field dropping to 235.6±32.4 as opposed to 
376.6±56.9 when untreated (Figure 3.31). 
3.4 Discussion 
In line with the EndMT-associated lncRNA transcriptional profile described by our 
exploratory RNAseq analysis, in this chapter we identify the loss of the lncRNA 
MIR503HG as a key event in the induction of EndMT in vitro across multiple EC 
phenotypes. Crucially, based on available publications, in the context of this thesis we 
have defined EndMT as a significant decrease in the expression of the endothelial 
marker PECAM1, accompanied by an increase in the transcription factor SNAI2, as 
well as the mesenchymal markers ACTA2 and COL1A1 10,14,15,25,53. However, it is 
important to highlight that there are a wealth of other valid markers used to define this 
transition. For example, expression of the transcription factors SNAI1, TWIST1 a 
ZEB1/2 has been shown to be associated with the loss of EC markers and an EndMT 
profile 37,38,40,444. Unsurprisingly, as shown in Chapter 3.3.2, our RNAseq analysis 
identifies a pool of over 1000 differentially expressed genes in both transitioning 
HUVEC and HPAEC. However, such an exhaustive validation process both at the 
RNA and protein level could not be implemented, thus our choice to limit this to a 
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well-established group of markers whose change in expression strongly supports the 
appearance of an EndMT phenotype. 
Further, while the loss of MIR503HG after TGF-β2 and IL-1β co-treatment was 
consistent across ECs from different vascular beds, conditions such as PAH often 
involve the remodelling of pre-capillary micro-vessels 445. Additional validation 
studies should therefore include a panel of relevant pulmonary microvascular ECs such 
as pulmonary microvascular ECs (PMVEC), previously shown to undergo EndMT 
130,159,446.  
 
Although MIR503HG was first considered to function solely as a miRNA precursor 
gene, it is now understood that the lncRNA has its own independent transcriptional 
pattern and functional role. Importantly, despite the lack of evolutionary conservation 
commonly seen with lncRNA genes, the MIR503HG locus displays remarkable 
conservation across vertebrates. As described by Necsulea and colleagues, the genetic 
locus of MIR503HG likely originated from a common tetrapod ancestor 370  million 
years ago 435. Our own analysis of the locus showed that the final exonic 595 base-pair 
region of MIR503HG_2, largely separated from the conserved miRNA cluster, was 
the transcriptional area with the highest conservation. 
Further, lncRNAs also present secondary structure conservation which may rely on 
short sequences preserved across species rather than large regions 421,422,447. 
Interestingly, when analysed, the secondary structure formed by the final exonic region 
of MIR503HG_2 was similar to that of several non-human primates 438. Ultimately, 
this remarkable sequence and structural conservation suggests the existence of 
functional transcriptional domains beyond its role as a host gene. 
159 
 
DsiRNA-mediated knockdown of MIR503HG induced a robust EndMT profile in the 
absence of any other treatment, including TGF-β2 and IL-1β co-stimulation. While 
this strategy was clearly effective, knockdown of lncRNAs may be heavily impacted 
by their cellular localisation. Given the nuclear accumulation of MIR503HG, the 
reduced presence of RNA interference (RNAi) machinery in the nucleus may limit the 
efficacy of our knockdown strategy. Thus, while nuclear RNAs can still be targeted by 
siRNAs 448,449, the use of an alternative strategy was needed to confirm our results. As 
an alternative, we used an antisense GapmeR target MIR503HG in HUVEC. While 
there was a strong downregulation of all transcripts by day 3, this was not sustained 
for a full 7 days. Nonetheless, this was sufficient to replicate our initial results. As with 
our DsiRNA, changes were seen both at the mRNA and protein level, with a clear 
downregulation of PECAM1, and increased expression of SNAI2, ACTA2 and 
COL1A1.  
Despite the clear association between MIR503HG knockdown and the induction of 
EndMT, we should acknowledge that MIR503HG is encoded and likely transcribed 
alongside miR-424(322) and miR-503. While DsiRNA and GapmeR-mediated 
knockdown are commonly used strategies to target functional RNAs, these reagents 
may also promote the cleavage of unspliced nascent RNA transcripts 450. Thus, our 
knockdown strategy could additionally target the miRNA cluster and confound the 
results show in this chapter. We have attempted to address these issues fully in Chapter 
4. 
Given the complexity of the MIR503HG locus and risk of DsiRNA/Gapmer-induced 
off-target effects, the use of gain-of-function experiments was imperative to further 
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confirm our results. As such, we have also attempted to examine the effects of 
MIR503HG overexpression on EC function and phenotypic commitment. In contrast 
to our knockdown experiments, by increasing the availability of MIR503HG_2 alone 
during our EndMT in vitro model we effectively supressed the appearance of 
mesenchymal markers, while preventing further depletion of endothelial cell-cell 
adhesion molecules. This, along with our knockdown model, suggests that MIR503HG 
may have a key regulatory role in maintaining endothelial homeostasis and that its 
absence allows for the adoption of a mesenchymal phenotype.  
Despite the success of MIR503HG_2 overexpression in repressing EndMT after 
continuous exposure to TGFβ2 and IL1β, this was still a partial inhibition of transition. 
Seeing that this may be due to the over expression of a single isoform and not the 
totality of the MIR503HG locus, in Chapter 6 of this thesis we have outlined a series 
of future studies that may expand on the results presented here.   
 
Along with crucial transcriptional changes to EndMT marker expression, depletion of 
MIR503HG also induced a significant decrease in cell migration and proliferation. 
This appears, in part, to be due to a delay in cell cycle progression leading to an 
accumulation of G1-phase cells, resulting in a significant increase in cell size. This, 
not only fully mimics our TGF-β2 and IL-1β EndMT model, but largely corroborates 
previous published data by Fiedler and colleagues, showing similar changes to EC 
proliferation and migration profiles after MIR503HG knockdown 381.  
Distinct stages of EndMT with different characteristics have also been reported 52. In 
particular, cells with partial versus complete EndMT have been isolated based on the 
level of endothelial markers, with those cells with complete EndMT showing high 
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proliferative and migratory capacity 172. While advanced EndMT may lead to increased 
mesenchymal proliferation, early stage EndMT models, like ours, have been 
associated with a decrease in endothelial proliferation 53,119,451.  Despite canonical 
TGF-β signalling being one of the major drivers of EndMT, its effect will largely 
depend on which receptor pathway is activated. In ECs, TGF-β can act via two distinct 
type I receptors, ALK1 and ALK5 14,56,59. Activation of ALK1, for example, will lead 
to Smad1/5 phosphorylation promoting endothelial migration and proliferation at the 
expense of EndMT 56,59,452,453. On the other hand, despite inducing EMT and EndMT, 
ALK5 signalling and consequent SMAD2/3 phosphorylation will inhibit EC 
proliferation and migration 14,56,454,455. Crucially, as demonstrated by Cooley and 
colleagues, EndMT in a murine vein graft model is dependent on the early activation 
of ALK5 signalling. The appearance of phosphorylated SMAD2/3 was detected in 
transitioning EC at day 3 and 7 but declined after day 14, eventually becoming 
undetectable by day 35 14. 
Of note, while both our EndMT model and MIR503HG knockdown strategy induce 
the expression of mesenchymal markers, by day 7 these cells are still in the initial 
stages of the transition and continue to express endothelial markers. One can speculate 
that, once in a more advanced mesenchymal state, these cells would ultimately reach 
an enhanced proliferative and migratory state. Further in-depth studies are necessary 
to confirm this however. 
 
Given their functional versatility, uncovering the cell-specific molecular interactions 
that dictate the function of lncRNAs is crucial. Unlike mRNAs, which are generally 
exported to the cytoplasm for further processing, lncRNAs can be functionally active 
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in both the cytoplasmic or nuclear compartments. Thus, the nuclear enrichment of 
MIR503HG may narrow down its window of putative mechanistic interactions. For 
example, several nuclear lncRNAs have been shown to regulate gene transcription via 
recruitment of chromatin modifying complexes or chromosome spatial conformation 
or acting as scaffolds joining distal enhancer elements to gene promoters 456.  
With reports suggesting that 60% of annotated LncRNAs are chromatin enriched, 
future studies may implement additional fractionation techniques to isolate chromatin-
associated RNA, in addition to the cytoplasmic and nuclear portions 457. While beyond 
the scope of this thesis, this may guide future RNA-centred studies using techniques 
such as RNA antisense purification (RAP) and chromatin isolation by RNA 
purification (ChIRP) to isolate MIR503HG-associated RNAs, proteins or genomic 
regions 458–460. 
The use of RNAseq-based transcriptome analysis of MIR503HG overexpression 
during EndMT also confirmed its key role in maintaining EC commitment, with over 
28% of transition genes affected by its expression. However, while these 
transcriptional changes may help dictate further experiments, they were too broad to 
find any specific candidates. 
Additionally, our analysis also highlighted several migration regulatory functions. As 
ECs undergoing EndMT have bene reported to migrate into the surrounding tissue this 
may be a biologically conserved function of MIR503HG 14,53. In fact, overexpression 
of MIR503HG has also been previously linked to hepatocellular carcinoma cell 
migration through its interaction with the heterogeneous nuclear ribonucleoprotein 
A2/B1 (HNRNPA2B1) and consequent inhibition of NF-κB, central for migration 437. 
Similarly, during EMT, increased HNRNPA2B1 expression has been shown to 
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promote cell invasion and migration 461 again connecting MIR503HG with regulation 
of migration. It’s important, however, to note that given the cell-specific functions of 
MIR503HG suggested earlier in this chapter, this interaction may not be present in 
ECs. Thus, confirming an interaction between MIR503HG and HNRNPA2B1 in EC 
via RNA immunoprecipitation would be necessary. 
Lastly, while we have provided initial findings on the effect of MIR503HG on gene 
expression and cell function, it is important to point out that further comprehensive 
mechanistic studies are required to identify the molecular targets of MIR503HG.  
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Chapter 4: Identifying the Function of the 
MIR503HG Locus in EndMT
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4.1 Introduction 
Spanning a total of ~7 kb on the minus strand of Xq26.3, the MIR503HG locus encodes 
6 district miRNAs (miR-424, -503, -542, -450-1, - 450-2 and -450b).  Unlike its other 
miRNA counterparts, the miR-424 and miR-503 cluster is found within the intronic 
and exonic regions of MIR503HG and share common regulatory regions ( 
 
Figure 4.1). Both the ENCODE and GeneHancer projects have identified a variety of 
regulatory elements approximately 2 kb upstream from the MIR503HG locus, 
including the gene regulatory histone modification marker H3K27Ac and DNAse I-
hypersensitive clusters 462. Over the past decade miR-424 and miR-503 have also been 
shown, either individually or in unison, to drive a variety of processes key to tissue 
differentiation and remodelling both during development and disease.  
During embryogenesis, for example, miR-424 and miR-503 expression was found to 
be largely restricted to the developing heart and skeletal muscles. This expression 
pattern was found to match that of the transcription factor Mesp1, a master regulator 
of cardiovascular progenitor cell specification and skeletal myogenic differentiation 
463. In an embryonic stem cell (ESC) differentiation model, ectopic expression of miR-
424/-503 was able to specifically drive cardiomyocyte lineage programming while its 
inhibition repressed cardiomyocyte formation 463. Crucially, during heart development 
EMT and EndMT are believed to control formation the mitral and tricuspid valves in 
the atrioventricular canal and the aortic and pulmonary valves in the outflow tract 464–
468. Unsurprisingly, several publications now show that regulating EMT is one of the 
key functions of miR-424/-503 able to deregulate epithelial function and enhance 
mesenchymal programming 469–472. A mechanism by which miR-424/503 amplify 
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TGF-β signalling, and with it EMT, has also been reported. For example, during TGF-
β-induced EMT in human lung epithelial cells miR-424 targeted the E3 ubiquitin 
ligase SMURF2, preventing the degradation of phosphorylated SMAD2 and thus 
enhance TGF-β signalling 473. A similar mechanism was seen with miR-503, which 
again directly interacted with SMURF2 mRNA potentiating TGF-β/SMAD2 
signalling and in turn disrupting intestinal epithelial homeostasis 474. Nonetheless, and 
central the work described herein, a link between the miRNA cluster and EndMT is 
yet to be established. 
Further, much like their lncRNA host, miR-424/503 have also been described as 
hypoxia-sensitive non-coding RNAs with a role in cell proliferation, migration and 
angiogenic response. A seminal paper by Ghosh et al was the first to demonstrate this 
in a variety of human primary ECs, where miR-424 levels were significantly increased 
under hypoxic conditions 475. The paper went on to show that the rodent homolog of 
human miR-424, miR-322, was significantly upregulated in experimental rat 
myocardial infarction and mouse hindlimb ischemia models. Similarly, the expression 
of miR-503 was also strongly upregulated in vitro in ECs after hypoxia and in vivo in 
ischemic limb muscles of diabetic mice 381,476.  
 
 
Figure 4.1: Regulatory regions of the MIR503HG locus. 
MIR503HG locus annotation and regulatory regions based on UCSC genome Browser data 
(GENCODE v24).  
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However, while several papers have continued to show an acute increase in the 
expression of the miRNAs in response to ischemic injury in a variety of tissues 477,478, 
this seems to be largely a context dependent effect. For example, in a cerebral 
ischemia/reperfusion injury mouse model, the expression levels of miR-424 where 
significantly upregulated in the surrounding infarct area at 1 and 4 h after injury but 
downregulated at 24 h 478. The expression of miR-503 was also found to be decreased 
in endothelial progenitor cells (EPCs) under hypoxic conditions, and when 
overexpressed the miRNA suppressed EPC proliferation, migration and tube 
formation 479. Similarly, mice with an endothelial-specific deletion of miR-424(322) 
and miR-503 were reported to have augmented angiogenic responses as demonstrated 
by increased neovascularisation 480.  
Interestingly, in hypoxia/Sugen-induced PH the expression of both miR-424 and miR-
503 was also found to be significantly decreased in association with disrupted apelin 
signalling 203. Apelin is itself is known to maintain pulmonary vascular homeostasis 
and reduced expression and has been linked to hyperproliferative EC phenotypes and 
the development of PAH 203,481,482. As demonstrated by Kim and colleagues, miR-
424/503 are able to exert antiproliferative effects in both pulmonary ECs and SMCs 
by directly targeting FGF2 and FGFR1 203. In fact, restoration of miR-424 and miR-
503 was able to both decrease right ventricular systolic pressures (RVSP), reduce the 
number of muscularised lung microvasculature and drop FGF2/FGFR1 expression in 
a hypoxia/Sugen rat model of PH 203.  
Finally, given the body of evidence presented here, both miR-424 and miR-503 present 
within similar regulatory networks of MIR503HG. Thus, further dissection of the locus 
is necessary to validate the function miRNA cluster independently of MIR503HG. 
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4.2 Aims 
A growing body of evidence now suggests that miRNAs and lncRNAs may be co-
transcribed and/or co-regulated. However, despite the range of studies published, the 
transcriptional and functional overlap between the miRNA cluster and its lncRNA host 
has been largely ignored. As such, the aims of this chapter were as follows: 
• To quantify the expression of the miR-424 and miR-503 during EndMT;  
• To verify if the miRNA cluster is modulated by MIR503HG manipulation; 
• Evaluate the function of miR-424 and miR-503 in EndMT to see if their 






As with previous experiments, miRNA expression was measured in HUVEC co-
stimulated with a continuous dose of TGF-β2 (10 ng/mL) and IL-1β (1 ng/mL) for a 
total of 7 days. qRT-PCR analysis showed a significant down regulation of both 5’ and 
3’ arms (guide and passenger strand) of miR-424(322) and miR-503, much like their 
lncRNA counterpart (Figure 4.2). Further, while both DsiRNA and Gapmer strategies 
described in Chapter 3 were successful in depleting MIR503HG, these may also led to 
the cleavage of nascent RNA transcripts prior to pre-miRNA excision 450. Consistent 
with our experimental EndMT model, knockdown of MIR503HG via si503HG was 
associated with a significant drop in expression of the 5’ arms of miR-424(322) and 
miR-503 (Figure 4.3). However, while mean RQ values were lower, this was not 
significant with gap503HG (Figure 4.3). 
 
 
Figure 4.2:  MIR503HG expression during EndMT in vitro.  
Expression of miRNA-424-5p/3p and miR-503-5p/3p in HUVEC ± EndMT treatment. RQ value for 
gene expression was quantified by qRT-PCR assay relative to untreated control cells (n=4 biological 
replicates). Analysis by two-tailed t-test; *p≤0.05, ** p≤0.01 and *** p≤0.001 vs paired control. Data 
represented as mean ±SEM. 
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Figure 4.3: miR-424 and miR-503 expression after MIR503HG knockdown.  
Expression of miRNA-424-5p/3p and miR-503-5p/3p in HUVEC 7 days after knockdown using 
si503HG (20 nM) or Gap503HG (20 nM) compared to a paired control. RQ values for gene expression 
were quantified by qRT-PCR assay relative to RNU48 (n=3 biological replicates). Analysis by two-




Figure 4.4: miR-424 and miR-503 expression after MIR503HG overexpression.  
Expression of miRNA-424-5p/3p and miR-503-5p/3p in HUVEC 7 days following MIR503HG 
overexpression with LNT_503_2 (MOI 5) ± EndMT. RQ values for gene expression were quantified 
by qRT-PCR assay relative to RNU48 (n=3 biological replicates). Analysis by two-way ANOVA; 
*p≤0.05, ** p≤0.01, and *** p≤0.001 vs paired control. Data represented as mean ±SEM. 
 
In order to understand the role of MIR503HG during EndMT, we designed a lentiviral 
vector carrying the entire 760 bp sequence of the MIR503HG_2 mature transcript 
(LNT_503HG), which did not include the sequences encoding the two miRNAs. 
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Crucially, overexpression of MIR503HG in untreated HUVEC did not affect miR-424-
5p or miR-503-5p levels compared to LNT_CT alone (Figure 4.4). In EndMT-treated 
cells, MIR503HG overexpression again did not affect miRNA levels, compared to 
EndMT-LNT_CT cells; suggesting that the effects of MIR503HG on EndMT may be 
independent of miRNA regulation. 
 
 
Figure 4.5: Gene expression profile of miR-503 and miR-424 mRNA targets during EndMT.  
Heatmap of predicted miR-503 and miR-424 targets relative to their expression levels in the RNAseq. 
Target list obtained using miRTarbase.  Z-score represents the deviation from the mean by standard 
deviation units of the Log2 (FPKM) for each gene. Bioinformatics analysis shown was carried out by 
























Loss of MIR503HG, be it via targeted knockdown or EndMT co-treatment, was 
associated with a significant reduction in the expression of both miR-424 and miR-
503. If the transcriptional changes observed during EndMT were to be driven by the 
associated miRNAs, it would stand to reason that their respective miRNA-targets 
should be enriched in the up-regulated gene pool of our RNAseq analysis. Thus, using 
miRTarBase v7.0 483, we selected 183 previously validated targets common to miR-
424 and miR-503 (Figure 4.5). Of the 183 selected miRNA target genes, 157 were 
detected in our RNA-seq dataset for both HUVEC and HPAEC. However, of these, 
only a total of 8 were up-regulated in co-treated HUVEC and HPAEC. Given the small 
percentage of upregulated target genes and lack of target overlap between EC 
populations, this led us to believe that miR424/503 were unlikely to be major drivers 
of EndMT. Nonetheless, further research using gain- and loss-of-function strategies 
were necessary to confirm our findings. 
 
Given the pronounced downregulation observed during EndMT, an anti-miR-based 
approach was used to knockdown either miR-424-5p or miR-503-5p. Knockdown was 
first confirmed at day 3 after transfection, showing a significant depletion of both 
miRNA in untreated HUVEC (Figure 4.6). Given that both miRNA have been 
previously shown to target phosphatases of the cell division cycle 25 family (CDC25) 
and fibroblast growth factor (FGF) signalling via FGF2 and FGFR1, these targets were 
used to validate our knockdown strategy 476,484,485. While only FGF2 was increased at 
day 3 after miR-424 knockdown, the availability of CDC25A1, FGF2 and FGFR1 was 
significantly increased after miR-503 knockdown (Figure 4.7).  
When allowed to culture for a total of 7 days, our miRNA knockdown strategy did not 
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induce an EndMT profile in HUVEC, as no changes in endothelial or mesenchymal 
markers were observed (Figure 4.8). Notably, unlike our si503HG and gap503HG-
based strategies, knockdown of either miRNA did not affect MIR503HG expression 
(Figure 4.9). Based on these results, we conclude that depletion of either miR-424 or 
miR-503 alone is not sufficient to induce EndMT. Thus, the effects observed after loss 
of MIR503HG appear to be independent of changes in canonical miR-424 and miR-
503 function. 
 
Figure 4.6: Anti-miR mediated knockdown of miR-424-5p and mirR-503-5p at day 3.  
Expression of miR-424-5p and miR-503-5p in HUVEC at day 3 after transfection with either anti-miR-
424 (25nM) or anti-miR-503 (25nM) compared to paired control. RQ value for gene expression was 
quantified by qRT-PCR assay relative to RNU48 (n=3 technical replicates). Analysis by two-tailed t-
test; *p≤0.05, ** p≤0.01, and *** p≤0.001 vs paired Anti-miR Control (Anti-miR CT). Data represented 




Figure 4.7: Anti-miR mediated knockdown of miR-424-5p and mirR-503-5p at day 3.  
Expression of CDC25A, FGF2 and FGFR1 in HUVEC at day 3 after transfection with either anti-miR-
424 (25nM) or anti-miR-503 (25nM) compared to paired control. RQ value for gene expression was 
quantified by qRT-PCR assay relative to RNU48 (n=3 technical replicates). Analysis by one-way 
ANOVA; *p≤0.05, ** p≤0.01, and *** p≤0.001 vs paired Anti-miR Control (Anti-miR CT). Data 
represented as mean ±SEM 
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Figure 4.8: Anti-miR mediated knockdown of miR-424-5p and mirR-503-5p at day 7.  
Expression of PECAM1, SNAI2, ACTA2 and COL1A1 in HUVEC at day 7 after transfection with 
either anti-miR-424 (25nM) or anti-miR-503 (25nM) compared to paired control. RQ value for gene 
expression was quantified by qRT-PCR assay relative to RNU48 (n=3 biological replicates). Analysis 
by one-way ANOVA; *p≤0.05, ** p≤0.01, and *** p≤0.001 vs paired Anti-miR Control (Anti-miR 
CT). Data represented as mean ±SEM. 
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Figure 4.9: Anti-miR mediated knockdown of miR-424-5p and mirR-503-5p at day 7.  
Expression of MIR503HG_2/3/5 in HUVEC at day 7 after transfection with either anti-miR-424 (25nM) 
or anti-miR-503 (25nM) compared to paired control. RQ value for gene expression was quantified by 
qRT-PCR assay relative to RNU48 (n=3 biological replicates). Analysis by one-way ANOVA; *p≤0.05, 




In an attempt to mimic our MIR503HG overexpression experiments, we next 
overexpressed both miR-424-5p and miR-503-5p in the context of EndMT. In order to 
do this, we used synthetic pre-miR RNA precursors carrying the mature sequence for 
either miR-424-5p or miR-503-5p and introduced them during EndMT treatment. 
Overexpression was first confirmed at day 3 after transfection in untreated HUVEC, 
with both miRNAs showing significant upregulation compared to a control pre-miR 
(Figure 4.10). In contrast to our anti-miR strategy, overexpression of either miRNA 
induced a significant downregulation of CDC25A1 and FGFR1 (Figure 4.11). While 
there were no significant changes to FGF2 expression, this confirmed our 
overexpression strategy was functionally successful.  
At 7 days after transfection, in contrast to MIR503HG overexpression, increased 
miRNA availability in untreated HUVEC led to a pronounced EndMT-like profile 
(Figure 4.12). Overexpression of either miR-424 or miR-503 was accompanied by a 
significant loss in PECAM1 expression along with increased SNAI2 and COL1A1. 
Again, in direct contrast to MIR503HG overexpression, this EndMT profile was 
further potentiated by TGF-β2 and IL-1β co-treatment (Figure 4.12). Notably, 
expression MIR503HG appeared to be decreased in all pre-miR samples (Figure 4.13). 
While only MIR503HG_3 was significantly downregulated, this suggests that the 
EndMT phenotype observed after miRNA overexpression may be due to regulation of 
MIR503HG.  
Based on these results, despite being downregulated during EndMT, overexpression 
of either miR-424 or miR-503 does not supress endothelial transition. However, a 
cross-regulatory mechanism between the miRNA cluster and MIR503HG may exist. 
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Figure 4.10: Pre-miR mediated overexpression of miR-424-5p and mirR-503-5p at day 3.  
Expression of miR-424-5p and miR-503-5p in HUVEC at day 3 after transfection with either Pre-miR-
424 (15nM) or Pre-miR-503 (15nM) compared to a paired control. RQ value for gene expression was 
quantified by qRT-PCR assay relative to RNU48 (n=3 technical replicates). Analysis by two-tailed t-
test; *p≤0.05, ** p≤0.01, and *** p≤0.001 vs paired Pre-miR Control (Pre-miR CT). Data represented 





Figure 4.11: Pre-miR mediated overexpression of miR-424-5p and mirR-503-5p at day 3.  
Expression of CDC25A, FGF2 and FGFR1 in HUVEC at day 3 after transfection with either Pre-miR-
424 (15nM) or Pre-miR-503 (15nM) compared to a paired control. RQ value for gene expression was 
quantified by qRT-PCR assay relative to RNU48 (n=3 technical replicates). Analysis by one-way 
ANOVA; *p≤0.05, ** p≤0.01, and *** p≤0.001 vs paired Pre-miR Control (Pre-miR CT). Data 





Figure 4.12: Pre-miR mediated overexpression of miR-424-5p and mirR-503-5p at day 7.  
Expression of PECAM1, SNAI2, ACTA2 and COL1A1 in HUVEC at day 7 after transfection with 
either Pre-miR-424 (15nM) or Pre-miR-503 (15nM) ± EndMT compared to a paired control. RQ value 
for gene expression was quantified by qRT-PCR assay relative to RNU48 (n=3 biological replicates). 
Analysis by two-way ANOVA; *p≤0.05, ** p≤0.01, and *** p≤0.001 vs paired Pre-miR Control (Pre-





Figure 4.13: Pre-miR mediated overexpression of miR-424-5p and mirR-503-5p at day 7.  
Expression of MIR503HG_2/3/5 in HUVEC at day 7 after transfection with either Pre-miR-424 (15nM) 
or Pre-miR-503 (15nM) ± EndMT compared to a paired control. RQ value for gene expression was 
quantified by qRT-PCR assay relative to RNU48 (n=3 biological replicates). Analysis by two-way 
ANOVA; *p≤0.05, ** p≤0.01, and *** p≤0.001 vs paired Pre-miR Control (Pre-miR CT). Data 






This chapter crucially demonstrates that both EndMT treatment and targeted 
knockdown of MIR503HG are accompanied by a reduction in miR-424/-503 
expression. Conversely, overexpression of MIR503HG_2 had no effect on miRNA 
availability while still inhibiting EndMT. Moreover, targeted depletion of either 
miRNA using anti-miRs is not sufficient induce an EndMT phenotype. Interestingly, 
overexpression of either miRNA, while triggering the appearance of a moderate 
EndMT phenotype, was accompanied by a decrease in MIR503HG expression.  
Studies on miR-424 report a similar positive correlation between increased miRNA 
expression and the appearance of EMT 469,470. For example, stable overexpression of 
miR-424 was accompanied by increased production of mesenchymal markers, which 
could be reversed when miRNA expression was lowered 470.  
Moreover, miR-424/503 have also been shown to supress FGF signalling by directly 
targeting FGF2 and FGFR1 203. FGF signalling itself is known to be critical in the 
maintenance of endothelial homeostasis and the prevention of EndMT 486,487.  For 
example, knockdown of FGFR1 alone in HUVEC activated TGFβ signalling and 
resulted in decreased CD31 levels and the increased mesenchymal marker expression 
488. Similarly, FGF2 has also been recently shown to prevent TGF‐β‐induced EndMT 
by repressing the α‐SMA promoter activity via Elk1 489. However, a direct link 
between miR-424/503 overexpression and EndMT is yet to be shown and, as 
demonstrated by our own model, the miRNA cluster is clearly downregulated during 
transition. Nevertheless, while beyond the scope of this thesis, further studies should 
continue to explore the impact of miR-424/50 mediated suppression of FGF signalling 
and its role during EndMT.  
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Further, in chapter 3 we described a clear decrease in endothelial proliferation and 
G1/S-phase transition arrest after MIR503HG knockdown. In contrast, while no 
proliferation assays were conducted in this chapter, previous studies have shown that 
in vitro overexpression of miR-424/503 in non-tumorigenic epithelial cells was 
associated with decreased cell proliferation mediated by CDC25 targeting 490. Notably, 
these changes were also accompanied by cell cycle arrest at the G1-phase 490. miR-424 
has also shown to be decreased in a variety of cervical cancer tissues and cells, which 
are often associated highly proliferative cell phenotypes 491,492. Crucially, when 
overexpressed in these cell types, miR-424 suppressed proliferation and again blocked 
G1/S-phase transition 491,492. Similarly, miR-503 has also been reported to suppress 
cell proliferation and metastasis in multiple cancers , including glioma 493, 
osteosarcoma 494, colorectal cancer 495, breast cancer 496, prostate cancer 497 and 
oesophageal squamous cell carcinoma 498.  
While a miRNA/lncRNA cross-regulatory axis may be possible, the link between miR-
424/503 overexpression and loss of MIR503HG was not confirmed in any of these 
studies. However, based on the results presented in this chapter, induction of EndMT 
during miRNA overexpression may be due to the accompanying downregulation of 
MIR503HG.  
 
Despite the reported functional differences between the miR-424/503 cluster and 
MIR503HG, both in this chapter and throughout the prevailing literature, several 
studies suggest that miRNAs are generally transcribed in parallel with their host 
transcripts 499,500. Unsurprisingly, the locus was shown to be consistently 
downregulated during EndMT. Similarly, the reported upregulation of MIR503HG 
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during hypoxia by Fiedler and colleagues was also accompanied by increased miR-
424 and miR-503 availability 381, suggesting  that the locus may be activated and 
repressed by the same transcriptional mechanisms.  
In ECs, miR-424 and miR-503 expression was reported to be directly regulated by the 
peroxisome proliferator-activated receptor gamma (PPARγ), which is decreased in 
response to inflammatory factors known to promote EndMT, such as TNFα. Work by 
Lee et al demonstrated the expression of miR-424/503 was not only increased upon 
treatment using a PPARγ agonist, but that this could be reversed after PPARγ 
knockdown in HUVEC 480. Additionally, the group described the presence of two 
binding sites in the miR-424/503 promotor region to which PPARγ binds acting as a 
transcriptional regulator 480. Interestingly, PPARγ activation has been shown to 
attenuate EndMT both in vitro and in vivo 501–504.  
Of note, studies by Llobet-Navas et al have also highlighted the existence SMAD and 
E2F-binding sites, which the group linked to TGF-β1 and TGF-β3 mediated 
upregulation of the miR-424/503 cluster in non-tumorigenic epithelial cell lines 485. 
This was further emphasised in a recent study showing that the transcription factor 
E2F1 could bind to the miR-424 promoter and directly activate its transcription during 
G1/S transition, but not G2/M progression, in oesophageal squamous cell carcinoma 
lines 505.  Strikingly, this is at odds with the results presented throughout this chapter, 
showing that both miR-425 and miR-503 were significantly downregulated in ECs 
after TGF-β2 and IL-1β co-treatment. This highlights not only the complexity of 
MIR503HG locus but also a finely regulated, context and cell-specific transcription 
pattern. 
Ultimately, it is clear that further in-depth dissection of the locus is necessary to 
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unravel any cross-regulatory functional mechanisms present. With its simplicity of 
implementation and high efficiency, a CRISPR/Cas9 gene editing system could be 
introduced to manipulate the locus in such precise manner. For example, this could be 
used to specifically target and delete the final 595 base-pair exonic region of 
MIR503HG_2 without disturbing the miRNA cluster upstream. Such a strategy would 
prospectively generate truncated MIR503HG transcripts containing only the pri-
miRNA portion of the gene and lacking other key functional regions. Nevertheless, 
caveats may emerge from deleting such a large genomic region, leading to spurious 
results. Deletion may lead to unpredicted wider changes to chromatin organisation 506 
or  locally by influencing the expression of neighbouring genes by removing cis-
regulatory elements overlapping with the lncRNA gene 507,508. This was elegantly 
demonstrated by Engreitz and colleagues, which after manipulating 12 lncRNA-
producing genomic loci, found that 5 of these had an impact on the expression of 
neighbouring genes in a manner not mediated by the lncRNA transcripts themselves 
347. 
Alternatively, in order to avoid any structural alteration of the locus, a short synthetic 
poly(A) (SPA) site could be introduced downstream of the miRNA locus thus 
prematurely stopping transcription of MIR503HG. This strategy takes advantage of a 
homology directed repair (HDR) a mechanism in cells used to repair double-strand 
DNA lesions such as those produced after Cas9-induced cleavage. In this case, a single 
sgRNA would be used to guide the Cas9 endonuclease, where it would then produce 
a double-stranded break (DSB). Paired with a single-stranded DNA (ssDNA) insert 
containing our gene of interest and homology arms with sequences matching the region 
on either side the break, this would enable homologous recombination by HDR after 
186 
cleavage 509–512. However, while conceptually possible, this has never been attempted 
in such a manner to dissect a miRNA host gene locus and thus would require lengthy 
and thorough validation. Additionally, transfection of primary cell lines with 
CRISPR/Cas9 components can often be challenging due to their sensitivity and finite 
number of division cycles compared to immortalised cell lines. As such, this strategy 
may be largely limited to clonal cell lines or mutant animal models. We have further 
explored the application of these strategies in Chapter 5 to generate a viable 
MIR503HG mouse homolog knockout model. 
In conclusion, although miR-424 and miR-503 have been shown to been involved in 
EMT and vascular remodelling 203,470,513, the data presented in this chapter has 
demonstrated that their contribution to EndMT was mostly associated with the loss of 
MIR503HG. Nevertheless, the possibility of cross-regulatory activity within the locus 
still exists.  
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The study of EndMT during disease has remained largely obscure and mostly limited 
to observational or in vitro work. However, with the emergence of novel cell lineage 
tracing strategies and development of better disease models both in vitro and in vivo, 
this has allowed for new insights into the presence and relevance of EndMT during 
disease 14,52,53. 
The reduced availability of ECs isolated from patients with vascular disease has often 
been one of the main limiting factors when studying the underlying molecular 
mechanisms of endothelial function and dysfunction. However, the identification of 
blood outgrowth endothelial cells (BOECs), generated from circulating endothelial 
progenitors in adult peripheral blood, has started to emerge as a way to circumvent 
these limitations offering a patient-derived EC surrogate. In the study of PAH, for 
example, a seminal paper by Toshner and colleagues demonstrated that BOEC derived 
from HPAH patients with mutations in the gene encoding for BMPRII presented with 
an hyperproliferative phenotype and impaired ability to form vascular networks 423. 
Later studies by the same group went on to show that normal proliferation could be 
restored in these cells by overexpressing miR-124, or by silencing its molecular target 
PTPB1 514. Interestingly, despite the link between EndMT and BMPR2 deficiency, this 
is yet to be studied in PAH patient-derived BOEC 120,126,515.   
Further, early reports of EndMT during disease have largely focused on histological 
analysis of tissue samples from both patients and animal models showing the presence 
of cells with a mixed mesenchymal and endothelial phenotype seen throughout the 
remodelled vasculature. This is true for several publications, not only on PAH 10,119,120, 
but also idiopathic portal hypertension 516, atherosclerosis 29, vein graft restenosis 14 
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and in artery transplant rejection 487. However, while these reports may be important 
to demonstrate the presence of active EndMT during disease and indicative of its 
contribution to vascular remodelling, they cannot show the full extent of EndMT in 
these vessels. This is largely due to the fact that despite co-expressing endothelial and 
mesenchymal markers during the early stages of EndMT, cells that have complete 
transition will be undiscernible from the surrounding mesenchymal population. This 
has led to the eventual widespread use of lineage tracing transgenic animal models in 
the study of vascular remodelling, which allow for the continued expression of 
endothelial-specific reporter genes, regardless of subsequent changes in cellular 
phenotype. When implemented along with a 35-day vein graft mouse model, prone to 
the development of an occlusive neointima, Cooley and colleagues demonstrated a 
progressive increase in the number of reporter cells co-expressing endothelial and 
early SMC markers. By day 35, however, reporter cells within the neointima mostly 
lost their expression of endothelial markers and thus would be undetectable using 
classical histological staining strategies 14. This was also recently established in a 
mouse model of PH, where over 14% of lung reporter cells of endothelial origin had 
undergone complete EndMT and no longer colocalised with CDH5+ ECs. Interesting, 
cells that had undergone partial EndMT and still retained endothelial markers only 
accounted for 5% of the population 172. Additionally, when isolated and cultured, 
complete EndMT reporter cells presented with a significantly higher proliferative and 
migratory phenotype than non-endothelial lung mesenchymal cells 172.  
Lastly, despite its high evolutionary conservation in mammals, the growing number of 
publications on MIR503HG have been largely limited to in vitro work while its 
function in vivo remains unexplored. In contrast, with publications ranging from 
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overexpression during PH to knockdown animal models, the impact of miR-424 and 
miR-503 manipulation in vivo has been thoroughly explored over the past decade. 
However, as demonstrated throughout this thesis, there may be a cross-regulatory axis 
between the two miRNAs and the host lncRNA, making it particularly difficult to draw 
definite conclusions about their function in vivo. Nonetheless, the emergence of 
CRISPR/Cas9-based genome manipulation techniques have now made it possible to 
thoroughly dissect and study such a complex genomic locus.  
5.2 Aims 
Given the wide range of publications reporting on the presence of active EndMT 
during PAH, along with the advancements in EC lineage tracing and disease modelling 
strategies, the aims of this chapter were as follows: 
• To explore the link between the loss of MIR503HG and vascular remodelling 
in PAH patients. 
• To elucidate the MIR503HG expression profile in vivo during vascular 
remodelling in association with EndMT. 
• Target MIR503HG expression in vivo. 




As described throughout this thesis, the decreased expression of MIR503HG has been 
consistently linked to the appearance of an EndMT profile in vitro. This, however, 
does not provide a functional association between MIR503HG and EndMT during 
vascular remodelling or the expression in patient samples vs control to quantify 
association in human disease. As such, it is crucial that we also assess changes to 
MIR503HG expression in patient samples and relevant disease models. 
 
 
The use of BOECs derived from the adult circulation has proven to be a clinically 
relevant, patient-derived, EC surrogate for the investigation of vascular disease, 
particularly  PAH 514. As such, in order to assess EC transcriptional differences in 
PAH, we compared BOECs isolated from PAH patients harbouring BMPR2 mutations 
and from healthy controls. As with our previous in vitro work, these were cultured in 
endothelial growth media for a total of 7 days. Notably, BOECs derived from PAH 
patients presented with a partial, but meaningful, EndMT phenotype when compared 
to healthy controls. As demonstrated by qRT-PCR, these cells showed an enhanced 
expression of ACTA2 and COL1A1, and reduced expression of PECAM1 (Figure 5.1). 
However, due to limited cell availability, this was not confirmed at the protein level. 
Nonetheless, further qRT-PCR analysis revealed that MIR503HG_ 2 expression alone 
was significantly lowered in cells from PAH patients compared to controls, again 




Figure 5.1:  EndMT profile analysis in PAH patient-derived BOEC.  
Expression of PECAM1, SNAI2, ACTA2 and COL1A1 in PAH patient-derived BOEC at day 7 
compared to healthy controls.  RQ value for gene expression was quantified by qRT-PCR assay relative 
to UBC (n=4 biological replicates). Analysis by two-tailed t-test; *p≤0.05 vs control. Data represented 






















































































Figure 5.2 :  MIR503HG expression in PAH patient-derived BOEC.  
Expression of MIR503HG_2/3/5 in PAH patient-derived BOEC at day 7 compared to healthy controls.  
RQ value for gene expression was quantified by qRT-PCR assay relative to UBC (n=4 biological 








































































Having shown that MIR503HG expression is significantly reduced in ECs from PAH 
patients in association with an EndMT profile, we sought to examine if these changes 
were also present during vascular remodelling in human PAH. In order to determine 
the association between the downregulation of MIR503HG and vascular remodelling 
during PAH, we analysed lung tissue sections collected from patients diagnosed with 
idiopathic PAH (IPAH) and healthy donor control lungs. MIR503HG expression was 
detected by in situ hybridisation (ISH) using a small, digoxigenin (DIG)-labelled, 
RNA probe designed to target an 84bp exonic region common to all MIR503HG 
transcripts. To further assess its vascular localisation, ISH for MIR503HG expression 
was performed along with immunofluorescence staining for endothelial and 
mesenchymal markers on matching serial sections.  
In healthy control lungs, we found that MIR503HG expression was present throughout 
the lung vasculature, co-localising with von Willebrand Factor (vWF) in the 
endothelium (Figure 5.3 A-B; Figure 5.4 A-B). Conversely, this expression was 
largely absent from the PAH lung vasculature, particularly in small remodelled vessels 
with constrictive and complex lesions (Figure 5.3 A-B; Figure 5.4 A-B).  Crucially, 
these lesions were associated not only with generalised medial hypertrophy but also 
altered intimal endothelial structure (Figure 5.3 B; Figure 5.4 B). Ultimately, this 
demonstrates not only that MIR503HG is expressed in the human lung vasculature but 
also that its loss is associated with vascular remodelling found in PAH patients.  
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Figure 5.3:  MIR503HG expression during lung vascular remodelling in PAH patients.  
Representative images from human PAH patient and healthy control lung tissue samples on serial 
sections. (A) Tissue in situ hybridisation for MIR503HG expression with brightfield staining showing 
MIR503HG (purple) and cell nucleus (pink). (B) Accompanying tissue immunofluorescence for smooth 
muscle cells (αSMA, green), ECs (vWF, red), cell nucleus (DAPI, blue) and IgG controls. Dotted 
squares denote high-power view of vessels. Images acquired using an Axioscan slide scanner and 
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Figure 5.4:  MIR503HG expression during lung vascular remodelling in PAH patients.  
Representative images from human PAH patient and healthy control lung tissue samples on serial 
sections. (A) Tissue in situ hybridisation for MIR503HG expression with brightfield staining showing 
MIR503HG (purple) and cell nucleus (pink). (B) Accompanying tissue immunofluorescence for smooth 
muscle cells (αSMA, green), ECs (vWF, red), cell nucleus (DAPI, blue) and IgG controls. Dotted 
squares denote high-power view of vessels. Images acquired using an Axioscan slide scanner and 
processed with Zen software. Scale bar 50µm. This work was performed in collaboration with Dr Jessica 
Scanlon.  





































Next, we sought to confirm that the changes in MIR503HG expression were associated 
not only with vascular remodelling but also active EndMT. In order to do this, an 
inducible endothelial tracking (Ind.EndoTrack) transgenic mouse line (Cdh5-Cre-
ERT2-TdTomato) was generated. In brief, this was achieved by crossing Cdh5-Cre-
ERT2 (strain Tg(Cdh5-cre/ERT2)1Rha) with a ROSA-TdTomato reporter mouse line 
(strain B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J). Here, induction of Cre-
recombinase activity by tamoxifen allows for the VE-cadherin (Cdh5) promotor to 
direct endothelial-specific gene expression of the TdTomato reporter gene in pan-EC 
regardless of subsequent changes in cellular phenotype. Next, to model PH in vivo, we 
used a well-established Sugen 5146/Hypoxia (SuHx) mouse model of PH in which 
active vessel remodelling has previously been shown to involve EndMT 119,120. The 
presence of active EndMT was further confirmed by our group using confocal 
microscopy, which established that cells in the pulmonary vascular intima of SuHx 
mouse lungs presented with a mixed mesenchymal/endothelial phenotype (Figure 5.5).  
After 1 week of tamoxifen treatment and a 2 week washout period, the Ind.EndoTrack 
mice were subjected to either SuHx or normoxic conditions for a total of 3 weeks, total 
and TdT+ lung cells were then isolated by flow cytometry (Figure 5.6). TdT+ cells 
isolated from SuHx lungs presented with a distinct EndMT profile, showing increased 
expression of the transcription factor SNAI2, as well as the mesenchymal markers 
ACTA2 and COL1A1. This was accompanied by the loss of endothelial specificity as 
reflected by decreased PECAM1 expression (Figure 5.7). Notably, expression of the 
MIR503HG mouse homolog, Gm28730, was found to be significantly reduced in the 
SuHx TdT+ cell population (Figure 5.8).  
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Comparable to our human PAH in situ analysis, Gm28730 expression was decreased 
in SuHX whole lung RNA samples with a mean relative quantification (RQ) of 0.5 
(Figure 5.8). However, these changes were more pronounced in TdT+ cell of 
endothelial origin, where Gm28730 expression was largely absent with mean RQ of 
0.1 (Figure 5.8). 
 
Figure 5.5:  EndMT profile during lung vascular remodelling in PH mouse model.  
Representative immunofluorescence staining of normoxia/vehicle or SuHx mouse lung tissue samples 
for CD31 (green), Dapi (blue) and ACTA2 or SNAI2 (red). Single-channel (right) and merged (left) 
images acquired with Andor Revolution XDi spinning disk confocal microscope and analysed with 
Image J Software.  Scale bar 50 µm. This work was performed by Dr Axelle Caudrillier using tissue 
























Figure 5.6:  Diagram Sugen 5146/Hypoxia PH model in inducible endothelial-lineage tracing mice.  
Induction of Cre-recombinase activity was achieved by administering 400 mg/kg body weight per dose 
of tamoxifen dissolved in sterile corn oil by gavage on 3 alternate days for 5 days (D1, D3 and D5). 
This was followed by a two week (D6-D19) washout period before initiating the Hypoxia/SU5416 PH 
model for a total of 3 weeks (D20-D40). Lung tissues were then harvested for cell isolation by flow 
cytometry.  
 
Figure 5.7:  EndMT profile analysis during lung vascular remodelling in SuHx mice.  
Expression of Pecam1, Snai2, Acta2 and Col1a1 in TdT+ cells isolated from normoxia/vehicle 
(n=8mice/group) or SuHx mouse lung tissue (n=7mice/group).  RQ value for gene expression was 
quantified by qRT-PCR assay relative to UBC (n=4 biological replicates). Analysis by two-tailed t-test; 
*p≤0.05, ** p≤0.01, and *** p≤0.001 vs normoxic control (Normoxia). Data represented as individual 
data points and mean ± SEM. 
Tamoxifen (D1, D3, D5) Rest (D6-D19) PH induction (D20-D40) Collection
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Figure 5.8:  MIR503HG expression during lung vascular remodelling in SuHx mice. 
Expression of MIR503HG_2/3/4 in TdT+ cells isolated from normoxia/vehicle (n=8mice/group) or 
SuHx mouse lung tissue (n=7mice/group).  RQ value for gene expression was quantified by qRT-PCR 
assay relative to UBC (n=4 biological replicates). Analysis by two-tailed t-test; *p≤0.05, ** p≤0.01, and 
*** p≤0.001 vs normoxic control (Normoxia). Data represented as individual data points and mean ± 
SEM. 
 
As both the human and in vivo disease data sets presented so far were largely 
associative, showing no causation between the loss of MIR503HG and EndMT, we 
attempted to mimic our initial in vitro results by overexpressing the lncRNA in SuHX 
mice only and assess its impact on lung ECs. Crucially, as a proof of concept, we first 
tested lentiviral uptake efficiency in the lung vasculature of normoxic mice. A GFP 
lentiviral construct was delivered intranasally to 8 to 10-week-old C57BL/6 mice, 
which were then given a 2 week rest period prior to tissue collection in order to confirm 
that viral overexpression could be maintained throughout the period required for the 
induction of PH during subsequent studies (Figure 5.9). Flow cytometry analysis 
confirmed that 5% of isolated lung cells were GFP+, of which 13.7% were of 
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201 
Despite our use of a global Gm28730 probe for RT-qPCR analysis, so far there are no 
publications on the mouse Gm28730 locus, and its predicted transcript sequence 
arrangement is yet to be validated. As such, given the depth of sequence conservation 
across vertebrates, we chose to overexpress the human MIR503HG_2 transcript used 
throughout Chapter 3 of this thesis. Either LNT_503HG or LNT_CT were delivered 
intranasally to 8 to 10-week-old C57BL/6 mice, which were then given a 2 day rest 
period prior to PH induction by SuHx (Figure 5.11). Finally, both endothelial (CD31+) 
and non-endothelial (CD31-) lung cells were isolated by flow cytometry and the 
expression of MIR503HG/Gm28730 and EndMT markers was assessed (Figure 5.12).  
In line with our initial GFP proof of concept, RT-qPCR analysis showed that the 
expression of the human MIR503HG_2 was significantly higher in CD31+ lung EC of 
LNT_503HG mice compared to the LNT_CT group (Figure 5.13). Interestingly, 
overexpression of MIR503HG also led an increased availability of the endogenous 
mouse homologue, Gm28730 (Figure 5.13).  Concordantly, while there were no 
changes to Pecam1 expression, we observed a significant downregulation of the 
mesenchymal markers Acta2 and Col1a1 upon MIR503HG overexpression in CD31+ 
ECs (Figure 5.14). Interestingly, while not significant, an increase in Snai2 was 
observed in CD31+ cells. These results were then compared to CD31- cell, which 
despite the increased availability of MIR503HG in non-ECs from LNT_503HG mice 
(Figure 5.15), showed no changes in Gm28730 or mesenchymal maker expression 
(Figure 5.15; Figure 5.16).  
Finally, this initial set of results provides robust preliminary evidence for a 





Figure 5.9:  Diagram of GFP lentivirus intranasal delivery to mice lung cells. 
GFP lentiviral construct was delivered by administering intranasally a 25uL dose at 4.00E+08 piu/mL 
on 3 alternate days for 5 days (D1, D3 and D5). This was followed by a 2 week (D6-D19) rest period 




Figure 5.10:  Flow cytometry gating strategy used to identify mouse lung GFP+ cells. 
Viable (live) total lung cells were first selected by gating for DAPI negative events. Transduced cells 
were then selected by gating for GFP+ events, from which ECs were selected by gating for CD31+ 
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Figure 5.11:  Diagram of Sugen 5146/Hypoxia PH model after MIR503HG_2 overexpression. 
Lentiviral constructs were delivered by administering intranasally a 25uL dose at 4.00E+08 piu/mL on 
3 alternate days for 5 days (D1, D3 and D5). This was followed by a 2 day (D6-D7) rest period before 
initiating the Hypoxia/SU5416 PH model for a total of 3 weeks (D20-D40). Lung tissues were then 





Figure 5.12:  Flow cytometry gating strategy used to identify SuHx mouse lung CD31+ cells. 
Total lung cells were first separated from debris by plotting forward versus side scatter. Single cells 
(singlets) were then selected using forward scatter area (FSC-A) versus forward scatter height (FSC-H) 
and side scatter area (SSC-A) versus side scatter height (SSC-H). From the singlet population, viable 
(live) cells were selected by gating for DAPI negative events. ECs from the viable cell population were 
finally selected by gating for CD31+ events compared to control unstained samples. 
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Figure 5.13:  MIR503HG_2 overexpression in SuHx mouse lung CD31+ cells. 
Expression of MIR503HG_2 and Gm28730 in CD31+ cells isolated only from SuHx mouse lung tissue  
after intranasal delivery of LNT_MIR503HG compared to LNT_Control (n=5 mice/group). RQ value 
for gene expression was quantified by qRT-PCR assay relative to 18S. Analysis by two-tailed t-test; 
















































Figure 5.14:  MIR503HG_2 overexpression in SuHx mouse lung CD31+ cells. 
Expression of Pecam1, Snai2, Acta2 and Col1a1 in CD31+ cells isolated only from SuHx mouse lung 
tissue after intranasal delivery of LNT_MIR503HG compared to LNT_Control (n=5 mice/group). RQ 
value for gene expression was quantified by qRT-PCR assay relative to 18S. Analysis by two-tailed t-























































































Figure 5.15:  MIR503HG_2 overexpression in SuHx mouse lung CD31- cells. 
Expression of MIR503HG_2 and Gm28730 in CD31- cells isolated only from SuHx mouse lung tissue 
after intranasal delivery of LNT_MIR503HG compared to LNT_Control (n=5 mice/group). RQ value 
for gene expression was quantified by qRT-PCR assay relative to 18S. Analysis by two-tailed t-test; 


















































Figure 5.16:  MIR503HG_2 overexpression in SuHx mouse lung CD31- cells. 
Expression of Pecam1, Snai2, Acta2 and Col1a1 in CD31- cells isolated only from SuHx mouse lung 
tissue after intranasal delivery of LNT_MIR503HG compared to LNT_Control (n=5 mice/group). RQ 
value for gene expression was quantified by qRT-PCR assay relative to 18S. Analysis by two-tailed t-























































































In order to further dissect the lncRNA/miRNA axis and understand the role of 
MIR503HG in vivo, a CRISPR/Cas9 system was used to generate a Gm28730 null 
allele in mice. To avoid unpredicted alterations to the locus structure and function, 
often seen with large genomic deletions 347,506–508, we have developed a Gm28730-/- 
mutant containing a synthetic polyadenylation signal aimed at prematurely stopping 
transcription of Gm28730 without disrupting miRNA expression. Based on the work 
of Ballarino et al, which generated a functional knockout for the lncRNA Charme in 
mice 517, our strategy used a SPA-MAZ cassette containing a compact and highly 
efficient synthetic poly(A) (SPA) 518 followed by two MAZ protein binding sites 
known to further promote transcriptional termination  519,520. The SPA-MAZ site was 
introduced within Exon 1 of the Gm28730 locus, down-stream from the miR-
322(424)/503 cluster allowing for the expression of the miRNA alone (Figure 5.17). 
Despite current advancements to CRISPR/Cas9-sgRNA systems, the on-target 
efficiency of sgRNA to distinct DNA loci can vary widely. As such, prior to mutant 
generation, the effectiveness of three sgRNAs designed to target Exon 1 of Gm28730 
was first tested in vitro. This was done using human embryonic kidney (HEK) 293 
cells co-transfected with a pX330 vector carrying the sgRNA and a mCherry/eGFP 
dual reporter vector containing the corresponding target sequence. Of the tested 
guides, sgRNA #2 showed the highest efficiency with 21.4% of cells transfected cells 
positive for both fluorescent markers, which was then selected for downstream 
application (Figure 5.18).  
Genomic insertion of the SPA-MAZ cassette was first confirmed using DNA extracted 
from each F0-generation mouse. This was analysed by PCR amplification using two 
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different primer-pairs targeting either the cassette sequence or the genomic region on 
either side of it. Gel electrophoresis analysis and subsequence sequencing of the PCR 
products showed that the insertion of the entire SPA-MAZ sequence was present on a 
single allele of pup #6, which was selected as a founder for successive breeding (Figure 
5.19). The Gm28730 null allele was then backcrossed and carefully monitored for a 
total of four generations to obtain homozygous animals.  
Preliminary analysis of RNA isolated from heart and lung tissue of 8-week-old 
Gm28730-/- mutants confirmed a significant a depletion in Gm28730 availability 
compared to WT littermates (Figure 5.20). Crucially, the expression of miR-322(424) 
and miR-503 was not altered in Gm28730-/- mutants (Figure 5.21 and Figure 5.22). 
While beyond the scope of this thesis, extensive work is still required to fully 























































































































































































































































































Figure 5.18:  sgRNA on-target efficiency. 
Flow cytometry analysis of sgRNA on-target efficiency in HEK293 at day 3 after co-transfection with 
px330 and pBS-SK-mCherryY66HeGFP-forw vectors. sgRNA/Cas9 on-target cleavage was assessed 
based on mCherry+/GFP+ cell subset compared to a no-sgRNA negative control. This work was 
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Figure 5.19:  Gm28730 knockout F0-generation genotyping. 
Gel electrophoresis analysis of PCR amplification products from F0‐generation mice DNA. PCR 
primers-pair were designed to amplify (A) the genomic region on either side of the insertion site or (B) 
the SPA-MAZ cassette sequence. SPA-MAZ cassette insertion was confirmed on a single allele in pup 
#6 (red arrow), which was selected for successive breeding. This work was performed in collaboration 




Figure 5.20:  Gm28730 expression in Gm29730-/- mice. 
Expression of Gm28730 in heart and lung tissue from homozygous Gm28730-/- mice compared to 
wildtype Gm28730+/+ littermates (n=8 mice/group). RQ value for gene expression was quantified by 
qRT-PCR assay relative to 18S. Analysis by two-tailed t-test; ***p≤0.001 vs Gm28730+/+. Data 
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Figure 5.21:  miR-424(322) expression in Gm29730-/- mice. 
Expression of miR-424(322)-5p in heart and lung tissue from homozygous Gm28730-/- mice compared 
to wildtype Gm28730+/+ littermates (n=8 mice/group). RQ value for gene expression was quantified by 
qRT-PCR assay relative to U6. Analysis by two-tailed t-test; ***p≤0.001 vs Gm28730+/+. Data 





Figure 5.22:  miR-503 expression in Gm29730-/- mice. 
Expression of miR-503-5p in heart and lung tissue from homozygous Gm28730-/- mice compared to 
wildtype Gm28730+/+ littermates (n=8 mice/group). RQ value for gene expression was quantified by 
qRT-PCR assay relative to U6. Analysis by two-tailed t-test; ***p≤0.001 vs Gm28730+/+. Data 



































































































Building on the in vitro work presented in Chapters 3 and 4, here we have 
demonstrated that the expression of MIR503HG is significantly lost in the remodelled 
lung vasculature during PH in association with EndMT. Additionally, we provide 
preliminary evidence supporting a MIR503HG-mediated mechanism in the 
suppression of EndMT during vascular remodelling. 
 
 
As demonstrated in this chapter, BOEC derived from PAH patients with BMPR2 
mutations present with an EndMT-like profile, showing an increase in mesenchymal 
markers and decreased endothelial marker expression. Interestingly, mutations to the 
gene encoding for BMPR2, while being the most common cause of heritable PAH, 
have also been implicated in the initiation of EndMT in vitro 120,126. Crucially, we have 
further shown that the appearance of an EndMT-like profile in in PAH BOEC also 
happens in association with a decrease in MIR503HG_2 availability. While largely 
associative, this data set reinforces the proposed role of the MIR503HG in regulating 
EC phenotype commitment described in chapter 3. Nonetheless, it’s important to 
acknowledge that despite PAH patient-derived BOEC presenting with an EndMT-like 
phenotype, only MIR503HG_ 2 was found to be downregulated while all other 
transcripts remained unaltered. Additionally, the analysis shown here focused solely 
on baseline marker expression and did not include more in-depth analysis of these 
cells.  Future studies would therefore require additional, in-depth, manipulation of the 
MIR503HG locus. For example, if the loss of MIR503HG_2 is involved in the 
emergence of an EndMT profile in these cells, overexpression of the lncRNA using 
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our LNT_503HG construct may work to reverse mesenchymal marker expression and 
maintain endothelial commitment. Furthermore, the experiments described were 
limited to BOEC between passages 6 and 8. While these have been shown to retain 
endothelial function 423,514, as with other primary endothelial cell lines , after long-term 
serial passaging these may become quiescent and start to exhibit changes gene 
expression patterns, as well as physiological function 521–524. 
Moreover, despite using a disease relevant EC subset, the studies presented were 
performed in vitro and did not account for crucial external changes to the vascular 
environment that also regulate EC function and therefore EndMT 525.  We have 
attempted to mitigate this by observing MIR503HG in situ across the lung vasculature 
of PAH patients. With this, we have shown that MIR503HG expression was largely 
abolished in the remodelled lung vasculature of PAH patients in association with a loss 
of endothelial structure in these vessels. However, while the in situ protocol used 
provides convincing qualitative evidence, the nuclear lncRNA staining shown is 
diffuse and difficult to accurately quantify. Future studies may benefit from using 
novel ISH assays such as RNAscope, which allow for single RNA molecules to be 
presented as quantifiable punctate dots within the cell.  Further, it is also important to 
acknowledge that, despite the changes to EC structure, no evidence of active EndMT 
was found in these vessels. 
Lastly, by introducing an inducible EC lineage tracing mouse model (Ind.EndoTrack) 
we were able to specifically isolate lung cells of endothelial origin. Crucially, we have 
shown that mouse lung cells of endothelial origin presented with a clear EndMT profile 
in association with the decreased expression of the MIR503HG mouse homologue 
Gm28730. While, EndMT has previously been identified in PH, this is the first 
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instance where the Gm28730 lncRNA locus was linked to both EndMT and vascular 
remodelling during disease. Exposure to our 3 week SuHx model induces a severe PH 
phenotype accompanied by RVSP overload, RV hypertrophy and the development of 
angioobliterative lesions comparable to those seen in our advanced PAH patient 
samples 526,527. Thus, at this time point, changes in Gm28730 expression may not be 
directly linked to EndMT and instead due to global changes to the vessel cellular 
architecture. This is particularly important, given that the loss of Gm28730 expression 
in our SuHx samples was not limited to ECs. Future studies would therefore need to  
also validate lncRNA expression changes at earlier time points to confirm if drop in 
expression matches with that of early EndMT compared to other cell types. 
Unbiased exploratory RNAseq of isolated lung ECs could also prospectively be 
implemented, not only to validate changes to Gm28730 transcript expression, but to 
identify novel targets not detected in our initial in vitro analysis. For example, using 
high-throughput RNAseq of fluorescently labelled cells isolated from a Confetti EC 
lineage-tracing mouse line after acute myocardial infarction, Manavski et al 
demonstrated that ECs undergo clonal expansion and begin to express a variety of 
EndMT-associated mesenchymal markers 528. Moreover, single-cell RNA sequencing 
(sgRNAseq) may also start to emerge as a powerful tool for study of EndMT in vivo 
due to its added ability to validate EC signatures while simultaneously showing 
mesenchymal gene up-regulation in individual cells. Nonetheless, a known caveat to 
the use of RNAseq is the need for sufficient read depth to reliably detect and annotate 
lowly expressed transcripts, such as that of lncRNAs. 
 
Recapitulating the in vitro results presented in chapter 3 of this thesis, overexpression 
217 
of the human MIR503HG isoform 2 in mice prior to PH induction was linked to a 
decrease of mesenchymal marker expression in mouse CD31+ lung ECs, suggesting a 
partial prevention of the EndMT process in vivo. As noted, however, a non-significant 
increase in Snai2 was observed in CD31+ cells overexpressing MIR503HG. While this 
effect was not present during our in vitro studies, it is worth considering that 
MIR503HG may target pathways downstream or independent of  Snai2. This 
reinforces the need for additional mechanist studies, as highlighted in Chapter 6.6. 
Further, given the preliminary nature of our study, the reduced sample size used (n=5 
mice/group) was not sufficient to confirm changes to PH outcomes such as increased 
RVSP and RV hypertrophy. Additionally, overexpression of MIR503HG_2 was only 
carried out prior to PH induction, without a paired normoxic treatment group was also 
not included. With our limited observation data and use of the human MIR503HG, as 
opposed to the endogenous Gm28730 lncRNA, we could not ethically justify a large-
scale study prior to proof-of-consent. Given the results presented here, however, a full-
scale study can now be in implemented alongside a normoxic control group not 
exposed to SuHx conditions, to further confirm the changes at the molecular level and 
thoroughly assess the impact on the severity of PH. Moreover, due to the limited 
availability of Ind.EndoTrack mice, overexpression of MIR503HG_2 in vivo was 
carried out on a C57BL/6 mouse line. Thus, the cell sorting strategy used was restricted 
to endothelial surface markers shown to be lost during EndMT, which may have 
ultimately obscured the impact MIR503HG overexpression had on EndMT cell that 
no longer express these markers. As such, a future full-scale study should also include 
our Ind.EndoTrack mouse line, allowing us to capture all cells of endothelial origin. 
Despite the positive results presented, our overexpression strategy was not restricted 
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to the endothelium, and MIR503HG_2 expression was found present in both CD31+ 
and CD31- lung cells. Moreover, while shown to be an effective delivery route to the 
lung endothelium 203,529,530, high-titre lentiviral administered intranasally will first be 
exposed to airway epithelium prior to reaching the underlying vasculature. Thus, given 
the cell-specific and context-dependent nature of the lncRNA, it is worth considering 
the negative impact that unrestrained global overexpression may have on airway 
function as well as the lung vasculature and disease progression. Nonetheless, 
MIR503HG_2 overexpression was accompanied by an increase in endogenous 
Gm28730 availability in CD31+ ECs but not in CD31- cells, which highlights a pro-
endothelial function.  
Notably, it has also been previously established that reconstitution of miR-424(322) 
and miR-503 in the rat lung can reduce the number of number of muscularised 
microvessels and with it prevent increased RVSP and RV hypertrophy associated with 
the SuHx model 203. While both miRNAs were shown to be overexpressed in CD31+ 
SuHx lung ECs, the overexpression strategy used in the study, like ours, relied on the 
use of a lentivirus constructs that did not specifically target the endothelium. Thus, the 
cell-specific effects of miRNA overexpression most also be considered. For example, 
overexpression of miR-503 was found suppress proliferation and migration of EPCs 
in vitro 479, the opposite was reported in ECs and SMCs 203. Nonetheless, these results 
are in conflict with our in vitro assessment and warrant additional dissection of the 
locus in vivo. Given the technical hurdles and limitations associated with selectively 
targeting the Gm28730 locus in the pulmonary endothelium, genetic manipulation 
approaches may be required as further proof-of-concept. 
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Has highlighted throughout this thesis and the prevailing literature it is likely that a 
cross-regulatory transcriptional and functional axis may exist between the miR-
424(322)/503 cluster and its lncRNA host. While our in vitro lncRNA overexpression 
strategy suggested a function independent of the miRNA cluster, loss of MIR503HG 
(Gm28730) has been consistently accompanied by a significant downregulation of 
both miR-424(322) and miR-503. As such, additional loss-of-function experiments 
would require precise manipulation of the MIR503HG (Gm28730) locus. We have 
attempted to do this by using a novel CRIPR/Cas9 system to introduce a premature 
transcriptional termination site (SPA-MAZ) within exon 1 of the lncRNA locus. The 
presence of the SPA-MAZ cassette effectively stopped transcription of the lncRNA 
without disrupting miRNA processing upstream. Here, we have confirmed the 
effectiveness of this strategy by showing a significant reduction in Gm28730 
expression in the mouse heart and lung, while retaining miRNA expression 
throughout. Thus, to our knowledge, generating the first true murine Gm28730 
knockout. However, while our genotyping efforts have confirmed the absence of 
Gm28730, due to the pleiotropic effects that the KO may have on the function of 
different organ systems and during development, further in-depth phenotypical 
assessment is still necessary 531–533.  
Once fully phenotyped, Gm28730-/- mutants can be used to assess the role of the 
lncRNA during vascular remodelling in disease.  For example, implementing the 
SuHx-induced model of PH described in this chapter would be crucial in order to study 
the effect of Gm28730 KO on PH hallmarks such as increased RVSP and RV 
hypertrophy 526,527. Additionally, given the reported role of EndMT in atherosclerosis, 
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a proprotein convertase subtilisin/kexin type 9 (PCSK9)-induced model of accelerated 
atherosclerosis in mice could also be implemented for future studies 534,535. 
Lastly, we acknowledge that despite the success in generating Gm28730-/- mutants, 
there are still a number of limitations to this KO model that may confound future 
studies. Namely, the lack of endothelial specificity of the Gm28730-/- mutants. As 
described in the previous chapters, this is particularly important given the cell and 
context specific nature of lncRNA. Further, given the potential for developmental 
pathologies to arise, the non-inducible nature of our KO strategy may exacerbate the 
pathological response of Gm28730-/- mutants to disease models.  However, given the 
additional SPA-MAZ cassette insertion step need, an inducible Gm28730-/- would 
require the use of multiple viral vectors in adult mice which may result only in a partial 
KD. As demonstrated here, no discernible changes in Gm28730 expression were 
present in heterozygous Gm28730+/-, highlighting the need for biallelic insertion. 
Nonetheless, drug-inducible CRISPR/Cas9 systems have recently been described and 
may be possible to use in the near future 536.  
 
Our analysis of both human PAH and in vivo animal models, has provided important 
insights into the role of MIR503HG in regulating EndMT during disease. Taken 
together with the fact that EndMT can be inhibited by the restoration of MIR503HG 
expression in vitro, the results presented in this chapter suggest a critical role played 
by MIR503HG in maintaining endothelial function during active vascular remodelling 
in PH. Our results open new avenues for targeting EndMT during disease, showing a 
previously unknown regulatory function of MIR503HG in driving the process.
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Chapter 6: General Discussion 
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6.1 Summary 
As evidence continues to emerge highlighting the role of EndMT in pathological 
vascular remodelling seen during the development of conditions such as PAH, 
understanding the underlying mechanisms that drive this phenotypical transition may 
ultimately offer novel therapeutic opportunities. In this thesis we demonstrate for the 
first time that the loss of the lncRNA MIR503HG is a pivotal event during the 
induction of EndMT both in vitro and in vivo (Figure 6.1). We show that targeted 
downregulation of this lncRNA can induce a spontaneous EndMT phenotype in 
HUVEC in the absence of any other treatment, including TGF-β2 and IL-1β co-
stimulation, while upregulation of a single conserved transcript is sufficient to inhibit 
this process. In a mouse model of PAH, MIR503HG expression in lung ECs was also 
found to be lost in association with an EndMT profile. When overexpressed in the 
mouse lung, the data presented here shows that the presence of MIR503HG can 
suppress the appearance of mesenchymal markers despite induction of PAH. 
Similarly, the loss of MIR503HG was associated with human PAH, demonstrating a 
putative clinical role. Ultimately, the data presented here highlights the potential for 
lncRNA-based therapeutic interventions, positioning MIR503HG as a novel putative 
target during the treatment of vascular remodelling in the context of PAH. 
Nonetheless, despite the novelty of the evidence presented, several limiting factors 
have been identified which must be considered in future studies. Similarly, lingering 
concerns still exist regarding the efficacy of lncRNA-based therapeutic strategies.  We 
will discuss these topics in further detail through this chapter. 
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Figure 6.1: Diagram Summarising the Role of MIR503HG in Regulating EndMT. 
Graphical summary of the role played by MIR503HG in regulating EC function, where loss of the 
lncRNA is sufficient to induce a spontaneous EndMT phenotype, in the absence of TGF-β2 and IL-1β 
co-stimulation. Conversely overexpression of MIR503HG during transition can supress transition, in a 
manner independent of miR-424 and miR-503. 
6.2 MIR503HG as a Master Regulator of EndMT 
The work presented in Chapter 3 of this thesis showed a large overlap between the 
transcriptional changes of HUVEC and HPAEC undergoing EndMT after TGF-β2 and 
IL-1β co-treatment, supporting the existence of shared regulatory mechanisms. Among 
these, we identify for the first time the loss of MIR503HG as a key event during the 
induction of EndMT in EC from various vascular beds.  
Remarkably, DsiRNA or GapmeR-mediated knockdown of MIR503HG was sufficient 
to induce a robust EndMT profile in vitro, without the need for TGF-β2 and IL-1β co-
treatment. While other lncRNAs have been previously associated with EndMT, to our 
knowledge, this is the first report of spontaneous EndMT after manipulation of a single 
lncRNA. Upregulation of the lncRNA MALAT1, for example, was previously linked 
to EndMT in endothelial progenitor cells (EPCs); however, this was shown to happen 
via a MALAT1-mediated suppression of miR-145, which in turn increased the 









to GATA6, was also implicated in the regulation of endothelial gene expression no 
direct link was made between its expression and the induction of EndMT 398. 
We additionally show that the upregulation of a single MIR503HG isoform, containing 
a highly conserved exonic region, is sufficient to inhibit transition in HUVEC after 
continuous exposure to TGF-β2 and IL-1β. Nonetheless, as described in Section 3.3.6, 
it is important to highlight that this was still a partial inhibition of transition. 
Conceptually, this could be mitigated by overexpressing the totality of the MIR503HG 
locus using a CRISPR activation (CRISPRa) system targeting the lncRNA promotor 
region. This system uses a catalytically-inactive Cas9 nuclease (dCas9) with additional 
transcription activation domains such as VP64, which can then use a single guide RNA 
(sgRNA) to bind complementary DNA. Along with the desired target sequence, the 
sgRNA structure can be modified to recruit and bind additional transcriptional 
activators for an enhanced effect 537–539. Further experiments may also include 
additional transcript-specific overexpression of the remaining MIR503HG isoforms, 
again using the same lentiviral-mediated transduction system described here. This, 
however, may be limited by the lack of reliable MIR503HG transcript annotations. 
Lastly, several other lncRNAs candidates with a potential role in EndMT have 
emerged from the RNAseq analysis described in Chapter 3. While beyond the scope 
of this thesis, their presence highlights the existence of an unexplored regulatory 
network of lncRNAs which warrants further research. 
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6.3 Identifying the Mechanistic Interactions of 
MIR503HG 
In order to identify the contribution of MIR503HG to endothelial function and which 
associated pathways may be regulated during EndMT, in Chapter 3 we performed bulk 
RNAseq analysis of ECs overexpressing MIR503HG_2 during EndMT treatment. 
This approach showed that the expression of over 28% of EndMT-associated genes 
was affected by the presence of MIR503HG, however these changes were too far-
reaching to select specific target genes. Thus, further mechanistic studies must be 
employed to identify the molecular targets and pathways associated with MIR503HG 
in ECs. 
With a wide range of described mechanisms, lncRNAs carry out their function by 
interacting with a variety of other nucleic acids and proteins. While large-scale 
databases such as StarBase v2.0 now offer a repository of thousands of experimentally 
validated RNA:RNA and protein:RNA interactions 540, many of these regulatory 
networks remain largely unknown. The application of fitting, RNA-centric, tools to 
elucidate such complex interactions is therefore essential. The role of lncRNA:Protein 
interactions in regulating gene expression has been of particular interest and several 
pulldown assays have been developed over the past decade to identify these 
interactions. RNA-affinity chromatography assays, for example, are now widely used 
in mechanist studies. These require the in vitro transcription of a labelled lncRNA 
transcript, which is allowed to form complexes with protein obtained from cell extracts 
and later purified 541. Alternatively, methods such as RNA antisense purification 
(RAP)458,459 will instead capture endogenous lncRNA transcripts using labeled 
antisense oligos. While their methodology can vary significantly, both techniques 
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ultimately allow for the purification specific lncRNA:protein complexes which are 
identified by quantitative mass spectrometry or western blot.  
Interestingly, using in vitro-transcribed biotinylated MIR503HG transcripts, Wang et 
al have identified a direct interaction with the RNA-binding protein HNRNPA2B1 437. 
This was found to promote the degradation of HNRNPA2B1, resulting in the 
suppression of NF-kB signalling in hepatocellular carcinoma. Given that 
HNRNPA2B1 has been shown to promote cell invasion and migration in EMT 461, this 
interaction may also prove relevant during EndMT. Nonetheless, it’s worth 
considering that a MIR503HG-mediated degradation of HNRNPA2B1 may be cell-
specific and thus not present in ECs. We propose that future mechanistic studies first 
confirm MIR503HG binding in HUVEC or HPAEC via RNA immunoprecipitation 
(RIP) using HNRNPA2B1 antibodies. Additionally, this should be further validated in 
an independent and unbiased manner by exposing biotinylated MIR503HG_2 
transcripts to EC nuclear protein lysate.  
Although proven successful, it has been recently suggested that this approach may be 
limited to identifying highly abundant RNA binding proteins and does not provide a 
complete picture of other, perhaps more relevant, lncRNA:protein interactions 
occurring in parallel 542. As such, the capture of endogenous MIR503HG transcripts 
using biotin-labelled RNA antisense probes may add an additional layer of stringency.  
This system was recently used to identify GATA6-AS:protein complexes in HUVEC 
undergoing EndMT  398. With this, the study successfully demonstrated that the 
lncRNA was capable of binding the nuclear enzyme LOXL2 to partially regulate 
endothelial gene expression via changes in histone methylation.  
Lastly, MIR503HG expression was previously found to be positively altered in ECs 
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by hypoxia, with its depletion resulting in proliferative defects. Crucially, depletion of 
MIR503HG also lead to the repression of the endothelial transcription factor GATA-
binding factor 2 (GATA2) 381. Abrogation of GATA2 alone has previously been shown 
to regulate Endomucin-1 (EMCN) gene expression, leading to a reduction in the 
expression of endothelial markers and promoting EndMT gene expression 543. While 
beyond the scope of this thesis, an EndMT regulatory axis involving MIR503HG and 
GATA2 is plausible and warrants further research. 
6.4 Dissecting the MIR503HG Locus 
In Chapter 4 we have attempted to dissect the MIR503HG locus critically 
demonstrating that the contribution of miR-424 and miR-503 to EndMT was largely 
associated with the loss of MIR503HG. Although a significant decrease in miR-503 
and miR-424 availability was observed during EndMT, this is may be due to the 
transcriptional repression of shared regulatory regions 462. Indeed, targeted depletion 
of either miRNA did not change the expression of EndMT markers, unlike that seen 
after MIR503HG knockdown. Crucially, overexpression of a mature MIR503HG 
transcript, lacking the miRNA seed sequences, effectively repressed EndMT without 
changing miR-424/-503 expression levels.  
Whilst several putative miRNA host lncRNAs have been described, publications 
determining the miRNA-independent roles of these transcripts are rare. Notable 
exceptions include the recently characterised lncRNA MIR205HG, which despite 
acting as the de facto pri-miRNA transcript for miR-205, has also been shown to 
independently regulate differentiation of human prostate basal cells 544. Similarly, the 
lncRNA MIR100HG, host to miR-100, let7a2 and miR-125b, regulates cell cycle 
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through its interaction with the RNA binding protein HuR 545. Adding to this poorly 
described lncRNA subset, our data provides a novel example of a miRNA host gene 
with an independent functional role.  
Nonetheless, the potential for cross-regulatory functional mechanisms between 
MIR503HG and miR-424/-503 still exists. As demonstrated in Chapter 4, 
overexpression of either miRNA triggered the appearance of an EndMT profile, 
accompanied by a decrease in MIR503HG expression. Moreover, siRNA-mediated 
knockdown of MIR503HG also lead to a significant decrease in miRNA expression. 
It is clear that further dissection of the locus is necessary to unravel any potential 
overlapping mechanisms present. In order to do this, future studies should take 
advantage of established CRISPR/Cas9 gene editing systems to manipulate the locus 
to recapitulate the MIR503HG knockdown phenotype without affecting miR424/503 
expression. Deletion of the conserved final 595 base-pair exonic region of 
MIR503HG_2, for example, would prospectively generate truncated lncRNA 
transcripts containing only the unsliced pri-miRNAs. The implementation of this 
system in primary EC lines, however, comes with an additional set of challenges due 
to their inherent sensitivity and finite number of division cycles compared to 
immortalised counterparts. Nonetheless, while rare, emerging publications have 
demonstrated that this is possible in ECs 546,547. Recently showcased by Leisegang et 
al, the use of lentiviral vectors to introduce Cas9 nucleases and constitutively express 
sgRNA strands in HUVEC was sufficient to produce distinct bi-allelic deletions of the 
lncRNA MANTIS, phenocopying results obtained using siRNA and GapmeR-based 
approaches 547. 
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6.5 MIR503HG Expression During Disease 
The involvement of several lncRNAs has been implicated during the initiation and 
progression of multiple cardiovascular pathologies, however little is known about their 
role in PAH. In Chapter 5 we have for the first time established a link between the loss 
of MIR503HG expression and lung vascular remodelling in association with EndMT, 
using a mouse model of PH, human BOECs and lung samples obtained from PAH 
patients.  More specifically, using in situ hybridisation for MIR503HG, supported by 
sequential staining for endothelial and mesenchymal markers, MIR503HG expression 
was found to be largely abolished in the remodelled lung vasculature of PAH patients. 
Moreover, our use of a SuHx-induced PAH model established in Ind.EndoTrack 
lineage tracing transgenic mouse further allowed us specifically isolate lung cells of 
endothelial origin regardless of any changes to cell phenotype. Consistent with our 
patient data, we have confirmed that the expression of the MIR503HG mouse 
homolog, Gm28730, is lost during PAH in association with an EndMT profile.  
Nevertheless, while the data provided focused solely on vascular remodelling in PAH, 
EndMT has been implicated in a variety of cardiovascular pathologies. For example, 
as demonstrated by Evrard and colleagues, cells co-expressing endothelial and 
mesenchymal markers were commonly found in complex and unstable human 
atherosclerotic plaque 53. Similar observations have also been reported in vein graft 
remodelling, valvular calcification and cardiac fibrosis 12,14,548–550. It would therefore 
be important to assess if MIR503HG down-regulation is also relevant in these 
scenarios and if any changes to its expression are also associated with EndMT. A 
similar in situ hybridisation strategy for MIR503HG visualisation could prospectively 
be applied to human samples with and without atherosclerotic lesions. Given its 
230 
versatility, our Ind.EndoTrack mouse line could prospectively be exposed to other 
vascular remodelling-associated disease models, such as atherosclerosis, and used to 
validate not only the presence of EndMT but also changes in Gm28730 expression in 
these cells. This could be achieved by establishing the Ind.EndoTrack transgenic 
mouse lineage in an atherosclerosis prone ApoE-/- background, as recently 
demonstrated by Chen et al 116. 
6.6 Manipulating MIR503HG In Vivo and Clinical 
Translation 
Although persuasive, the data presented throughout Chapter 5 was largely associative 
and as such must be complemented with targeted manipulation of the lncRNA. We 
have attempted to mitigate these limitations by overexpressing the human 
MIR503HG_2 transcript in the mouse lung prior to induction of PAH. In line with the 
in vitro data presented, our overexpression strategy led to a significant decrease in 
mesenchymal marker expression in PAH lung mouse ECs, suggesting that MIR503HG 
can prevent the EndMT process during disease. However, several factors must be 
thoroughly tested before definite conclusions can be drawn.  
Larger comprehensive studies, including normoxic control mice along with optimised 
delivery strategies, are required in order to fully elucidate the role MIR503HG in PAH. 
Crucially, previous publications have made conflicting reports regarding the 
MIR503HG effect on cell proliferation and invasion 441,442. Given the unrestrained 
overexpression of MIR503HG_2 induced by our delivery strategy, the use of 
endothelial-specific gene transfer viral vectors should be considered during future 
applications 551–553. Moreover, while the impact on mesenchymal gene expression is 
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meaningful, in the context of PAH future studies must also consider a full 
haemodynamic and histological evaluation of disease hallmarks such as increased 
right ventricular systolic pressure (RVSP) measurements and the formation of 
plexiform lesions 165,190. 
We go on to describe the development of, to our knowledge, the first true murine 
MIR503HG (Gm28730) knockout line (Gm28730-/-). Here, using a novel CRIPR/Cas9 
system to introduce a premature transcriptional termination site (SPA-MAZ) within 
exon 1 of the lncRNA locus, we have successfully stopped Gm28730 expression 
without disrupting that of miR-424(322) and miR-503. This unique transgenic mouse 
line will be crucial in discerning the role of MIR503HG (Gm28730) in EC function 
and EndMT. However, as suggested in Section 5.4.3, while the loss of Gm28730 
expression has been confirmed in these mice, in-depth phenotypical assessment is still 
necessary. It is known that cardiac ECs in the atrio-ventricular (AV) canal give rise to 
the mesenchymal cells through active EndMT during cardiac septa and valve 
formation 92,95,554. As such, if the loss of MIR503HG (Gm28730) truly drives 
endothelial transition, Gm28730-/- mice may present with cardiac abnormalities.  
Moreover, there are still a number of limitations to this model possibly confounding 
future studies, these have been discussed in-depth through Section 5.4.3.  
Lastly, we must also consider the broader implications of EndMT during disease. As 
proposed throughout this thesis, the transition process has established itself as an 
important factor in the progression of vascular disease 52. However, as is common with 
complex vascular diseases, including PAH, a number of different pathological and 
cellular processes will actively mediate the disease progression. It is clear that EndMT 
cannot account for the totality of structural alterations present during vascular 
232 
remodelling. In PAH, a recent study has proposed more conservative figures than those 
previously estimated, showing that while EndMT is present in remodelled vessels it 
only accounts for approximately 14% of the cell population 172. Nevertheless, this is 
still a significant population that, if managed, could improve patient outcomes. As 
highlighted in Section 1.3, combined therapy is now regarded as the standard of care 
in PAH, significantly improving patient outcomes 219,555–557. Thus, a novel therapeutic 
target, combined with traditional therapeutic strategies, may ultimately extend PAH 
patient survival and improve quality of life. This thesis offers a promising initial 
outline for the role of MIR503HG during EndMT in PAH, however continuous 
research will be necessary for it to be considered for clinical therapy.  
6.7 Conclusions 
Taken together, the analysis described in this thesis provides important insights into 
EndMT highlighting the critical role of the lncRNA MIR503HG in maintaining EC 
function. While our results open new avenues for targeting EndMT, showing a 
previously unknown regulatory function of lncRNAs in driving this process, further 
research is still necessary to fully validate the mechanistic interactions of MIR503HG 
during EndMT and its role during disease. Nevertheless, as evidence underlining the 
finer regulatory mechanisms controlling EndMT continues to emerge, new lncRNA-
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